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ABSTRACT   
 
 Cancer cells require increased rates of protein synthesis to sustain rapid cell growth and 
proliferation. Increased secretory and membrane protein synthesis relies on an upregulation of the 
translational and protein folding machinery in the endoplasmic reticulum to aid tumor growth. For 
example, many critical cancer signaling kinases, such as EGFR (epithelial growth factor receptor), 
function as membrane proteins. Protein disulfide isomerase (PDI) is the major enzyme responsible 
for disulfide bond formation in the endoplasmic reticulum, and knockdown of PDI halts tumor 
progression. Thus, the goal of this dissertation project was to identify novel PDI inhibitors and 
provide an extensive preclinical evaluation of their activity for the treatment of cancer, specifically 
glioblastoma. 
 Through a phenotypic screening approach, we identified the pyrimidotriazinedione 35G8 
as a potent cytotoxic agent that inhibited PDI. Because of its known pan-assay interference 
(PAINS) properties, we first validated that the activity of 35G8 was not due to its redox cycling 
characteristics and used a variety of assays to confirm PDI inhibition. 35G8 destabilized PDI in 
cell-based target-engagement assays and had a transcriptomic profile similar to PDI knockdown. 




 The chalcone BAP2 was also identified through a phenotypic screening approach, and an 
initial structure-activity relationship (SAR) campaign with 67 analogues revealed important 
binding characteristics that allowed us to hypothesize that the compounds were binding in the b’ 
domain of PDI. Mutation of His256 to Ala abolished BAP2 activity and confirmed the binding 
hypothesis. Furthermore, BAP2 and analogues inhibit glioblastoma cell growth, induce ER stress, 
increase expression of G2M checkpoint proteins, and reduce expression of DNA repair proteins. 
BAP2 and analogues also sensitized glioblastoma (GBM) cells to radiation. These results establish 
the BAP2 series as PDI inhibitors and support their further study as a novel strategy to treat 
glioblastoma.   
 Finally, a manual biochemical screen of over 1,000 compounds in the PDI reductase assay 
produced a benzyl-benzodioxole, AS15, as a potent hit with an IC50 value under 1 μM. SAR 
analysis was performed with over 100 analogues of AS15. The SAR indicated that the compounds 
were binding PDI via a retro-Michael addition onto the cysteines, and protein mass spectrometry 
confirmed covalent binding. Cytotoxicity of the AS15 analogues was improved when combined 
with glutathione synthesis inhibitor buthionine sulfoximine (BSO), which confirmed that PDI 
competed with glutathione for binding the AS15 series in the cells. Thus, this study provides an 
excellent foundation to build analogues that are less sensitive to glutathione and more selective for 
PDI in the cells. 
 The work as a whole provides an extensive characterization of PDI inhibition and its role 
in cancer. We were able to provide extensive preclinical evaluation of lead PDI inhibitors 
identified from medium throughput screens. This work provides the foundation for a guided 
optimization of the PDI inhibitors discovered to further improve the potency and selectivity of the 









Current Challenges and Opportunities in Treating Glioblastoma 
Introduction1 
Glioblastoma (GBM) is the most malignant primary central nervous system tumor, and the 
prognosis for patients is often bleak. Currently, there are no curative treatment options for GBM, 
and despite rigorous therapeutic research, the survival rate of patients diagnosed with GBM 
remains low. Median overall survival is 15-23 months and five-year survival is less than 6 %, 
which is the lowest long-term survival rate of malignant brain tumors.1 An estimated 79,270 new 
cases of primary brain and other central nervous system (CNS) tumors were expected to be 
diagnosed in 2017.1 To improve therapeutic options, studies to identify and validate single protein 
targets are underway. However, in most cases, targeted compounds that perform well in preclinical 
studies have failed expensive Phase III clinical trials in humans. Ultimately, several major factors 
are responsible for drug failure, including poor pharmacokinetic properties, emergence of 
resistance pathways, complex intratumoral heterogeneity, and suboptimal clinical trial design. 
Thus, there is a desperate need for an efficient approach to identify and vet potential drugs at the 
preclinical stage, to prevent late stage failure. Genomic- and proteomic-scale analysis can identify 
 
1 This work has been published and is being reprinted with permission from Shergalis, A., Bankhead, A., Luesakul, 
U., Muangsin, N., & Neamati, N. (2018). Current challenges and opportunities in treating 
glioblastoma. Pharmacological reviews, 70(3), 412-445. 
Author contributions: Andrea Shergalis was the primary author, Armand Bankhead III generated figures I-5, I-6, 




proteins and pathways involved in the development of chemotherapeutic resistance mechanisms 
responsible for recurrent disease. 
   With the advent of TCGA (The Cancer Genome Atlas) consortium and resources, 
genomic analysis of cancers is at the forefront of drug discovery. Additionally, proteomics is 
gaining widespread use in drug discovery efforts. Quantitative proteomics can measure the 
expression and, in some cases, post-translational modification status of up to and over 8,000 
proteins in the cell at any given time. The advent of novel proteomic techniques in the last decade, 
in tandem with the resources allocated to address the lack of a cure for GBM, will accelerate the 
discovery of a treatment and shed light on the feasibility of precision medicine.  
   The target and mechanism of action of many Food and Drug Administration (FDA)-
approved drugs are not fully established. Of the approximately 1,600 FDA-approved drugs with 
known targets, most belong to four classes: GPCRs (33 %), ion channels (18 %), nuclear receptors 
(16 %), and kinases (3 %).2 This suggests uncharted proteomic space exists in which novel drug 
targets may be identified. Of the six drugs approved for the treatment of GBM, three act as DNA 
alkylators, two are kinase inhibitors, and one is a tubulin inhibitor. Burgeoning research efforts in 
novel treatment areas, including alternating electric field therapy (tumor-treating fields), 
immunotherapy, and antibody-drug conjugates are improving patient outcomes. Much of the 
challenge in developing a GBM therapy lies in reaching therapeutic concentrations at the target 
site. Few drug molecules cross the blood-brain barrier (BBB), and those that do may be exported 
via efflux pumps. Therefore, valid target selection, permeability, and drug pharmacokinetics are 




   In this review, we highlight the importance of genomic and proteomic research on 
identifying novel biomarkers and drug targets for GBM treatment. Additionally, we demonstrate 
a genomic approach to drug discovery and uncover novel potential drug targets by performing 
bioinformatics analysis of TCGA data. While further validation is necessary and increased 
expression of some of these targets may be a response to oncogenic stress, this approach provides 
a list of proteins that, if inhibited alone or in combination with other targets, could effectively treat 
GBM. Furthermore, we address the challenges faced in the drug discovery and delivery process 
and discuss potential solutions to those problems. In particular, we focus on the challenge of BBB 
permeability, nanocarrier design, and the application of computational methods to aid compound 
optimization. In recent years, major clinical trials for small molecule treatment of GBM have failed 
because the compounds did not reach effective concentrations in the brain (i.e. gefitinib and 
erlotinib).3, 4 Thus, an understanding of BBB function and physiology is crucial for the 
development of efficacious small molecule treatment strategies and the avoidance of failed 
expensive clinical trials. The lack of effective treatment options for GBM emphasizes the unmet 
need for successful target inhibition and drug delivery strategies.  
Current treatment options for glioblastoma 
Upon diagnosis, GBM treatment includes maximal surgical resection, followed by 
temozolomide and radiation.5 Due to the invasive nature of GBM, surgical resection rarely 
eliminates all tumor cells, and post-surgical treatment is usually necessary to prevent recurrence. 
Treatment varies based on the age of the patient and stage of the disease. Depending on the overall 




The standard-of-care temozolomide is a DNA-alkylating agent discovered in the 1970s and 
approved in 2005 by the FDA to treat newly diagnosed brain tumors. The first clinical trial with 
temozolomide was conducted in 1993, and, of the ten patients who received adjuvant 
temozolomide, five patients showed significant clinical and radiographic improvement.6 The 
success of this initial study prompted further successful studies of temozolomide treatment in 
GBM patients. In these studies, subsets of patients were more responsive to temozolomide 
treatment than others. Responsive patients had methyl-guanine-methyltransferase (MGMT) genes 
with methylated promoters and showed higher survival rates than patients with hypomethylated 
MGMT genes.7 MGMT is a DNA repair enzyme that repairs the N7 and O6 positions of guanine 
alkylated by temozolomide. While MGMT depletion does not seem to be an effective treatment 
strategy,8, 9 MGMT gene methylation status nevertheless remains an important biomarker for GBM 
prognosis. Although temozolomide is part of the standard chemotherapeutic regimen for GBM, it 
presents unwanted toxicity and does not eliminate the disease. As an alternative approach, targeted 
therapies may limit unwanted toxicity and more effectively block tumor proliferation.  
A promising targeted treatment is the anti-vascular endothelial growth factor (VEGF) 
monoclonal antibody bevacizumab. Bevacizumab was first approved by the FDA in 2004 to treat 
metastatic colorectal cancer. Since then, it has been approved for several different types of cancer, 
including GBM in 2009. Angiogenesis is a key survival feature of many cancers as tumors rely on 
nutrients from the vasculature to proliferate. VEGF is a broad mediator of tumor 
neovascularization, and VEGF expression is linked with GBM tumorgenicity.10 Bevacizumab was 
first tested in 21 patients with malignant glioma in 2004. Patients were treated with bevacizumab 




rate.11 However, the Phase III “Avaglio” trial, conducted on 921 patients with newly diagnosed 
GBM, resulted in no overall survival benefit in bevacizumab-treated versus placebo-treated 
patients (median overall survival of 16.8 months for bevacizumab-treated patients and 16.7 months 
for placebo-treated patients).12 A second Phase III trial, the RTOG 0825 trial, produced similar 
results. Out of 637 patients receiving either 10 mg/kg bevacizumab every two weeks or placebo, 
there was no significant difference in overall survival between the two groups (median overall 
survival of 15.7 months for bevacizumab-treated patients vs. 16.1 months for the placebo group).13 
Therefore, bevacizumab treatment is an option reserved for patients with recurrent GBM.  
Almost all GBM tumors that respond to first-line therapy recur. There is no standard 
approach for a successful treatment of recurrent GBM. Second-line treatment may take several 
directions, depending on factors such as tumor size and location, previous treatments, age, and 
time from initial diagnosis. Treatment can include surgical resection, reirradiation, nitrosoureas, 
temozolomide rechallenge, bevacizumab, or tyrosine kinase inhibitors.14 Even with these 
treatments, median overall survival after recurrence is 6.2 months.15 In a Phase II study that led to 
conditional FDA approval, the longest median progression-free survival (5.6 months) was seen 
with a combination of bevacizumab and irinotecan,16 while longest overall survival (12 months) 





Figure I-1 Classification of brain tumors as reported from the Central Brain Tumor Registry of the United States.18 Numbers in 
parentheses indicate incidence or cases per 100,000 individuals and are age-adjusted to the 2000 United States standard population.  
Molecular diagnostic signature of glioblastoma 
 Glioblastoma is a grade IV glioma and the most malignant astrocytoma (Figure I-1).19 
GBM tumors consist of a complex mixture of heterogeneous cells, complicating the search for the 
cell of origin. Previously, GBM was thought to originate from neural stem cells. However, studies 
have suggested that gliomas may differentiate directly from progenitor cells, and the type of 
progenitor cell each tumor originates from dictates their chemosensitivity.20 Until recently, GBM 
tumors have been diagnosed histologically and are characterized by increased cell density, 




histological diagnosis hinders therapeutic approaches at personalized therapy. TCGA project 
improved characterization of GBM tumors with whole genome sequencing and identified key 
oncogenic signaling pathways to further classify tumor types. The molecular aberrations required 
for gliomagenesis include: mutations in the P53, retinoblastoma (RB), and receptor tyrosine kinase 
(RTK)/Ras/phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) signaling pathways (Figure 
I-3).21 RB and P53 are tumor suppressors that lose function in several cancers.22, 23 Additionally, 
epithelial growth factor receptor (EGFR) expression is amplified in some GBM tumors, leading to 
increased cell proliferation through the RTK/Ras/PI3K/AKT signaling pathway.24 Through TCGA 
project, tumors were also profiled with Reverse Phase Protein Array (RPPA), a high-throughput 
technique similar to Western blotting that detects and quantifies protein expression levels. Out of 
171 antibodies, 127 correlated with transcriptomal subtype, and signaling pathway alterations were 
confirmed, including increased EGFR, Notch1, and Notch3 expression and activated MAPK 
pathway signaling.21 While this is a useful tool, only 171 antibodies were used in this study and 
therefore only 171 gene products could be profiled, providing a limited scope of potential novel 
drug targets. TCGA results were used by the World Health Organization to describe novel 
guidelines for GBM diagnosis to supplement histological findings with the mutation status of 
several biomarkers of GBM, including IDH1/2, ATRX, and Histone Cluster 1 H3 Family Member 
A (HIST1H3A or H3F3A) (mutation at position K27M or simply H3-K27M mutation).25 The 
novel classification of GBM subtypes will aid patient stratification and the development of targeted 





Figure I-2 Common characteristics of glioblastoma. Object images obtained from Servier Medical Art by Servier.  
Molecular profiling has been used to classify GBM into four subtypes: Classical, 
Mesenchymal, Proneural, and Neural. Expression and aberrations of specific genes associated with 
each subtype have been identified.26 All Classical GBM tumors contain chromosome 7 
amplification and chromosome 10 loss, and almost all (97 %) display EGFR amplification.26 
Mesenchymal GBM tumors show loss of NF1, contain markers of epithelial-to-mesenchymal 
transition (CD44 and MERTYK), and highly express genes in the tumor necrosis factor super 
family and NF-κB pathways. Alterations of PDGFRA and point mutations in the IDH1 gene are 
characteristic of Proneural subtypes. Tumors with expression of neural markers NEFL, GABRA1, 
SYT1, and SLC12A5 are classified as the Neural subtype. Of these subtypes, patients classified 
with the Proneural subtype generally had a longer overall survival, though the results were not 
statistically significant. Furthermore, the Proneural subtype is most common in younger patients. 




treatment (concurrent chemo- and radiotherapy, or more than three subsequent cycles of 
chemotherapy).26  
 
Figure I-3 Canonical gliomagenesis mediators EGFR, P53, and RB1 are important for cancer signaling. EGFR is amplified or 
mutated to the constitutively active EGFRvIII and propagates kinase signaling cascades to promote proliferation, invasion, and 
angiogenesis. P53 is a tumor suppressor that is mutated in GBM, allowing BCL2 to inhibit apoptosis. RB is another tumor 
suppressor gene that, when inactivated, releases E2F1 to activate cell cycling and growth. Percentages of aberrations of commonly 
mutated genes (in yellow) are reported, determined from TCGA analysis of patient samples.21 
Improvements in tumor profiling may drastically alter how GBM is treated and may 
improve the fidelity of new diagnoses. Furthermore, treatment of each tumor subtype may be 
individualized for optimal success. Although no targeted therapies have been approved for GBM 
yet, these diagnostic criteria may lead to more effective personalized treatments. Moreover, 
targeted therapies should be evaluated in a specific GBM subtype for optimal response. Further 
complicating the development of targeted treatments is the fact that a single cell of origin may not 




and, in fact, the cell of origin may not be the cell type that contains the transforming mutation. 
However, deciphering the cell of origin of GBM may be important to properly identify targets for 
drug discovery, stratify patient diagnosis, and optimize an effective treatment strategy. 
Characteristics of protein expression in glioblastoma 
 Dynamic signaling pathways govern cancer cell proliferation. A major consequence of 
cancer signaling is an imbalance in protein expression to allow the cells to evade apoptosis, 
proliferate, and metastasize. Approximately 40% of GBM tumors are characterized by 
amplification and overexpression of EGFR, an effector of several signaling cascades that aid tumor 
growth, angiogenesis, migration, and metastatic spread.21 EGFR is a receptor tyrosine kinase that, 
upon ligand binding, dimerizes and activates downstream signaling through the Ras/PI3K/AKT 
pathway. EGFR overexpression and EGFRvIII amplification may be prognostic markers that 
correlate with decreased overall survival of GBM patients27; however, a recent meta-analysis 
disputes this claim.28 Nevertheless, because EGFR amplification and mutations promote glioma 
growth and survival, EGFR has been proposed as an attractive therapeutic target. Unfortunately, 
several clinical trials with EGFR inhibitors have failed, likely due to poor BBB permeability, 
intratumoral heterogeneity, and the difference between local versus systemic administration.29 
Gliomagenesis is driven by mutations such as EGFRvIII, and those gene mutations promote tumor 
growth and proliferation through protein expression networks. 
Large-scale proteomic research has shown that GBM tumors have increased expression of 
membrane proteins involved in cellular function and maintenance (p = 2.03 x 10-8), protein 
synthesis (p = 7.74 x 10-11), cell-to-cell signaling and interaction (p = 1.82 x 10-10), cellular 




tissue (Figure I-4).30 More specifically, GBM tumors had increased expression of membrane 
proteins involved in acute phase response signaling, caveolar-mediated endocytosis signaling, and 
calcium signaling.30  
 
Figure I-4 Signaling pathways involving membrane proteins upregulated in GBM as determined by LC-MS/MS and iTRAQ. 
Results are from proteomics analysis of human GBM tumors with Ingenuity Pathway Analysis software.30 Representative genes 
from each category are shown. 
Proteomic approaches have identified proteins that are involved in chemotherapeutic 
resistance. For example, a study using 2D gel electrophoresis (2DGE) and mass spectrometry 
identified that lipocalin 2 (LCN2) and integrin β3 (ITGB3) were downregulated in BCNU-resistant 
rat models of glioma.31 Furthermore, 2DGE coupled with liquid chromatography-mass 
spectrometry analysis identified several proteins important for the invasive properties of gliomas.32 
In particular, annexin A2 was highly expressed in an angiogenesis-dependent cell line,32 and its 




Although many other proteins have been found to contribute to GBM tumor growth, for 
this review, we will focus on targets that have been discovered through proteomic approaches and 
TCGA data mining. Some examples of proteins overexpressed in GBM that may represent novel 
drug targets that were not discovered via proteomic approaches include heat-shock protein 47 
(HSP47),34 cathepsin L (CTSL),35 glycoprotein nonmetastatic melanoma protein B (GPNMB),36 
transcription factor 12 (HEB),37 targeting protein for Xenopus kinesin-like protein 2 (TPX2),38 and 
B-cell CLL/lymphoma 3 (BCL3).39 Due to the characteristic intratumoral heterogeneity of GBM, 
it is likely that a single target approach will not be effective, and appropriate drug combinations 
will be necessary. 
Emerging targets in glioblastoma 
Numerous proteins are overexpressed in GBM, and abundant research has identified 
potential targets; however, extensive genomic and proteomic research suggests that tumor 
heterogeneity will likely render GBM unresponsive to single agent therapy. Of equal importance 
to target discovery is biomarker identification. Disease biomarkers can be used for early diagnosis 
and monitoring responsiveness to treatment. 
Biomarker identification 
Biomarkers have been used successfully as tools for cancer diagnosis. Prostate cancer was 
one of the first to benefit significantly with the discovery of prostate specific antigen to inform 
early diagnosis and response to treatment. In addition, biomarkers have been discovered for 
ovarian, head and neck, lung, and breast cancer, among others.40-43 Gliomas are characterized in 
the clinic by IDH1 and IDH2 mutations and MGMT gene promoter methylation status to better 




studying glioma tumorigenesis in detail, prognostic markers can be identified. Better prognostic 
markers would allow physicians to diagnose and begin treatment of GBM at early onset, possibly 
preventing disease progression. 
Several groups have used proteomic techniques to analyze GBM and identify potential 
biomarkers for early diagnosis. For example, small extracellular vesicles transporting RNA and 
protein between cells can help clinicians diagnose and begin treatment of GBM at an earlier stage. 
Small extracellular vesicles in the cerebrospinal fluid (CSF) carry important microRNA that could 
be used as biomarkers.44 In addition, the oncometabolite 2-hydroxyglutarate (2-HG) has been 
studied as a noninvasive biomarker in gliomas. In one study, urinary 2-HG levels were elevated in 
patients diagnosed with IDH1-mutant gliomas.45 However, it is still unclear whether 2-HG levels 
could be used as a diagnostic measure for IDH1-mutant GBM, and whether 2-HG levels could 
determine patient health outcome in response to chemotherapy and radiation. A computational 
approach was used to identify dysregulated pathways associated with short-term survival including 
proteins associated with gene ontology terms “protein kinase cascade” and “NFκB pathway.”46 
Despite this research, novel disease biomarkers identified with mass spectrometry-based 
proteomics have yet to reach the clinic.47  
Drug discovery targets 
Genomic and proteomic techniques inform the development of precision medicine. The 
evolution of large-scale proteomic efforts is likely to benefit future drug discovery, and 
information on genomic events in GBM could lead to valuable insights about protein target 
candidates. Using TCGA GBM project cohort genomic analysis, we identified 20 genes with high 




the aggressive nature of GBM tumors and therefore may be important drug targets. However, 
further validation is necessary to confirm that the increased expression is not a response to 
oncogenic stress.  
Gene expression associated with reduced patient survival 
In an effort to better understand the landscape of known and unknown GBM drug targets 
based on available gene expression data, we performed an analysis on 141 GBM samples from the 
TCGA cohort with both survival metadata and RNASeq expression data 
(http://cancergenome.nih.gov/). Patient sample RNASeq RSEM-normalized gene expression 
values and survival metadata were sourced from the TCGA GDAC Firehose.48 When multiple 
samples were available for a given patient, barcodes were sorted alphabetically and the first was 





Figure I-5 Twenty genes associated with reduced survivability in the TCGA GBM patient cohort profiled with RNASeq expression 
data. Patients were stratified by high and low gene expression based on one of five expression percentile thresholds. Kaplan-Meier 
survival plots are shown with patients having increased expression in red and all other GBM patients shown in green. Non-adjusted 
p-values generated using the log-rank test are shown. All p-values shown survived multiple testing corrections (qValue ≤ 0.1) 
across all 5 percentile thresholds and 20,531 genes. 
GBM patient samples were evaluated for reduced survivability by comparing survival 
outcomes for patients with high and low expression of each gene (Figure I-5). Thresholding for 
high and low expression patient populations was evaluated using five different quantile cutoffs: 
95%, 90%, 75%, 50%, and 25%. A log-rank test statistic was calculated for each cutoff to compare 
the survival distributions of high and low expression patient populations with the null hypothesis 




quantile cutoffs, and genes evaluated. To reduce over-fitting of a single cutoff per gene, genes for 
which the high expression population was associated with reduced survivability were required to 
have FDR-adjusted p-values ≤ 0.1 for at least two quantile cutoffs. Survival test statistics were 
calculated in R using the survival package.49 
Twenty genes were identified as significantly associated with reduced survivability using 
the criteria described in the previous paragraph. Several of the 20 significant genes encode proteins 
involved in EGFR signaling. Our results reveal novel EGFR signaling proteins that may have more 
prominent roles than previously thought. These proteins include proteases (FURIN, GZMB, and 
NDEL1), transcription factors (LITAF, IRX3, NKX3-1, and VEGFC), and receptors (ERβ, BOC, 
EREG, and PTPRN). Agglomerative hierarchical clustering was performed using the 20 
significant genes across TCGA GBM patients, and patients were stratified based on cluster 
membership. One cluster group had higher average expression across the 20 genes, and this higher 
expression corresponded with reduced time to death and disease-free survival (Figure I-6). Patients 
belonging to the cluster group with higher average expression had significantly reduced survival 
compared to those not included. Survival stratification significance (p = 5.59 x 10-11) was greater 
when evaluating by cluster group across all 20 genes compared with any of the 20 genes separately 
(Figure I-6). Gene expression association with poor overall survival was further validated by 
applying survival test statistics to samples from three independent GBM cohorts.50-52 Eight of the 
20 genes (LITAF, FURIN, VEGFC, C20orf166-AS1, ELOVL6, PODNL1, ESR2, and QSOX1) were 
significantly associated with reduced survivability in at least one additional GBM cohort. This 






Figure I-6 Hierarchical clustering of 20 genes (A) Hierarchical clustering was performed to identify groups of patients with similar 
RNASeq expression of 20 genes associated with reduced survivability in the TCGA GBM patient cohort. (B) Patients stratified 
using clustering dendrogram assignment into high and low expression groups showed significant differences in survival. Heatmap 
z-scores were calculated per gene. Agglomerative hierarchical clustering with complete linkage was performed using Euclidean 
and Pearson correlation distance metrics on rows and columns respectively. 
Further validation of the proteins was performed with the open-access resource Pharos.53 
The majority of the identified genes (12) had Tbio classifications while two (ESR2 and TH) had 
Tclin classifications and three (ELOVL6, FURIN, GZMB) were assigned a Tchem classification. 
All targets that were mapped to GTEx expression were classified as having high or medium 
expression levels in normal brain tissue. From the analysis, 21 out of 25 genes in Figure I-4 and 
12 out of 20 genes (Table I-1) have a known link to brain cancer. Of the 12 genes, seven are linked 
to GBM: BOC, ELOVL6, IRX3, LITAF, NDEL1, PTPRN, and QSOX1. Furthermore, ELOVL6 
small molecule probes have been identified and could be used to validate ELOVL6 as a drug target. 
Given that ELOVL6, ESR2, TH, FURIN, and GZMB have probes or inhibitors identified, these 




Table I-1 Gene descriptions from DAVID bioinformatics database (https://david.ncifcrf.gov). 
No. Name Full Name Description Refs. 
1 BOC 




Component of a cell-surface receptor complex 
that mediates cell-cell interactions between 




domain family 4 
member G 
pseudogene 1 
function unknown N/A 
3 ELOVL6 
ELOVL fatty acid 
elongase 6 
Fatty acid elongase specific to C12-C16 
saturated and monounsaturated fatty acids 
55 
4 EREG epiregulin 
May be a mediator of localized cell 
proliferation 
56 
5 ESR2 estrogen receptor 2 
Nuclear hormone receptor that binds estrogens 
with an affinity similar to that of ESR1 and 
activates expression of reporter genes 










Can bind to the surface of B-lymphoma cells, 
but not T-lymphoma cells, consistent with a 




furin, paired basic 
amino acid 
cleaving enzyme 
Release of mature proteins from their 
proproteins by cleavage of -Arg-Xaa-Yaa-Arg-
|-Zaa- bonds, where Xaa can be any amino acid 





8 antisense RNA 1 
Fucosylation of proteins, including EGFR  
62 
9 GZMB granzyme B 
This enzyme is necessary for target cell lysis in 
cell-mediated immune responses. It cleaves 
after Asp. Seems to be linked to an activation 
cascade of caspases (aspartate-specific cysteine 
proteases) responsible for apoptosis execution. 
It has been associated with both tumor 






Belongs to the TALE/IRO homeobox family 
and may have a direct functional relationship to 
both obesity and type 2 diabetes. IRX3 is a 










Probable role in regulating transcription of 
specific genes. May regulate through NFκB1 
the expression of the CCL2/MCP-1 chemokine. 
May play a role in tumor necrosis factor alpha 





protein 1 like 1 
Facilitates the polymerization of 
neurofilaments from the individual subunits 
NEFH and NEFL. Required for organization of 
the cellular microtubule array and microtubule 
anchoring at the centrosome 
68 
13 NKX3-1 NK3 homeobox 1 
Transcription factor, which binds preferentially 
the consensus sequence 5'-TAAGT[AG]-3' and 
can behave as a transcriptional repressor. Could 
play an important role in regulating 
proliferation of glandular epithelium and in the 
formation of ducts in prostate 
69 
14 PODNL1 podocan like 1 






receptor type N 
Implicated in neuroendocrine secretory 
processes. May be involved in processes 
specific for neurosecretory granules, such as 
their biogenesis, trafficking or regulated 









Catalyzes the oxidation of sulfhydryl groups in 
peptide and protein thiols to disulfides with the 
reduction of oxygen to hydrogen peroxide. May 
contribute to disulfide bond formation in a 
variety of secreted proteins 
75 
17 SEMA4F semaphorin 4F 
Estrogen-regulated semaphorin ligand with 













Growth factor active in angiogenesis and 
endothelial cell growth, stimulating 
proliferation and migration. Has effects on the 
permeability of blood vessels. May function in 
angiogenesis of the venous and lymphatic 
vascular systems during embryogenesis, and in 
the maintenance of differentiated lymphatic 




open reading frame 
166 antisense RNA 
1 







Figure I-7 Expression of 20 genes significantly associated with reduced survivability in GBM across 33 TCGA diseases. Gene 




to show relative expression. Regions of the heatmap are circled to highlight genes with consistent higher expression (10th percentile 
> 0.5) and previously published support for relevance to disease progression (cyan) or high expression without previously published 
support for disease progression (purple). Diseases are ranked by decreasing average expression and ribbon on the right is colored 
to indicate average expression per patient sample. 
We expanded our analysis of the 20 genes to include 33 TCGA diseases (Figure I-7). Head 
and neck squamous cancer had the highest average expression of the 20 genes in the analyzed 
patient samples. In addition, several genes were identified that have consistently higher expression 
in several cancers. For example, PTPRN was highly expressed in pancreatic adenocarcinoma and 
the pheochromocytoma and paraganglioma cohort; and therefore, those cancer subsets may be 
more sensitive to targeted PTPRN therapy. Several of the genes are involved in the transcriptional 
regulation of EGFR, including ESR2, EREG, and VEGFC. In addition, several genes are indirectly 
involved in EGFR regulation, including FUT8, LITAF, FURIN, NKX3-1, and TH. Upon further 
validation, these transcription factors may prove to be relevant to the progression and recurrence 
of GBM. 
Below, we briefly summarize the 20 genes significantly associated with reduced 
survivability and discuss current research on the link between each gene and cancer. Further 
validation of each target is necessary to confirm the importance of each gene in the context of 
GBM. Inhibiting the activity or expression of one, or a combination, of the proteins discussed 
below may prove to be a viable treatment strategy for GBM. 
BOC cell adhesion associated, oncogene regulated (BOC) 
BOC is a member of the immunoglobulin/fibronectin type III repeat family and promotes 
myogenic differentiation. During oncogenesis, BOC promotes hedgehog pathway signaling by 
sustaining a feedback mechanism that enhances the concentration of Sonic hedgehog (Shh) 




embryogenesis and growth of hair follicles and taste papillae in adults.81 In the absence of the Shh 
ligand, the GPCR Ptch is active, which blocks Smo signaling. When Shh ligand is present, it 
inactivates Ptch, allowing Smo to signal transcription of target genes. Since BOC activates 
hedgehog pathway signaling, it likely contributes to GBM progression and may be a potential drug 
target. In our analysis, increased BOC expression is strongly associated with poor overall survival 
(p = 1.36 x 10-6). This is the first report, to our knowledge, of BOC associated with GBM.  
C-type lectin domain family 4 member G pseudogene 1 (CLEC4GP1)  
CLEC4G is a 32.6-kDa membrane-bound protein expressed in the liver and lymph nodes 
and plays a role in T-cell immune response. TCGA whole-genome sequencing revealed CLEC4G 
was downregulated in hepatocellular carcinoma tissue.82 As a pseudogene, CLEC4GP1 is likely a 
non-functional copy of the enzyme. Pseudogenes can arise during duplication if a mutation occurs 
in the DNA, or with retrotransposition, in which the cDNA product of the reverse-transcribed 
mRNA becomes incorporated in the genome. In our analysis, increased CLEC4GP1 expression is 
strongly associated with poor overall survival (p = 2.63 x 10-5). CLEC4GP1 is located on 
chromosome 19. In one study, CLEC4GP1 mRNA expression increased in response to an mRNA-
based vaccine encoding influenza A hemagglutinin from a pandemic strain.83 Additionally, 
expression of CLEC4GP1 is high in samples from patients diagnosed with adenoid cystic 
carcinoma (Figure I-7).  
ELOVL fatty acid elongase 6 (ELOVL6) 
ELOVL6 is highly expressed in the brain, and the gene is often hypomethylated in GBM.84 
This enzyme performs the first and rate-limiting step of fatty acid elongation, with malonyl-CoA 




Phospholipids containing longer acyl chains are abundant in cancer tissue, and ELOVL6 is the 
main enzyme responsible for fatty acid elongation in cancer.86 The gene is located on chromosome 
4q25, adjacent to the EGF gene. Expression of ELOVL6 may be high because it shares an enhancer 
region with EGF. Enhancers perform complex functions and can activate transcription of specific 
genes upstream or downstream, by engaging the transcriptional machinery. In acute myeloid 
leukemia, a novel chromosomal rearrangement was found to activate ELOVL6 and EGF.87 
ELOVL6 has been studied in the context of many cancers. Increased ELOVL6 mRNA expression 
was found in triple-negative breast cancer tissue.88 Additionally, ELOVL6 and lipid composition 
may be regulated by the RB-E2F1 pathway.89 An ELOVL6 inhibitor, Compound A, inhibited 
tumor growth in an in vivo model of squamous cell carcinoma,86 and therefore validation and 
pursuit of ELOVL6 inhibition in GBM is warranted.  
Epiregulin (EREG) 
EREG is a 19-kDa peptide hormone that acts as a ligand for the EGF receptor and ErbB4. 
When cleaved by a disintegrin and metalloproteinase (ADAM) enzyme from the transmembrane 
pro-peptide to an active soluble form, EREG binds EGFR family members and initiates the 
signaling cascade. EREG expression is upregulated in gastric,90 colon,90 lung,91 and head and 
neck92 cancers, among others. In a colon cancer xenograft model, EREG expression correlated 
with a positive response to the anti-EGFR monoclonal antibody cetuximab, suggesting the tumors 
were dependent on the EGFR signaling pathway activated by EREG.93 EREG transcription is 
regulated by insulin, Sp1, NFκB, and AP-2.94-96 Silencing of EREG in a breast cancer cell line 
inhibited metastasis, angiogenesis, and tumor cell extravasation.97 EREG is a partial agonist of 




EREG as a key activator of EGFR signaling driving cancer cell proliferation suggests that 
inhibition of EREG binding to EGFR is a potential targeted cancer treatment. In our analysis, 
EREG expression was associated with poor overall survival in GBM patients (p = 5.6 x 10-5). High 
EREG expression was also found in TCGA samples from patients diagnosed with rectum 
adenocarcinoma (Figure I-7). Furthermore, EREG activates the ERK/MAPK pathway in GBM 
suggesting inhibition of the EREG-EGFR interaction may be a strategy for EREG-overexpressing 
GBM patients.99  
Estrogen receptor 2 (ESR2) 
ESR2 encodes the gene for estrogen receptor β (ERβ), a nuclear hormone receptor for 
estrogen, is considered a tumor suppressor in the context of GBM and other cancers,58, 100 and 
enhances chemosensitivity in NSCLC.101 Treatment with ERβ agonist, LY500307, is efficacious 
in a GBM tumor-bearing mouse model.58 Additionally, ERβ expression, analyzed 
immunohistochemically, declines as brain astrocytic tumors progress.57 In our analysis, increased 
ESR2 expression is strongly associated with poor overall survival (p = 1.68 x 10-4), which is in 
contrast with the tumor suppressing effects of the protein. Furthermore, expression of ESR2 is high 
in TCGA samples from patients diagnosed with diffuse large B-cell lymphoma (Figure I-7). The 
tumor-suppressing characteristics of ESRβ may prevent it from being a potential anticancer target. 
Follicular dendritic cell secreted protein (FDCSP) 
FDCSP (C4orf7) is a 9.7-kDa peptide that promotes invasion and metastasis of tumor cells. 
While relatively little is known about this peptide, overexpression of FDCSP is common in 
tumorigenesis, especially in ovarian cancer.60 FDCSP expression has also been implicated as a 




characteristics, including amino acid composition, molecular mass, and isoelectric point suggest 
FDCSP may be similar to the inflammatory C-X-C chemokines, such as IL-8.103 In our analysis, 
increased FDCSP expression is strongly associated with poor overall survival (p = 1.24 x 10-4). 
FDCSP expression may be important for GBM progression. 
Furin 
Furin is a protease that activates matrix metalloproteinases including proparathyroid 
hormone, transforming growth factor beta 1 precursor, proalbumin, pro-beta-secretase, membrane 
type-1 matrix metalloproteinase, beta subunit of pro-nerve growth factor, and von Willebrand 
factor. Furin is linked with tumor progression in several cancers including head and neck squamous 
cell carcinoma, breast cancer, and rhabdomyosarcoma.104 In astrocytoma cells, inhibition of furin 
decreases cell proliferation and invasiveness.105 Furthermore, furin promotes activation of pro-
TGFβ1 and pro-TGFβ2, demonstrating a tumorigenic role in glioma-initiating cells.106 In our 
analysis, increased furin expression is strongly associated with poor overall survival (p = 1.79 x 
10-4). Transcription of furin is promoted by AP-1 (activator protein-1), c-Jun, and ATF-2. 
Proteolysis is important in cancer, and furin activates several enzymes via proteolysis that 
contribute to cell migration and survival, including protein kinase C.107 Combined inhibition of 
furin, ADAM, calpain, and another serine protease is necessary to prevent glioma migration and 
slow growth mediated by protein tyrosine phosphatase μ.61 Inhibitors of furin demonstrate 
antiproliferative effects and are being optimized in the context of inhibition of viral replication.108, 
109 The extensive evidence of the tumorigenic role of furin in several cancers, including brain 





Fucosyltransferase 8 antisense RNA 1 (FUT8-AS1) 
FUT8 is a 66.5-kDa enzyme located in the Golgi apparatus and extracellular space and 
catalyzes the transfer of fucose from GDP-fucose to N-linked type complex glycopeptides. 
Fucosylation is an important post-translational glycosylation event that regulates cancer signaling 
processes including metastasis and epithelial-to-mesenchymal transition. The expression of FUT8-
AS1 suggests FUT8 expression may be downregulated in GBM patients. In our analysis, increased 
FUT8-AS1 expression is strongly associated with poor overall survival (p = 8.6 x 10-5). FUT8 
function has been studied in the context of several cancers. For example, knockdown of FUT8 
halted growth of in vitro and in vivo models of lung cancer.110 Additionally, inhibitors have been 
developed that block fucosylation in models of cancer.111 While FUT8 expression has been studied 
in the context of lung, liver, colon, and other cancers, it has not been evaluated in GBM. 
Granzyme B (GZMB) 
GZMB is a serine protease in the peptidase S1 family and is involved in mediating 
apoptosis. This enzyme cleaves after aspartate and plays a role in the cellular caspase cascade that 
leads to apoptosis. GZMB is the most abundant enzyme in cytotoxic granules responsible for the 
clearance of tumor cells, as well as cells infected with intracellular pathogens and allogeneic 
cells.112, 113 It is also a prognostic marker in colorectal cancer.114 In our analysis, increased GZMB 
expression is strongly associated with poor overall survival (p = 5.29 x 10-7). Additionally, there 
is high expression of GZMB in TCGA samples from patients diagnosed with diffuse large B-cell 
lymphoma (Figure I-7). GZMB transcription is regulated by nuclear factor of activated T cells, 




binds approximately 10 kilobases downstream from the GZMB transcription start site,116 and by 
JAK1/STAT signaling.117 The role of GZMB in apoptosis makes it an attractive anticancer target. 
Iroquois homeobox 3 (IRX3) 
IRX3 is a 5.2-kDa transcription factor in the Iroquois homeobox family of developmental 
factors and is involved in Shh-dependent neural patterning. IRX3 belongs to class I proteins of 
neural progenitor factors and is repressed by Shh signals. IRX3 contains transcription factor 
binding sites for ERα, Pax-5, AP-2α, AP-2β, AP-2γ, FOXD1, and C/EBP, among others. In our 
analysis, increased IRX3 expression is strongly associated with poor overall survival (p = 1.15 x 
10-4). In addition, consistently higher expression of IRX3 is observed in TCGA samples from 
patients diagnosed with breast cancer (Figure I-7). IRX3 is a target gene of WHSC1L1 (Wolf-
Hirschhorn syndrome candidate 1-like 1 gene, or NSD3), a known oncogene in breast cancer, and 
may be a regulator of WNT signaling.66 DNA methylation profiling of an oligodendroma-derived 
cell line revealed hypermethylation of the CpG island on an IRX3 exon, consistent with 
overexpression of IRX3 in tumor tissue compared to normal brain samples.118 Although IRX 
transcription factors have been identified in multiple genome-wide sequencing studies in cancer, 
they specifically hamper the tumor-suppressing activity of the TGF-β pathway.119 Therefore, 
blocking IRX3 expression, or inhibiting its ability to suppress the TGF-β pathway, may be an 
option for GBM treatment.  
Lipopolysaccharide-induced tissue-necrosis-factor factor (LITAF) 
LITAF is a lipopolysaccharide-regulated transcription factor located on chromosome 16 
that regulates VEGF and plays a role in angiogenesis and inflammatory response.120 LITAF 




(SLD) with a YXX ϕ motif that mediates transport of membrane proteins to and from the 
endosome, Golgi apparatus, and lysosomes. In several cancers, LITAF induces inflammation and 
promotes cancer cell survival. Stimulation by lipopolysaccharide (LPS) causes LITAF to 
translocate from the cytoplasm with its partner protein STAT6(B) to the nucleus to promote gene 
expression.67 In our analysis, increased LITAF expression is strongly associated with poor overall 
survival (p = 2.3 x 10-5). Furthermore, LITAF was in the top 30 overexpressed genes in GBM in a 
large-scale expression analysis study.121 Therefore, blocking the LITAF-STAT6(B) protein-
protein interaction may be a viable treatment strategy. However, LITAF possesses a tumor-
suppressing role in pancreatic cancer,122 and its expression can be induced by P53.123 LITAF 
knockdown promoted tumor malignancy and growth in nude mice injected subcutaneously with 
prostate cancer cells.124 Overall, LITAF plays a complex role in the progression of cancer. 
NudE neurodevelopment protein 1 like 1 (NDEL1) 
NDEL1 is a 38-kDa cytoskeletal protein that contains an N-terminal coiled coil NUDE 
domain and is important for the regulation of microtubule organization to promote neuronal 
migration. Expression of NDEL1 is highest during mitosis, and it is necessary for mitotic cell 
division.125 In our analysis, increased NDEL1 expression is strongly associated with poor overall 
survival (p = 5.7 x 10-5), and consistently higher expression is found in acute myeloid leukemia 
(Figure I-7). NDEL1 has also been implicated in the development of schizophrenia via its protein-
protein interactions with Disrupted-in-Schizophrenia 1 (DISC1).126 NDEL1 associates with 
microtubules, dynein, CENPF, and ZNF365. Additionally, the NDEL1 gene contains P53, c-myc, 




NDEL1 in cancer migration, effective, targeted inhibitors could be developed to control tumor 
growth. 
NK3 homeobox 1 (NKX3-1) 
NKX3-1 is a transcription factor that negatively regulates epithelial cell growth in prostate 
tissue. Loss of NKX3-1 is common in prostate cancer patients.69, 127 NKX3-1 negatively regulates 
the PI3K-AKT pathway to suppress tumor growth, and heterozygous deletions of NKX3-1 and 
PTEN cause prostate adenocarcinomas in mice.128 Additionally, NKX3-1 functions as a tumor 
suppressor in hepatocellular carcinoma.129 In our analysis, increased NKX3-1 expression is 
strongly associated with poor overall survival (p = 1.74 x 10-4), and consistently higher expression 
is also found in prostate adenocarcinoma (Figure I-7). To our knowledge, NKX3-1 has not yet 
been studied in the context of GBM. 
Podocan like 1 (PODNL1) 
PODNL1 is an extracellular protein expressed in tibial nerves, coronary arteries, and bone 
marrow mesenchymal stem cells and is involved in proteinaceous extracellular matrix formation. 
It belongs to the small leucine-rich proteoglycan (SLRP) family of 17 genes and is a member of 
Class V SLRPs, residing on chromosome 19q. SLRPs also act upstream of signaling cascades, 
including receptor tyrosine kinases like ErbB family members.130 Interestingly, the Class V SLRPs 
bind collagen I and inhibit cell growth by inducing p21 expression.131 Additionally, another SLRP 
family member, decorin, binds to EGFR and lowers receptor levels by caveolin-mediated 
internalization.132-134 High expression of PODNL1 correlates with poor prognosis in ovarian 
cancer.71 Methylation of the PODNL1 gene may be important for phenotypic changes that occur 




supports these findings; increased PODNL1 expression is strongly associated with poor overall 
survival (p = 3.61 x 10-6). Because several proteins in the SLRP family play a role in cancer 
progression, PODNL1 may have an important function as well. 
Protein tyrosine phosphatase, receptor type N (PTPRN) 
PTPRN (also known as islet antigen-2 or IA-2) is a gene encoding a 105.8-kDa protein in 
the protein tyrosine phosphatase family responsible for signaling processes related to cell growth, 
differentiation, and oncogenic transformation. Hypermethylation of PTPRN in ovarian cancer 
patients was associated with shorter survival.73 It was initially discovered as a gene differentially 
expressed in human pancreatic beta islet cells and is localized on the plasma membrane and in 
endosomes. PTPRN depletion reduced small cell lung cancer cell growth.135 Valproic acid induced 
the expression of PTPRN as a result of increased acetylation in the promoter region.136 Analysis 
of TCGA samples from patients with pancreatic adenocarcinoma, pheochromocytoma, 
paraganglioma, GBM, and LGG revealed consistently higher expression of PTPRN (Figure I-7). 
In our analysis, increased PTPRN expression is strongly associated with poor overall survival (p 
=2.19 x 10-5). While PTP family proteins have been well-studied in the context of cancer, little 
work has been done to elucidate the role of PTPRN in brain cancer. 
Quiescin sulfhydryl oxidase 1 (QSOX1) 
QSOX1 is a FAD (flavin adenine dinucleotide)-dependent 82.6-kDa enzyme that forms 
disulfide bonds in proteins by oxidizing sulfhydryl groups. It is found in the extracellular space, 
Golgi apparatus, and endoplasmic reticulum, where it functions alongside protein disulfide 
isomerase to fold nascent proteins.137 QSOX1 contains one thioredoxin domain and one ERV/ALR 




and survival, and QSOX1-mediated migration of pancreatic ductal carcinoma cells may be 
activated by MMP-2 and MMP-9.75 Interestingly, loss of NKX3-1 expression correlates with an 
increase in QSOX1 expression in prostate cancer.138 In our analysis, increased QSOX1 expression 
is strongly associated with poor overall survival (p = 1.96 x 10-8). Proteomic analysis using iTRAQ 
identified that QSOX1 expression was upregulated in hepatocellular carcinoma.139 Furthermore, 
knockdown of QSOX1 sensitizes nasopharyngeal carcinoma cells to radiation.140 Ebselen, a 
covalent inhibitor of QSOX1, suppressed pancreatic tumor growth in vivo.141 Much work has been 
done to elucidate the complex role of QSOX1 in several cancers, and it clearly plays an important 
role in disease progression. 
Semaphorin 4F (SEMA4F)  
SEMA4F is a membrane-bound glycoprotein in the semaphorin family of receptors. 
Semaphorins are involved in eliciting intracellular signaling cascades and may be receptors for 
EGFR signaling ligands. Therefore, semaphorins are important regulators of tumor growth, 
angiogenesis, migration, and apoptosis.142 For example, SEMA3B was found to be a marker for 
poor survival in patients over 50 diagnosed with GBM.143 In contrast, SEMA4D can stimulate or 
inhibit breast cancer cell migration and adhesion, depending on the presence of receptor tyrosine 
kinases ERBB2 and MET.144 In our analysis, increased SEMA4F expression is strongly associated 
with poor overall survival (p = 3.24 x 10-9). SEMA4F is linked to the induction of prostate cancer 
neurogenesis145 and may be important for breast cancer progression.146 SEMA4F knockdown was 
linked to Schwann cell proliferation in the development of neurofibroma downstream of the loss 
of NF1 tumor suppressor function.76 The molecular mechanisms driving the function of this 




Tyrosine hydroxylase (TH) 
TH, as its name suggests, hydroxylates tyrosine to form the precursor for dopamine, l-dopa, 
and is induced by hypoxic stress via HIF1α, common in the tumor microenvironment. TH is also 
a marker for neurons containing downstream products dopamine, norepinephrine, and epinephrine. 
In our analysis, increased TH expression is strongly associated with poor overall survival (p = 4.62 
x 10-5). TH gene expression is also significantly increased in pheochromocytoma and 
paraganglioma (Figure I-7). To date, eight inhibitors of TH have been studied. One of the 
inhibitors, alpha-methyl-p-tyrosine (AMPT), was used to treat pheochromocytoma; however, use 
was discontinued because of severe side effects. In general, inhibition of TH may rely on a small 
therapeutic window for safe usage, because of the crucial role of the enzyme in dopamine 
synthesis. 
Vascular endothelial growth factor C (VEGFC) 
VEGFC is a dimeric, secreted growth factor in the VEGF (vascular endothelial growth 
factor) family. The VEGF family contains five members, VEGFA, placenta growth factor (PGF), 
VEGFB, VEGFC, and VEGFD, and acts by binding tyrosine kinase VEGF receptors on the cell 
surface. VEGFC binds and activates VEGFR-2 and VEGFR-3. VEGFC is overexpressed in 
peripheral blood mononuclear cells and plays an important role in lymphoangiogenesis.147 VEGFC 
is also strongly overexpressed in patients with thyroid cancer (Figure I-7). Furthermore, VEGFC 
expression is upregulated in brain tumors including GBM and haemangioblastomas, suggesting 
this protein is important for tumor-associated inflammation.148 In our analysis, increased VEGFC 
expression is strongly associated with poor overall survival (p = 7.08 x 10-7). Expression of 




is targeted by microRNA-144 and microRNA-186 to halt tumor growth in cervical and bladder 
cancer, respectively.151, 152 High expression of this protein in GBM suggests VEGFR-3 plays a 
vital role in cancer proliferation, potentially as much as VEGFR-1. CS2164 is a novel multi-kinase 
inhibitor that targets VEGFR1, VEGFR2, VEGFR3, PDGFR alpha, c-Kit, Aurora kinase b, and 
CSF-R1, and exhibited anti-tumor potency in mouse xenograft models of colon, lung, liver, and 
stomach cancer.153 Inhibitors of VEGFR-1 or VEGFR-3, or inhibitors of the maturation of 
VEGFC, could be efficacious in GBM, based on the strong correlation between poor prognosis in 
several cancers and VEGFC expression. 
Chromosome 20 open reading frame 166 antisense RNA 1 (C20orf166AS1) 
C20orf166AS1 is an 8.5-kb long noncoding RNA (lncRNA). C20orf166AS1 was reported 
as a prostate-cancer-specific lncRNA that was negatively correlated with prostate cancer.80 
Analysis of TCGA samples supports these findings; C20orf166AS1 is consistently higher in 
prostate adenocarcinoma patient samples than in normal tissue (Figure I-7). In our analysis, 
increased C20orf166AS1 expression is strongly associated with poor overall survival (p = 3.6 x 
10-7). Aside from its possible role in prostate cancer, C20orf166AS1 function has not been fully 
elucidated. 
Protein targets identified via proteomic approaches 
Although the application of modern proteomic approaches has yet to reach its full potential 
in GBM research, several important studies have identified potential drug targets. Traditionally, 
proteomics has been performed with 2DGE and mass spectrometry. While useful, 2DGE has 
several major limitations. For example, 2DGE cannot detect low abundance proteins, proteins with 




proteins with isoelectric point (pI) values outside the pH range go undetected, including important 
GBM proteins such as EGFR and VEGFR.155 Proteomic technologies have overcome these 
challenges with several methods, namely targeted mass spectrometry via Selected Reaction 
Monitoring (SRM), iTRAQ, and SWATH-MS (Sequential Window Acquisition of All Theoretical 
Mass Spectra). Here we discuss several preclinical protein targets involved in GBM identified via 
proteomic approaches. 
Several GBM proteomic studies have identified annexin A2 as a possible drug target.30, 32, 
156 Annexin A2 is a calcium-binding cytoskeletal protein expressed in cancer cells and is strongly 
correlated with tumor aggression, metastasis, and glioma patient survival.33 The protein aids the 
conversion of plasminogen to plasmin, a serine protease that activates metalloproteinases and 
degrades the extracellular matrix to promote cell metastasis.157 Consistent overexpression of 
annexin A2 emphasizes its role in various subtypes of GBM. Thus, annexin A2 may be a promising 
drug target. Small molecule annexin A2 inhibitors have been developed to prevent human 
papilloma virus.158, 159 Further validation of annexin A2 inhibitors in models of GBM is warranted.  
One study identified nine potential GBM targets by comparing microarray data sets of 
neural stem cells and GBM stem cells and further validating the findings with RT-PCR and 
Western blot.160 Nine overexpressed proteins: PBK, CENPA, KIF15, DEPDC1, CDC6, DLG7, 
KIF18A, EZH2, and HMMR, correlated with poor patient survival and are potential GBM drug 
targets. CENPA was further validated as a potential target in GBM initiating cells.161 PBK is a 
MAPKK involved in p38-mediated cell motility and DNA damage response162 and has been 
validated in vivo as a GBM target.163 EZH2 has also been validated as a target in GBM, and 




pathway, was associated with decreased astrocytic glioma patient survival.166 Additionally, 
HMMR was validated as a potential target for GBM stem cell inhibition.167 The other proteins 
have not been validated further in the context of GBM but may also represent potential drug 
targets. 
Proteomic approaches may also explain potential reasons for drug or target failure. To 
determine why anti-angiogenic therapies failed, a proteomic approach based on SRM was 
employed on patient-derived intracranial GBM xenografts in rodents.49 Levels of tricarboxylic 
acid cycle enzymes such as isocitrate dehydrogenase and aldehyde dehydrogenase decrease in 
response to anti-angiogenic therapy, suggesting the cells evade death by increasing glycolysis.49 
Additionally, a systems-based statistical analysis of a proteomic and transcriptomic signature of 
GBM was identified, concluding a strong link between GBM invasive properties and the TGF-β 
signaling pathways.168 Targeting these pathways may inhibit GBM proliferation; however, target 
validation is necessary to rule out proteins that do not drive tumor growth.  
Target validation 
Correlation between gene expression and patient survival does not necessarily indicate the 
gene (or protein) is critical for tumor progression, or a viable drug target. For example, tyrosine 
hydroxylase is required for the synthesis of dopamine, and inhibition of TH, at least by the reported 
inhibitors, showed significant adverse effects. Therefore, rigorous validation of the 20 genes 
determined from TCGA analysis is crucial to move forward and develop a viable treatment option 
for GBM. 
Clinical trials fail often due to insufficient target validation in the preclinical stage of the 




knockdown can be used to assess tumor growth in vitro and in vivo. Gene knockouts that 
significantly inhibit tumor growth would be pursued for druggability. High throughput small 
molecule binding screens of each target could be run, using differential scanning fluorimetry or 
other binding determination methods. For targets with selective inhibitors, further validation can 
be performed. While our TCGA analysis results demonstrate a potential direction for GBM drug 
discovery research, target validation is required before further effort is used to develop inhibitors 
of these targets. 
Synthetic lethality  
GBM tumor heterogeneity will likely render single target inhibition ineffective. In general, 
combination therapies are necessary to halt tumor growth. A potential approach to identify 
synergistic interactions is to perform “synthetic lethal” screens. Synthetic lethality is the concept 
that a combination of two or more gene mutations or alterations is necessary for cell death, and the 
mutation or inhibition of only one of the genes allows tumor cells to survive.169 Synthetic lethal 
combinations can be identified via several strategies. For example, large, short hairpin RNA 
(shRNA) libraries can be used to screen cell lines with an inhibitor, that, when in combination with 
certain shRNAs, causes a lethal phenotype. Synthetic lethal pairs can also be discovered 
computationally, by mining large datasets. Using this method, the known synthetic lethal 
relationship between P53 and PLK1 was validated by comparing patient survival data with pairs 
of genes in which the expression of one of the genes was under-represented.170 
   Several other synthetic lethal combinations have been identified in the context of GBM. Large-
scale, shRNA library screening identified that the inhibition of MYC, P38MAPK, or ERK signaling 




synthetically lethal with pharmacological stabilization of P53.172 P53 mutations have also 
sensitized GBM cells to combined p-AKT inhibition and radiation, by antagonizing DNA repair.173 
Furthermore, IDH1-mutated gliomas are potentially more susceptible to BCL-xL inhibition than 
other gliomas.174 Continued work in this area is expected to generate novel effective treatment 
strategies for GBM. 
Preclinical models of glioblastoma 
Preclinical in vivo models of GBM can recapitulate hallmarks of cancer including tissue 
invasion, sustained angiogenesis, evasion of apoptosis, and cancer-specific metabolism that cannot 
be modeled in vitro. Robust models of GBM that mimic the human tumor microenvironment are 
needed to assess drug safety profiles and reduce clinical trial failure. There are three major types 
of preclinical GBM models: chemically induced models, xenograft models, and genetically 
engineered mouse models (GEMMs). Some of the current and state-of-the-art strategies for 
developing animal models of GBM will be summarized here.175, 176  
GBM mouse models have evolved in an attempt to mirror human tumor characteristics and 
microenvironment. One of the earliest models, the chemically induced GBM tumor, is generated 
by treating rats with N-nitroso compounds. The spontaneity of tumor generation in this model 
provides insight about the underlying molecular pathways involved in chemically induced 
mutagenesis. However, the rat tumors generally do not model human GBM histological 
characteristics, and cell lines suffer from genetic drift.175 Xenografts of human tumor cell lines 
injected into immunodeficient mice have also been used. However, these models can be difficult 
to establish and do not factor in immune response or changes in stromal environment.175 Therefore, 




of the human GBM tumor genome, which confirmed key mutations that drive oncogenesis. 
Compounds of interest can be tested on several variations of GEMMs, including those generated 
via combinations of P53, PTEN, NF1, RB, and PDGF alterations.177 GEMMs have also provided 
valuable insight on the cell of origin of GBM. For example, GBM tumors can form in mice with 
conditional tumor suppressor alleles of NF1, P53, and PTEN that are injected with cre 
recombinase-expressing adenovirus.178 The downsides of GEMMs are that they can be costly and 
time-consuming, and do not exhibit the heterogeneity of human GBM tumors. Additional in vivo 
models include orthotopic models in which GBM cells are injected intracranially, and patient-
derived xenograft (PDX) models, in which primary patient tumors are cultured and implanted in 
mice subcutaneously.179 Furthermore, a Human Glioblastoma Cell Culture (HGCC) open resource 
has been organized to promote in vitro and in vivo testing.180 The HGCC resource contains a bank 
of 48 GBM cell lines derived from patients, for translational research use. This bank allows robust 
in vivo representations of GBM to promote new discoveries. Numerous in vivo models of GBM 
exist, but none perfectly capture the complexity of tumor biology and microenvironment.  
Because each GBM tumor model has its shortcomings, there remains a need for better 
preclinical models for compound screening. One strategy to meet this need involves avatar mice 
and co-clinical models of GBM.181 The mouse avatar allows efficient testing of different treatment 
strategies by implanting GBM tumor tissue resected from the patient into mice with the goal of 
selecting a promising therapy for each individual patient.181 Unfortunately, grafted PDX tumors 
are altered by the mouse biology and do not predict response to treatment with great accuracy.182 
CRISPR/Cas9 technology was previously used to generate P53, PTEN, and NF1 gene deletions in 




development, the need for an accurate model of GBM still exists. In general, in vivo models that 
mimic human intratumoral heterogeneity, tumor initiation, and tumor microenvironment are 
needed to accurately assess in vivo efficacy of a drug.  
Blood-brain barrier  
Characteristics of the blood-brain barrier 
The BBB is responsible for nutrient transport, homeostasis, and communication between 
the body and the brain and also prevents foreign substances from reaching the brain. Research on 
the BBB dates to the 1880s, when a barrier to the transport of solutes from the blood to the brain 
was discovered. Paul Ehlrich furthered BBB research with experiments demonstrating that passage 
into the brain of peripherally injected dyes was impeded. Small molecule permeability of the BBB 
is an important consideration for drug development. Not only does the BBB impede small 
molecule transport, but active BBB transporters clear foreign material that passes the protective 





Figure I-8 The blood-brain barrier protects the brain from foreign material with a layer of endothelial cells bound by adherens 
junctions (i.e. vascular endothelial (VE)-cadherin) and tight junctions (i.e. junction adhesion molecules (JAMs), endothelial cell 
adhesion molecule (ESAM), claudins, and occludins). 
The BBB is composed of a monolayer of endothelial, ependymal, and tanycytic cells held 
together by restrictive tight junctions (Figure I-8). Two types of cellular junctions halt passive 
diffusion and prevent leakiness between the endothelial cells: intercellular adherens junctions and 
paracellular tight junctions. Adherens junctions are composed of vascular endothelium, cadherin, 
actinin, and catenin.184 Tight junctions consist of three major proteins: occludin, claudin, and 
junction adhesion molecules. Occludins are regulated by phosphorylation of serine, tyrosine, and 
threonine residues. Junction adhesion molecules regulate the formation of tight junctions during 
the acquisition of cell polarity.185 Furthermore, there are several other important cytoplasmic 
accessory proteins including zonula occludens and cingulin. Altogether, these proteins maintain 




Nutrients and small molecules may be transported in and out of the brain by various 
methods, including passive diffusion, carrier-mediated transport, endocytosis, and active transport. 
Small biomolecules, such as water and various lipid-soluble molecules, are transported by passive 
diffusion. Typically, small lipophilic compounds will diffuse through the BBB; however, these 
properties make compounds more likely to be P-glycoprotein (Pgp) substrates or be taken up by 
peripheral tissues.186 Thus, while lower molecular weight and ClogP values are often optimal in 
theory for CNS drug discovery, the determination of appropriate values is a balancing act. Carrier-
mediated transport is driven by two major protein families, the solute carrier (SLC) superfamily 
and ATP binding cassette (ABC) transporters. The main function of these transporters is to carry 
essential amino acids and glucose from the blood to the brain. Carrier-mediated transport may be 
hijacked by drug delivery. For example, System L has a broad substrate specificity for large 
molecules, and, therefore, can transport levodopa.187, 188 Endocytosis imports nutrients such as 
insulin via the formation of intracellular transport vesicles.189 Active transport requires energy in 
the form of ATP hydrolysis; the µ-opioid agonist fentanyl is likely taken up into the brain via 
active transport mechanisms.190 However, due to the complexity of the BBB neovascular unit, drug 
uptake and efflux likely proceed via multiple transport pathways.  
The BBB poses several challenges for effective drug discovery. One challenge is reaching 
and maintaining effective CNS permeation and drug concentration. The brain uses efflux pumps 
at the luminal side of the BBB to recognize and remove foreign substances. In particular, ABC 
transporters prevent a large influx of lipophilic molecules, xenobiotics, toxic metabolites, and 
drugs.191 CNS tumors compromise the structural integrity of the BBB, causing it to be leaky at the 




site, the BBB surrounding the proliferating cells at the tumor’s edge remains intact.193 Thus, BBB 
physiology and compound permeability are critical considerations for the CNS drug discovery 
process.  
BBB transporters may provide an opportunity for the pursuit of alternative drug targets. L-
dopa, melphalan, baclofen, and gabapentin are examples of drugs that cross the BBB via neutral 
amino acid transporters. Organic cation-carnitine transporters are used by verapamil, levofloxacin, 
and cephaloridine.194 Generally, compounds that use these transporters are similar in size and 
shape to the endogenous substrate of the protein. Additionally, uptake and efflux transporters can 
be inhibited by saturating the transporters. For example, saturating the LNAA (large neutral amino 
acid) transporter with LNAA competes off the excess branched chain amino acids that enter the 
brain and cause neurotoxicity in maple syrup urine disease.195 Furthermore, a recent study 
demonstrated that metastasizing cells may signal to break down the BBB with microRNA-181c, 
allowing the cells to propagate in the brain.196 As a whole, successful drug discovery and 
development will involve efficient and reliable drug delivery methods to significantly improve 
treatment.  
Blood-brain barrier computational modeling for drug discovery 
Lipinski et al. developed a groundbreaking method of screening for orally bioavailable, 
drug-like molecules by using physicochemical properties known as the “Rule of Five.”197 
Traditional CNS drugs are biased toward targeting monoamine GPCRs, transporters, and ion 
channels. Therefore, an assessment of the physicochemical properties of CNS drugs would 
conclude that CNS drugs should be small lipophilic compounds. Generally, CNS drugs are smaller 




topological polar surface area.198 However, with increasing drug discovery efforts focused on non-
traditional CNS targets, understanding of CNS-penetrant compounds could expand. To ameliorate 
this problem, a CNS multiparameter optimization (CNS MPO) algorithm was designed by Pfizer 
scientists, with the goal of streamlining the CNS drug discovery process.199 The CNS MPO 
algorithm involves six physicochemical parameters (lipophilicity (ClogP), distribution at pH = 7.4 
(ClogD), molecular weight (MW), topical polar surface area (TPSA), most basic center (pKa), and 
the number of hydrogen bond donors (HBD)) relative to CNS penetration and success. The value 
of each parameter is weighted (0-1) based on the probability of the compound crossing the BBB 
(0 = low probability; 1 = high probability). For example, it is well known that a compound with a 
ClogP value less than 0 will be less likely to cross the BBB, therefore a compound with a ClogP 
value less than zero would receive a 0 for the ClogP parameter. The total CNS MPO desirability 
score is the summation of the weighted scores based on each of the six properties, with a range 
from 0 to 6. An analysis of FDA-approved CNS drugs demonstrated 74 % have a CNS MPO 
desirability score > 4.199 To assess the BBB permeability of novel GBM clinical candidates, we 
applied the algorithm to 73 of the small molecule compounds currently undergoing clinical trials 





Figure I-9 CNS MPO Version 2 scores were calculated for 73 GBM drug candidates. Plots are shown for scores calculated for (A) 
Total CNS MPO score, (B) Molecular weight distribution, (C) LogP value distribution, (D) Polar surface area value distribution, 
(E) Hydrogen bond donor total distribution, and (F) pKa value (of the most basic center) distribution. 
We determined the CNS desirability score for 73 GBM drug candidates in clinical trials, 
using the CNS MPO.v2 algorithm (Figure I-9).200 The CNS MPO.v2 desirability score weighs five 
important CNS physicochemical properties: molecular weight, lipophilicity (ClogP), number of 
hydrogen bond donors, topical polar surface area, and pKa (of the most basic center), from 0 to 1. 
These properties were calculated with ADMET Predictor Version 8. The desirability score was the 
summation of the weighted score of each component, with the number of HBD score doubled. The 
HBD value was found to correlate strongly with BBB permeability, whereas ClogD, a variable 
used in the original equation, was somewhat redundant to ClogP and removed.200 Interestingly, 
only 37 % of the small molecule candidates in clinical trials currently have a score > 4, a much 
lower percentage than the 74 % of FDA-approved CNS drugs. This may highlight the significance 
of emphasizing BBB permeability in early-stage drug discovery and may explain future clinical 




highest, LB100 with a 5.68 out of 6, is a protein phosphatase 2A inhibitor. Compounds with a 
desirable molecular weight (score = 1) made up 23 % of the group, while an almost equal amount 
(25 %) had higher-than-optimal molecular weight values, over 500 Da. Most of the compounds 
(48 %) had a ClogP score of 1. A large portion of the compounds had a favorable TPSA (45 % 
between 40 and 90 Å2). Several of the compounds had an appropriate number of hydrogen bond 
donors as well (36 % with scores > 0.8). The majority of the compounds (64 %) had a pKa 
desirability score of 1 (pKa < 8 for the most basic center). Use of this CNS MPO algorithm together 
with other useful tools for predicting biological behavior of small molecules could enhance and 
accelerate the drug discovery process. 
Drug discovery challenges in GBM 
CNS drugs typically have a lower FDA-approval rate than non-CNS drugs. Additionally, 
oncology drug discovery attrition rates are characteristically high, second only to the therapeutic 
area of woman’s health.201 Thus, brain tumor drug discovery is characterized by major obstacles 
and historical failure.  
In a study of CNS drugs entered into clinical trials from 1990-2012, CNS drugs were 45 % 
less likely to pass Phase III trials than non-CNS drugs, with 46 % failing to show improved efficacy 
over placebo.202 Even though bevacizumab received FDA approval, other anti-angiogenesis drug 
candidates have been less effective. The Phase III “REGAL” (Recentin in Glioblastoma Alone and 
With Lomustine) trial comparing cediranib and cediranib + lomustine versus placebo in patients 
with recurrent GBM failed to reach the primary endpoint of progression-free survival (PFS) 
prolongation.203 Using a different approach, rindopepimut, a conjugate of the EGFRvIII mutation 




Phase I and II trials in combination with temozolomide. PFS and median overall survival (OS) 
were 10-15 and 22-26 months, respectively, compared to 6 and 15 months in historical controls.204 
Unfortunately, in the Phase III study, rindopepimut failed to meet OS endpoint criteria; however, 
this was due to a significant outperformance of the control arm (median OS = 21.1 months) 
compared to the treatment arm (median OS = 20.4 months).205 Trials with rindopepimut will 
continue, but this failure highlights an important obstacle faced when bringing a novel therapy to 
the market. 
Several obstacles impede the drug discovery process for GBM treatment. Challenges 
include identifying an effective target at the early research stages amidst the complex intratumoral 
molecular heterogeneity, identifying a therapy that is permeable to the BBB, and developing robust 
clinical trials to assess the effectiveness of the potential treatment. Furthermore, a recent study 
highlighted the variation in the epigenetic tumor microenvironment of in vitro and in vivo models, 
suggesting that research with in vitro cancer cell lines is a “therapeutic roadblock” to GBM drug 
discovery.206 This study identified a single gene, jumonji C-domain-containing protein 6 (JMJD6), 
as a potential target. JMJD6 interacts with bromodomain containing 4 (BRD4), and JMJD6 shRNA 
knockdown was lethal in both in vitro and in vivo models.206 
As for the pharmacokinetics of the drug, there are several important limitations to consider 
for any drug candidate. First, the compound must reach the tumor site without diffusing into other 
tissue and must reach therapeutic concentrations. For example, a retrospective pharmacokinetic 
analysis of lapatinib after a failed Phase I/II clinical trial revealed that therapeutic concentrations 
of the drug were not reached.207 Additionally, CNS drugs must be able to cross the BBB, which 




water partition coefficient of a compound (ClogP), and CNS drugs optimally have a ClogP = 2. 
The size of a compound is measured by its molecular weight and polar surface area, which are 
optimal below 450 g/mol and 90 Å2, respectively, for CNS drugs.208 This is a large obstacle for 
biologics, since EGFR antibodies cannot cross the BBB. Generally, only 0.1 - 0.2 % of an 
administered antibody crosses the BBB and reaches the tumor site.209 (Here, it should be noted 
that bevacizumab likely does not need to cross the BBB to target the VEGF receptors in the lumen 
of capillaries of blood vessels in the brain.) Drugs could be administered intratumorally, as with 
the case of DNX-2401. In a Phase I trial, DNX-2401, an oncolytic adenovirus, demonstrated 
antitumor activity with no dose-limiting side effects.210 Intratumoral injections, while effective, 
may be time-consuming, unfamiliar to oncologists, and pose biosafety concerns. Another 
consideration is the presence of Pgp efflux pumps that remove foreign material escaping past the 
BBB. While the BBB is impaired at the tumor site, allowing for increased permeability, the dense 
endothelium of vasculature providing nutrients to the tumor is not compromised, and therefore 
most of the BBB remains intact.211 These issues should be addressed in the preclinical phase, 
before bringing drug candidates into clinical trials. 
Retrospective analysis of EGFR inhibitors provided insight into their failure in GBM 
clinical trials. EGFR inhibitors are widely and effectively used in preclinical models of GBM; 
however, clinical trials with these inhibitors failed to detect any improvement in outcome. These 
tyrosine kinase inhibitors (TKI), namely erlotinib and gefitinib, likely failed clinical trials due to 
limited brain exposure from Pgp and ABCG2-mediated efflux.3, 4 Additionally, gefitinib inhibits 




absent in gliomas.212 This phenomenon suggests more rigorous preclinical research should be 
conducted before expensive clinical trials are initiated. 
A few recent successes in TKIs, osimertinib and GDC-0084, should be noted. The third 
generation EGFR inhibitor osimertinib (AZD9291) has been studied for its efficacy against non-
small cell lung cancer (NSCLC) and is undergoing a large Phase I/II trial to determine the 
maximum tolerated dose in patients with advanced NSCLC (NCT01802632). Preclinical 
evaluation of osimertinib demonstrated the compound is more BBB-permeable than gefitinib and 
other TKIs.213 Another TKI, GDC-0084, was demonstrated to cross the BBB in a first-in-human 
Phase I dose-escalation study in patients with high-grade glioma.214 Extensive structure-activity 
relationship analysis on the dual PI3K/mTOR inhibitor revealed that removal of a methyl group at 
the 2 position of the pyridine side chain of the purine-based scaffold increased cellular potency 
and human metabolic stability and decreased efflux ratios.215 Since BBB permeability has been a 
major problem with current EGFR TKIs, osimertinib and GDC-0084 both represent exciting 
inhibitors that have the potential to become efficacious treatments for brain and potentially other 
cancers. 
While recent efforts have advanced GBM drug discovery, non-pharmacokinetic problems, 
including clinical trial organization, remain a large obstacle to drug development. Because GBM 
is an orphan disease, clinical trial participation is low, which prevents the detection of subtle 
differences in treatment with statistical significance. Other challenges include determination of 
appropriate controls, stratification according to prognostic factors, and definition of clinical 
endpoint.216 In addition, it is difficult to monitor the molecular signature of a brain tumor because 




determining drug efficacy because targeted therapies may be cytostatic. In addition, biomarkers to 
measure treatment response will be useful for GBM clinical trials.  
Conclusions and future directions 
Treatment of GBM is a complex and formidable, but not unsolvable, problem. The girth of 
available genomic information directs research strategies, allowing researchers to pursue 
meaningful hypotheses supported by patterns in population-level genomics. In tandem, novel 
proteomic tools are a valuable resource that will enhance our understanding of GBM tumor 
complexity. Genomic methods have already revealed a molecular fingerprint of the disease and 
pathways on which to focus our research efforts. Despite the emergence of more specific molecular 
classifications of GBM, targeted therapies to treat specific GBM subtypes are not yet realized. 
Numerous failed clinical trials suggest combination therapies will likely be the most promising 
method of GBM treatment, and emphasis should be applied to drug design and pharmacokinetic 
properties. With this study, we have identified 20 genes that may play important roles in GBM 
progression. These genes should be validated as potential targets for GBM drug discovery, as they 
correlate with poor overall patient survival. We have also uncovered novel transcription factors 
and signaling molecules involved in GBM that may regulate EGFR signaling. Targeting 
transcription factors and membrane proteins upstream of EGFR signaling may prove a promising 
therapeutic strategy for the treatment of GBM. Several genes identified in our analysis have been 
linked with GBM or EGFR signaling in previous studies. It should be noted that gene expression 
of the 20 targets could be a consequence of oncogenic stress, rather than tumor growth and further 
target validation is necessary. This analysis may reorganize research priorities towards targeting 




approaches will be standard tools not only to identify novel drug targets, but also to identify non-






 The article in which the rationale for the CNS MPO.v2 algorithm was published was 
retracted in February 2019 by Eli Lilly in order to validate substantial changes made to the 
manuscript.200, 217 Thus, until the updated CNS MPO.v2 manuscript is published, caution should 
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Protein Disulfide Isomerase 
Historical background2 
The dithiol-disulfide oxidoreductase protein disulfide isomerase (PDI) was discovered in 
1963 as the first protein folding chaperone. Research groups led by Brunó Straub1 and Christian 
B. Anfinsen2 independently made pivotal discoveries about an enzyme that reactivated reduced 
ribonuclease. Straub and co-workers purified the reactivating system from chicken pancreas. 
Anfinsen studied the system in conjunction with his Nobel-prize-winning work on ribonuclease 
and purified a system with similar activity from rat liver microsomes. In 1972, the enzyme was 
given the name protein disulfide isomerase and its official classification number, EC 5.3.4.1. The 
newly purified protein was identified as the “ribonuclease-reactivating enzyme,” and was nearly 
identical to glutathione-insulin transhydrogenase, causing confusion in the field.3 Both enzymes 
catalyze disulfide exchanges, require a thiol for activity, and inactivate insulin. Confusion was 
cleared with key experiments using covalent chromatography to demonstrate that PDI is more 
sensitive to reducing conditions than glutathione-insulin transhydrogenase.4 The official name was 
first used in a publication on conformational barriers to disulfide bond formation in 1975.5 
Challenges in monitoring disulfide bond formation and isomerization slowed research on the 
 
2 This work has been published and is being reprinted with permission from Shergalis, A., & Neamati, N. (2017). 
Protein Disulfide Isomerase. Encyclopedia of Signaling Molecules, 1-12. 




enzyme until a pivotal review on PDI was published in 1984.6 Then, in 1985, Edman and 
colleagues identified the sequence of rat PDI, which led to the discovery that PDI contains 
sequences highly homologous to the cytoplasmic redox signaling enzyme thioredoxin.7 This 
discovery provided valuable insight into the mechanism of redox reactions catalyzed by PDI and 
indicated the active sites of PDI contained the critical WCGHC sequence. 
PDI has gained much attention in the following years due to its role in cancer, 
cardiovascular diseases, diabetes, and neurodegenerative diseases such as Huntington’s disease. 
In addition to its role as an oxidoreductase and molecular chaperone, PDI is important for several 
other physiological processes, including collagen biosynthesis, antigen presentation, and 
lipoprotein synthesis. PDI is the beta subunit of prolyl 4-hydroxylase, an essential collagen 
biosynthesis enzyme, and mutations in PDI lead to bone fragility disorders.8 In recent years, it was 
discovered that PDI is overexpressed in several cancers. Following this discovery, researchers 
have found that PDI contributes to tumor growth, progression, and chemotherapeutic resistance. 
In addition to its role in cancer, PDI has a pro-apoptotic function in Huntington’s disease and other 
brain dysfunction diseases.9 Targeting PDI function may be a promising therapeutic approach for 
multiple human diseases. The structure and function, as well as the role of PDI in various disease 
states, will be reviewed in detail in the subsequent paragraphs.  
Since there are numerous PDI family members, this chapter will focus on PDIA1, as it has 
been proven to be most relevant to several disease states. However, the other PDI family members 
will also be discussed in brief. The acronym PDI is often used to refer to PDIA1, but for clarity in 
this text, PDI will be used when making general statements about the protein family, and specific 
isoform nomenclature will be used when necessary. Several comprehensive reviews covering a 




Domain structure and isoforms 
 The PDI family consists of at least 22 members (Figure II-1) that share at least one 
thioredoxin-like fold domain (βαβαβαββα).10 PDI family members primarily reside in the 
endoplasmic reticulum (ER), but have also been found in the nucleus, cytoplasm, and on the 
plasma membrane (Table II-1). The full-length founding member of the PDI family, PDIA1, 
contains 508 amino acids, 17 of which form an ER signal peptide that is cleaved from the N-
terminal tail in the mature form. Most PDI family members contain the catalytic a and a’ domains 
that are structurally similar to thioredoxin, with the conserved CXXC active site surrounded by 
hydrophobic regions. The b and b’ domains are homologous to the a and a’ domains and also 
contain the thioredoxin-like fold, despite lacking sequence similarity to the a and a’ domains and 
the CXXC active site. The structures of several domains of mammalian,14 yeast,15 and fungal16 
PDI have been solved with X-ray crystallography and NMR; however, the full-length structure has 
yet to be resolved, likely due to its size and flexibility. The complete oxidized and reduced 
crystallized PDI structure with the exception of the C-terminal extension (i.e. containing abb’xa’ 
domains) demonstrated that the active site of the a’ domain shifts closer to the a domain active 
site upon reduction, shielding access to the hydrophobic pocket (Figure II-2).14 The b and b’ 
domains are non-catalytic; the b’ domain is primarily responsible for substrate recognition with 
help from the a’ domain, and to date, the function of the b domain is unclear. It has been suggested 
that the b domain in Pdip, a yeast paralog of PDI, plays a role in substrate recognition.15 PDI also 
contains a flexible x linker 19 amino acids long that spans between the a’ and b’ domains. The x 
region can move to obstruct the substrate binding site in the b’ domain, and therefore this 
conformational change may regulate the substrate binding cycle of PDI.15 PDI also contains an 




is important for catalytic activity of the a’ domain in yeast PDI,15 truncating the C-terminal region 
of mammalian PDI has little effect.14 
 
Table II-1 Function and subcellular localization of 22 PDI isoforms 
Isoform Subcellular Localization Function 
PDIA1 
Endoplasmic reticulum, extracellular 
space, plasma membrane 
Oxidoreductase, chaperone 
PDIA2 

















Endoplasmic reticulum, extracellular 
space, plasma membrane 
Oxidoreductase, chaperone, 
platelet aggregation and 
activation 
PDIA7 Endoplasmic reticulum Chaperone, spermatogenesis 
PDIA8 Endoplasmic reticulum Function unknown 
PDIA9 (ERp29) 
Endoplasmic reticulum, extracellular 
space 
Processes and transports 
secretory proteins 
PDIA10 (ERp44) 
Endoplasmic reticulum, extracellular 
space 
Mediator of ER retention of 
proteins such as ERO1 
PDIA11 (TMX1) 
Endoplasmic reticulum, extracellular 
space, nucleus 
Oxidoreductase 
PDIA12 (TMX2) Endoplasmic reticulum Function unknown 
PDIA13 (TMX3) Endoplasmic reticulum Oxidoreductase 
PDIA14 (TMX4) Endoplasmic reticulum Function unknown 





Endoplasmic reticulum, extracellular 




Endoplasmic reticulum Protein oxidase 
PDIA17 (AGR2, 
HAG-2) 
Endoplasmic reticulum, extracellular 
space 





Calcium-mediated regulation of 
ciliary beat frequency 
PDIA19 (ERdj5) Endoplasmic reticulum Oxidoreductase 
PDIB1 (CASQ1) 
Endoplasmic reticulum, 
mitochondrion, plasma membrane 
Calcium storage 








Figure II-1 Domain structure of PDI family members. Active site amino acids are shown. 
The PDI active sites are located on the a and a’ domains, which share 33.6% identity in 
PDIA1 and contain the four conserved amino acids Cys-Gly-His-Cys. The cysteine thiols on each 
domain sit about 30 Å apart when PDI is oxidized, and 15 Å apart when PDI is reduced.14 The 
cysteines are responsible for disulfide exchange on PDI and the kinetics of the reactions catalyzed 
by this enzyme rely on the conformation and pKa of the cysteines. For example, PDI catalyzes 
both the reduction and oxidation of various substrates, and the more favorable of the two reactions 
depends on the conformational state and pKa of the active site cysteine residues. The pKa of the 
N-terminal active-site cysteine is in the range of 4.4 to 6.7, lower than the pKa (8.3) of a typical 
cysteine thiol, allowing it to be more reactive. The pKa of the C-terminal active site cysteine is 




disulfide with the substrate. The inner histidine and glycine amino acids in the active site also 
affect the pKa of the thiols and the stability of the disulfide state.
10 
 
Figure II-2 PDI structure (A) Crystal structures of reduced (4EKZ, red) and oxidized (4EL1, blue) PDIA1. (B) Close up of the 
CGHC active site of the a domain of reduced PDIA1 and associated arginine residue (green). 
Even though the b and b’ domains contain the thioredoxin fold of the a and a’ domains, 
they are enzymatically inactive and do not contain the CGHC active site. The function of the b 
domain is still up for debate, however, the b’ domain is responsible for substrate interactions via 
a hydrophobic pocket. Exposed hydrophobic regions in unfolded or partially folded proteins 
associate with the hydrophobic region spanning the b’xa’ domain, thus allowing PDI to form 
disulfide bridges necessary for proper protein folding. Interestingly, small molecules binding in 
the substrate binding pocket can enhance PDI activity.17 
Function and regulation 
PDI catalyzes the reduction, oxidation, and rearrangement of disulfide bonds in nascent 




protein.6 It is also synthesized downstream of the unfolded protein response (UPR).18 PDI family 
members are also found on the cell surface and in the nucleus, suggesting PDI has multiple 
functions. Cell-surface PDI is involved in multiple biological processes, including glioma cell 
migration,19 T cell migration,20 and injury response.21 PDI family members that lack the ER 
retention sequence localize to other compartments such as the nucleus to influence gene 
transcription. For example, ERp57 mainly resides in the ER, but contains a nuclear localization 
signal that shuttles the enzyme to the nucleus in response to stress signals. In addition to its 
oxidoreductase activity, PDI is also involved in complex formation, substrate recognition, and 
molecular chaperone function. It is also a necessary component of the microsomal triglyceride 
transfer protein complex.22 Knockout experiments have not been reported for a whole-body PDIA1 
knockout model.  
PDI activity is regulated by the redox state of its active site cysteine thiols. In the oxidizing 
environment of the ER, the enzyme is primed to reduce free thiols on other proteins. ER 
oxidoreductin 1 (ERO1), a FAD-cofactor-containing enzyme, recycles PDI for reuse (Figure II-3). 
PDI expression is also regulated by ER stress and the unfolded protein response.18 Three central 
proteins are activated in response to the UPR, which is an overloading burden of unfolded proteins 
on the ER, to maintain homeostatic balance. One of these central effectors, PERK, is a kinase that 
phosphorylates eIF2α, a transcription factor that translocates to the nucleus and attenuates 





Figure II-3 Role of PDI in the endoplasmic reticulum. PDI catalyzes the oxidation and isomerization of misfolded proteins in the 
ER. PDI is reoxidized by ERO1, or PRDX4 in the presence of oxidized glutathione. Impairment of PDI activity leads to the unfolded 
protein response, which activates IRE1, PERK, and ATF6. IRE1 splices XBP1 mRNA, which causes it to translocate to the nucleus 
and promote gene expression. PERK phosphorylates eIF2a to inhibit translation and activate ATF4. ATF4 translocates to the 
nucleus and promotes autophagy and cell survival. ATF6 is also modified in the Golgi apparatus and translocated to the nucleus to 
impact ER biogenesis and ERAD to promote cell survival. ERSE: Endoplasmic reticulum stress element. XBP1u: X-box protein 1 
unspliced variant. XBP1s: X-box protein 1 spliced variant. 
PDI catalyzes three different types of reactions (Figure II-4). The first is the oxidation of a 
protein or peptide substrate to the disulfide state. The second is the reduction of a protein or peptide 
disulfide bond. The third reaction PDI is able to catalyze is an isomerization of a mixed disulfide 
bond in a protein or peptide substrate. The oxidoreductase activity of PDI depends on the reduction 




maintain a sufficiently high reduction potential to form intermediate disulfide species with a 
protein substrate. The transient heterodimer is attacked by the low-pKa C-terminal thiol in the 
“escape pathway,” forming an intramolecular bridge and displacing the thiol. A model substrate 
peptide consisting of 12 amino acids bound PDI with an apparent KM value less than 3 μM in an 
experiment analyzing disulfide bond formation.23 While PDI is generally understood to have 
several folding protein and peptide substrates, only a handful have been experimentally 
determined. These include bovine pancreatic trypsin inhibitor, Δ-somatostatin, mastoparan, 
insulin, and RNase. Interestingly, while PDI does exhibit flexibility in its a’ domain through the x 
linker, substrate binding studies reveal that the protein and peptide substrates of PDI are more 
likely to change conformation to fit into the hydrophobic binding pocket.10 After the reaction takes 
place, oxidized or reduced PDI can be recycled by a number of agents, including glutathione and 
ERO1. 
 
Figure II-4 Multifunctional roles of the PDI family. PDI catalyzes the oxidation (A), reduction (B), and isomerization (C) of 
cysteine thiols on substrate peptides and proteins. 
Before ERO1 was discovered in 1998, the consensus was that glutathione, the primary 




that in its reduced state, PDI is predominantly reoxidized by ERO1. There are two mammalian 
isoforms of ERO1: ERO1α and ERO1β. ERO1α is well-characterized and its activity is tightly 
regulated by the redox environment. The activity of ERO1β is less well-characterized, but it is less 
tightly regulated than ERO1α. The ERO1 enzymes rely on molecular oxygen as the electron 
acceptor and in return for each disulfide bond formed, produce one molecule of H2O2. ERO1 
primarily oxidizes PDIA1, and, to a lesser extent, ERp46.24, 25 Other PDI isoforms are selectively 
recycled by enzymes such as peroxiredoxin 4 (PRDX4) and vitamin K epoxide reductase (VKOR). 
In addition to ERO1 reoxidation, H2O2, PRDX4, docosahexaenoic acid (DHA), and 
vitamin K can reoxidize PDI.10 Moreover, several members of the PDI family can undergo 
disulfide exchanges with each other, without the need for an outside oxidant or reductant.26 The 
cysteine thiols in the active site of PDI are common in other redox-sensing proteins. The low pKa 
value of the active site thiols (around 4.4 to 6.7) means that at physiological pH, the residue is 
deprotonated as a thiolate anion (R-S-). The thiol group of typical cysteines is protonated (R-SH) 
and renders the group unreactive at physiological pH. The charge on the thiolate anion in PDI is 
stabilized by a charge–charge interaction with the nearby positively charged Arg120.27 The 
substrate binding/release cycle of PDI may be dependent on the redox state of the CXXC active 
sites. Oxidized PDI takes on an open conformation, promoting accessibility of the hydrophobic 
binding pocket. After PDI transfers a disulfide bond to its substrate, the conformational shift shuts 
off accessibility to the binding pocket. In addition to redox regulation, PDI can be regulated by 
other post-translational modifications, such as S-nitrosylation. 
Cell-surface PDI is regulated by S-nitrosylation on the thiol active sites, which has been 
shown to contribute to neurological diseases such as Alzheimer’s disease.28 S-nitrosylation can 




among other functions. Aberrant S-nitrosylation leads to protein misfolding that can stimulate 
synaptic loss and contribute to the pathogenesis of Alzheimer’s disease. 
PDI also plays a role as the noncatalytic β subunit of prolyl 4-hydroxylase (P4H).29 The 
P4H complex consists of two non-catalytic PDI subunits and two catalytic α subunits. P4H resides 
in the ER and catalyzes the proline hydroxylation of procollagens, crucial for mature collagen 
function. Hydroxylation of collagen is critical for the stability of the collagen triple helix. PDI is 
necessary to prevent the α subunit from aggregation and is likely responsible for maintaining ER 
localization of the complex.30 
Another well-established function of PDI is as a critical component of the microsomal 
triglyceride transfer protein (MTP) complex.22 MTP is composed of an αβ heterodimeric complex 
in which PDI makes up the smaller β subunit. MTP is a lipid transporter necessary for the 
biosynthesis of apolipoprotein B (apoB)-containing triglyceride-rich lipoproteins, regulation of 
cholesterol ester synthesis, and propagation of hepatitis C virus. The reduction, oxidation, and 
isomerization functions of PDI are not necessary for MTP to function properly; therefore, PDI 
likely plays a role in structural stability and solubilization of the complex.31 
 PDI also aids peptide loading onto major histocompatibility complex class 1 (MHC-1).16 
The MHC-1 complex binds antigenic peptides as they are synthesized through the ER and presents 
the synthesized peptides to cytotoxic T lymphocyte cells. 
Functions in disease 
Proper protein folding is essential for cellular homeostasis and signaling. Aberrant PDI 
expression leads to several types of diseases caused by misfolded proteins (Figure II-5). Therefore, 
PDI inhibitors may be important for preventing and curing a wide range of diseases. For example, 




knockdown of PDI in breast cancer cells leads to cell death via apoptosis.32 In models of 
Huntington’s disease, PDI induces apoptosis via mitochondrial membrane permeabilization 
(MOMP), and inhibition of PDI suppresses cell toxicity.9 Protein folding malfunctions also play 
an important role in diabetes due to the link between diabetes, misfolding of proinsulin, and the 
UPR. Malfunctions in PDI caused by mutations in PDIA1 and ERp57 contribute to abnormal 
motor control and dendritic morphology.33 
 
Figure II-5 PDI plays an important role in various disease states. In cancer, PDI folds nascent proteins to contribute to cell migration, 
invasion, and metastasis. In neurodegenerative diseases, SNO modification of PDI renders the enzyme incapable of protein folding, 
leading to the formation of Lewy bodies, inclusion bodies, amyloid β and hyperphosphorylated tau. In diabetes, PDI contributes to 
the production of insulin from proinsulin, but it also inhibits insulin secretion into the bloodstream, preventing insulin from lowering 
blood glucose levels. In cardiovascular diseases, in particular atherosclerosis, PDI is required for the PDGF-catalyzed vascular 






The connection between cancer and several PDI family members has been the subject of 
intense study for over a decade. In most cases, higher expression of PDI is protective for the cancer 
cells and correlates with poor patient survival. Inhibition of PDIA1 is cytotoxic to ovarian cancer 
cells.34 In breast cancer mammospheres, knockdown of PDIA1, ERp44, or ERp57 inhibits cell 
growth.35 Increased PDIA3 and PDIA6 gene expression correlates with aggressiveness of primary 
ductal breast cancer,36 and high AGR2 expression is inversely correlated with survival in lung 
cancer patients.37 
Although PDI inhibitors have yet to reach clinical trials, for the past several years, PDI has 
been actively pursued as a small molecule drug target. Several PDI inhibitors that interact with the 
reactive cysteine thiol active site have been identified for ovarian cancer,34 multiple myeloma,38 
and other cancers. A propynoic acid carbamoyl methyl amide, PACMA31 was demonstrated to be 
an orally bioavailable PDI inhibitor with anti-cancer properties against ovarian cancer.34 Small 
molecule inhibitors of PDI will be efficacious as cancer treatments, and research is actively being 
pursued in this area. 
Neurodegenerative diseases 
A common pathological characteristic of neurodegenerative diseases such as Alzheimer’s, 
Parkinson’s, and amyotrophic lateral sclerosis (ALS) is the misfolding of proteins. Changes in 
redox homeostasis in such cases can lead to impairments in PDI function. PDI malfunction is 
involved in protein misfolding in Alzheimer’s, Parkinson’s, and Huntington’s disease, as well as 
ALS and prion diseases. Increased levels of reactive oxygen species (ROS) and reactive nitrogen 
species (RNS) can modify target proteins. For example, the reactive thiol group on the CGHC 




S-nitrosylation is a post-translational modification in which nitric oxide species attach to a thiol to 
form an S-nitrosothiol. It can occur as a form of redox signaling, but has also been implicated in 
disease states. In the case of Alzheimer’s disease, disruption of normal PDI function by S-
nitrosylation triggers an important signaling event that leads to α-synuclein oligomerization.11 
Interestingly, normally-functioning PDI inhibits tau fibrillization, a possible contributor to the 
pathogenesis of Alzheimer’s disease.  
Similarly, under normal physiological conditions, PDI forms a complex with α-synuclein, 
which are protein aggregates common in Lewy bodies. PDI prevents protein aggregation in 
Parkinson’s disease.11 Patients with Parkinson’s disease also exhibit upregulated levels of brain 
PDIp.39 This suggests that PDI is upregulated in response to increased levels of ER stress; however, 
heightened levels of RNS lead to S-nitrosylation of PDI and prevent the enzyme from halting 
aggregate formation.  
PDI inhibitors are also effective in models of Huntington’s disease.9 Huntington’s disease 
is caused by a mutation in the huntingtin gene that causes the huntingtin protein to fold incorrectly. 
As a response to the mutant huntingtin protein, PDI localizes to the mitochondrial membrane and 
induces MOMP, an event in the intrinsic apoptotic pathway. Inhibitors of PDI are in pre-clinical 
development as a treatment for Huntington’s disease and may be applicable to a wide range of 
neurodegenerative diseases. 
Diabetes 
Dysfunction of human islet amyloid polypeptide (hIAPP) leads to misfolding events in 
diabetes similar to those contributing to the pathogenesis of Alzheimer’s disease.40 In addition, the 
hyperglycemic and hyperlipidemic conditions that occur with diabetes lead to a disruption in ER 




aggregation. Therefore PDI plays an important role in diabetes, but this role varies depending on 
several conditions.41 PDI also interacts with proinsulin in the ER of pancreatic β-cells, and blocks 
insulin export.42 PDI acts as a retention factor for proinsulin in β-cells, and PDI represents an 
attractive potential target in Type II diabetes.  
Other diseases 
The importance of PDI as an ER chaperone and oxidoreductase is realized under 
pathological conditions. PDI has also been implicated in several other protein conformation 
diseases, including liver disease, atherosclerosis, viral infection,43 and prion diseases.12 
Atherosclerosis is the hardening or thickening of the arteries, caused by plaque formation due to 
high cholesterol levels and other factors. In atherosclerosis, PDI is required for platelet derived 
growth factor (PDGF)-induced vascular smooth muscle cell migration that causes platelet 
accumulation.44 In platelets, PDI is localized in storage granules and on the extracellular surface 
of cells within the dense tubular system. UPR activation is involved in liver disease onset and 
progression.45 In viral infections, thiol-disulfide exchange is important for HIV-1 entry in primary 
T-lymphocytes and human monocyte-derived macrophages. Both PDI and thioredoxin play 
essential roles in this process. 
Summary 
Over 30% of secreted proteins rely on disulfide bond formation to both stabilize their 
tertiary structure and function properly. Thus, PDI is a crucial protein for the maintenance of 
cellular protein homeostasis. As a multifunctional protein with oxidoreductase and chaperone 
activity, PDI can be found not only in the ER, but also at the cell surface and in other locations in 
the cell. PDI overexpression is involved in various cancers, and PDI inhibitors are crucial tools for 




diseases. Both inhibitors of PDI function and inducers of PDI expression would be beneficial to 
combat PDI activity in different scenarios. For example, PDI inhibitors would be beneficial against 
cancer and viral infection; however, PDI oxidizers may prove useful against certain neurological 
diseases. PDI inhibitors are currently under pre-clinical development for many of these diseases 
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CHAPTER III  
Discovery and Mechanistic Elucidation of a Class of PDI Inhibitors for the Treatment of 
Glioblastoma 
Introduction3 
Glioblastoma is the most common type of malignant central nervous system (CNS) tumor. 
Prevalence increases with age with peak incidence in individuals aged 60-79 years.1 Despite the 
treatment options available – surgical resection followed by chemoradiotherapy and adjuvant 
chemotherapy (temozolomide) – the five-year survival rate of patients diagnosed with 
glioblastoma is only 5.0 %.1, 2 Current treatments are marginally effective and the number of cases 
is expected to grow with the aging population, emphasizing the urgent need for the development 
of novel and effective therapies for glioblastoma. Disease recurrence and drug resistance remain 
the major challenges for a successful cure.  
Protein disulfide isomerase (PDI; EC 5.3.4.1) is a 57-kDa endoplasmic reticulum (ER) 
oxidoreductase of the thioredoxin superfamily that assists protein folding in the ER by catalyzing 
 
3 This work has been published and is being reprinted with permission from Kyani, A., Tamura, S., Yang, S., Shergalis, 
A., Samanta, S., Kuang, Y., Ljungman, M., & Neamati, N. (2018). Discovery and Mechanistic Elucidation of a Class 
of Protein Disulfide Isomerase Inhibitors for the Treatment of Glioblastoma. ChemMedChem, 13(2), 164-177. 
Author contributions: Anahita Kyani, Shuzo Tamara, Suhui Yang, and Andrea Shergalis were the primary authors. 
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cytotoxicity data. Soma Somanta generated figure III-2, I-5, I-6, and I-7. Yuting Kuang performed experiments to 
generate figure III-6. Suhui Yang synthesized all compounds. Mats Ljungman generated figure III-5. Nouri Neamati 




disulfide rearrangements (isomerase activity), disulfide formation (oxidase activity), and disulfide 
reduction (reductase activity).3 PDI is overexpressed in several cancers but most significantly in 
glioblastoma.3 Previously, we demonstrated that PDI knockdown by siRNA leads to substantial 
cytotoxicity in ovarian cancer cells.4 PDI inhibitors and modulators are being developed to combat 
cancer and neurological diseases. The PDI inhibitor bacitracin inhibits migration and invasion of 
glioblastoma cells5 and enhances apoptosis caused by ER stress-inducing agents in melanoma 
cells.6 Another class of compounds, including PS89, are weak reversible inhibitors of PDI and, at 
moderately high concentrations, sensitize several cancer cell lines to etoposide treatment.7 
Interestingly, after further characterization, BAP31 (B-cell receptor-associated protein 31) was 
identified as the major target of PS89, instead of PDI.8 A reversible, selective, non-toxic PDI 
inhibitor, ML359, was developed as a probe to study thrombosis-related diseases.9 Modulators of 
PDI have also been shown to be neuroprotective. A reversible PDI modulator, LOC14 (EC50 = 
500 nM), has neuroprotective effects in cellular and rat models of Huntington’s disease.10 
Furthermore, PDI inhibitor CCF642 was demonstrated to be effective in a mouse xenograft model 
of multiple myeloma.11 Mounting evidence highlights PDI as an important target against several 
diseases including cancer, emphasizing the need for potent, clinically relevant PDI inhibitors for 
cancer treatment.  
Herein, we report on the development of 35G8 as a novel and potent PDI inhibitor that 
demonstrates activity in brain cancer cells and has drug-like properties. The activity of 35G8 in a 
diverse set of robust assays confirmed that the initial observation of activity was not a consequence 
of its redox-cycling status. Results from nascent RNA Bru-seq12 analysis showed that the 
transcription of 498 genes increased and 238 genes decreased at least 2-fold following a 4-hour 




the upregulated genes to be involved in the Nrf2 antioxidant response and the unfolded protein 
response (UPR). Genes with decreased transcription involved histone and DNA repair pathways. 
In addition, 35G8 upregulates two key genes, SLC7A11 and HMOX1, and may kill cells through 
an iron-dependent form of cell death independent of apoptosis and necrosis, called ferroptosis.13 
The alterations in the transcriptional landscape induced by 35G8 provide a more comprehensive 
understanding of the mechanisms of PDI inhibition in brain cancer therapy. 
 
Results and discussion 
35G8 is a nanomolar inhibitor of PDI 
To identify cytotoxic small molecules, we screened a highly diverse library of 20,000 
compounds, representing over one million compounds, in the colon cancer cell line HCT116 
(Figure III-1). From the initial screen, we identified 443 cytotoxic compounds with IC50 values 
under 10 μM. These 443 compounds were tested for PDI inhibition in an insulin turbidity assay.14 
Eight compounds demonstrated potent inhibition (IC50 < 1.0 μM), and after confirming the activity 
with re-purchased compound stocks and verifying a dose-dependent response, the most potent 
compound, 1,3,6-trimethylpyrimido[5,4-e] [1,2,4] triazine-5,7(1H,6H)-dione (35G8), was 





Figure III-1 Discovery of 35G8. Workflow summarizing the screening process that identified 35G8 as a potent PDI inhibitor. 
20,000 compounds were screened in an MTT assay with HCT116 cells and 443 compounds were cytotoxic in these cells. The 443 
compounds were tested further in an insulin turbidity assay; 35G8 had the most potent IC50 value and was taken for further 
biochemical analysis and optimization. 
We next used the thermal shift assay15 to validate whether 35G8 stabilizes its presumed target, 
PDI. Intriguingly, 35G8 destabilized PDI, indicated by the decrease in melting temperature of the 
protein (Figure III-2). The dose-dependence of the negative thermal shifts at all concentrations 
tested (ΔTm: −3.64 °C at 100 µM; −2.94 °C at 10 µM; −1.43 °C at 1 µM) provides further evidence 
that 35G8 associates with and destabilizes PDI. The melting temperature of a protein shifts 
positively or negatively in the presence of a ligand, and this change in melting temperature parallels 
the stability of the protein.16 These results suggest 35G8 interacts with PDI at a unique site 




PDI, we performed the cellular thermal shift assay (CETSA) and drug affinity responsive target 
stability (DARTS) assay. 35G8 also destabilized PDI via CETSA (Figure III-2). 35G8 had little 
effect on a related molecular chaperone, GRP78, but did seem to stabilize the cysteine-containing 
glutathione-transferase Omega 1 (GSTO1). In the DARTS assay, U87MG cell lysates were 
subjected to pronase degradation in the presence or absence of PACMA31 or 35G8. Both 
compounds protected PDI from proteolysis, but had no effect on the degradation of GRP78 or 
GSTO1. These results established 35G8 as a potent, selective inhibitor of PDI. 
 
Figure III-2 35G8 destabilizes PDI. (A) Thermal shifts observed for recombinant PDI (0.3 mg/ml) with various concentrations of 
35G8. DMSO was used as a control. (B) Apparent melting temperatures (Tm) and change in melting temperature derived from 
ThermoFluor assay (C) Protein expression of PDI, GRP78, GSTO1, and actin (loading control) in the absence or presence of 35G8 
at varying temperatures in the cellular thermal shift assay (D) Western blot analysis of DARTS assay with PDI, GRP78, and GSTO1 
subjected to 100 μM PACMA31 (P), 100 μM 35G8 (G), or DMSO (-). Samples were subjected to varying concentrations of 





Table III-1 PDI inhibitory activity of 35G8 analogues. IC50 values obtained in insulin turbidity assay. Data are means ± standard 
deviation from three independent experiments. 
[a] 1,3,6-Trimethylpyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione. [b] 1,6-Dimethyl-3-phenylpyrimido[5,4-e][1,2,4]triazine-
5,7(1H,6H)-dione. [c] 3-Benzyl-1,6-dimethylpyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione. [d] 3-(4-Methoxyphenyl)-1,6-
dimethylpyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione. [e] 3-(3-Methoxyphenyl)-1,6-dimethylpyrimido[5,4-e][1,2,4]triazine-






Compound Basic Module R1 R2 IC50 (μM) 
35G8 (4a)[a] A CH3 CH3 0.17 ± 0.01 
4b[b] A 
 
CH3 0.39 ± 0.03 
4c[c] A 
 
CH3 0.33 ± 0.04 
4d[d] A 
 
CH3 0.36 ± 0.05 
4e[e] A 
 
CH3 0.32 ± 0.01 
4f[f] A 
 
CH3 0.24 ± 0.04 
5d[g] B 
 
CH3 0.42 ± 0.07 
NC72 (NSC67078) A H CH3 0.105 ± 0.004 
NC75 (NSC99733) A H H         > 120 
NC79 (NSC280172) B CH3 CH3 6.55 ± 1.19 




We also synthesized several analogues of 35G8 to validate the above findings. The lead 
compound, 35G8, contains methyl substituents at the three N1, C3, and N6 positions (Figure III-1). 
We incorporated various substituents at the C3 position while maintaining the methyl groups at 
N1 and N6 due to the efficient introduction of the N1 and N6 methyl groups early in the synthesis 
(Scheme III-1). Nucleophilic attack of methylhydrazine on 6-chloro-3-methyl uracil (1) led to 
hydrazinylpyrimidine-2,4(1H,3H)-dione (2a).18 Further condensation with aldehydes furnished 
the corresponding hydrazones (3a-f). Each hydrazone was cyclized by treatment with sodium 
nitrite in acetic acid/water to afford a mixture of pyrimidotriazinediones (4a-f) and the 
corresponding N-oxide derivative (5d). 
 
All 35G8 analogues had strong PDI inhibitory activity with submicromolar IC50 values, 
except NC75 (> 120 μM) and NC79 (6.55 ± 1.19 μM) in the insulin turbidity assay (Table III-1). 
The pyrimidotriazinedione compound (35G8, IC50: 0.17 ± 0.01 μM) was more potent than the 
corresponding N-oxide compound (NC79). A similar trend was observed between 4d (IC50: 0.36 
± 0.05 μM) and 5d (IC50: 0.42 ± 0.07 μM). Among the pyrimidotriazinediones, the compounds 
Scheme III-1 Synthesis of 3-substituted 35G8 analogues. Reagents and conditions: (a) methylhydrazine, EtOH, reflux; (b) aldehyde 




containing a methyl group (4a) or no substituent (NC72) at R1 had enhanced activity compared to 
those with an aromatic moiety (4b-f), likely due to steric effects. Interestingly, the PDI inhibitory 
activity was abolished upon removal of the methyl substituent at R2 (NC75: IC50 > 120 µM) 
compared to NC72 (IC50: 0.11 µM), indicating that the methyl group at R2 may be necessary to 
retain PDI inhibitory activity. Furthermore, the removal of PDI inhibitory activity abolished the 
cytotoxicity of the compound. 
35G8 analogues inhibit glioblastoma cell proliferation 
All synthesized compounds demonstrated potent cytotoxicity in four glioblastoma cell 
lines, U87MG, U118MG, A172 and NU04, with IC50 values under 10 μM, except 4c (Table III-2).  
The IC50 value of 35G8 in U87MG cells is 1.1 ± 0.2 μM. NC72 demonstrated the most potent 
cytotoxicity (IC50 = 0.5 ± 0.1 μM), complementing its potency in the PDI assay. NC75 and NC79 
had little effect on cell growth. Interestingly, this suggests that the methyl substituent is important 












Table III-2 In vitro cytotoxicity of 35G8 analogues in a panel of human glioblastoma cell lines. Cytotoxicity measured in the MTT 
assay. Data are means from at least three independent experiments. 
 IC50 (μM) 
Compound U87MG U118MG NU04 A172 
35G8 1.1 ± 0.2 3.9 ± 0.1 0.8 ± 0.2 2.0 ± 0.6 
4b 3.0 ± 0.3 4.6 ± 0.5 3.7 ± 1.2 1.8 ± 0.4 
4c 12.7 ± 3.7 24.0 ± 7.4 > 30 8.2 ± 2.5 
4d 1.2 ± 0.2 3.9 ± 0.6 0.86 ± 0.04 1.5 ± 0.4 
4e 1.1 ± 0.2 2.4 ± 0.6 0.76 ± 0.22 1.5 ± 0.1 
4f 1.8 ± 0.7 6.2 ± 1.6 4.9 ± 1.2 1.1 ± 0.2 
5d 1.9 ± 0.7 4.3 ± 0.1 1.5 ± 0.7 1.7 ± 0.1 
NC72 0.5 ± 0.1 - - - 
NC75 > 100 - - - 
NC79 > 100 - - - 
PACMA31 0.13 ± 0.07 0.28 ± 0.04 0.4 ± 0.1 0.12 ± 0.10 
 
 
Pretreatment with Z-VAD-FMK, an irreversible caspase inhibitor,19 and necrostatin-1, a 
necroptosis inhibitor,20 did not protect the cells from 35G8-induced cell death (Table III-3). These 
results indicate that neither necrosis nor apoptosis are the main pathways responsible and another 
pathway may be implicated in cell death. To assess the role of ferroptosis upon 35G8 treatment, 
we treated the cells with deferoxamine (DFO), an iron chelator (Figure III-3). 35G8-induced cell 






Table III-3 Cell death rescue from 35G8 treatment in U87MG cells 
IC50 (µM) 
35G8 35G8+ZVAD 35G8+Necrostatin 
1.12 ± 0.04 1.22 ± 0.11 1.06 ± 0.01 
 
 
Figure III-3 DFO decreases the potency of 35G8. U87MG cells were subjected to 100 μM DFO at increasing concentrations of 
35G8. Results are means from three independent experiments; error bars show s.d. 
 
35G8 induces the Nrf2 antioxidant pathway and ER stress response 
To better elucidate the cellular response to the pyrimidotriazinediones, we performed 
nascent RNA sequencing using the Bru-seq21 method and analyzed changes in gene transcription 
rates in response to 35G8 in U87MG cells. Four hours after 35G8 treatment, 498 genes were 
upregulated at least two-fold and 238 genes were downregulated at least two-fold. Many of the top 
upregulated genes are implicated in the Nrf2 antioxidant response, ER stress response, and 
autophagy. We identified the top 20 upregulated and downregulated gene sets and analyzed the 
genes that were upregulated or downregulated at least two-fold with IPA (Ingenuity Pathway 
Analysis) (Figure III-4) and GSEA (Gene Set Enrichment Analysis). GSEA revealed enrichment 




correlates with KOBAYASHI_EGFR_SIGNALING_24HR_DN gene set, suggesting 35G8 may 
inhibit EGFR signaling. DAVID (the Database for Annotation, Visualization and Integrated 
Discovery) analysis and GSEA identified functional terms related to ER and redox-active 
disulfide, providing further evidence for PDI inhibition by 35G8 (Figure III-4).  
The upregulation of Nrf2 response genes, including HMOX1 (19-fold increase), SLC7A11 
(63-fold increase), AKR1C1 (59-fold increase), and LOC344887 (23-fold increase), is likely a 
protective response to the insults caused by 35G8. 
We also confirmed parallel increases in HMOX1 and SLC7A11 protein expression (Figure 
III-4). The Nrf2 antioxidant pathway mitigates oxidative stress by inducing antioxidant response 
elements.22 PDI is vital in the UPR, and inhibiting this key protein disrupts proteostasis, ultimately 
leading to ER stress and cell death when the cell cannot cope with the accumulation of misfolded 
proteins. ER stress target genes downstream the PERK-ATF4 ER stress response pathway, 
CHAC1 (46-fold increase), DDIT3 (4-fold increase), and HSPA5 (8-fold increase) increased as a 
result of 35G8 treatment. Protein expression of GRP78 (HSPA5) and DDIT3 increased upon 24-
hour treatment of 2 μM 35G8; however, CHAC1 protein was undetectable, likely because the 
CHAC1 protein is rapidly degraded by the proteasome.23 mRNA expression of other downstream 
targets of the PERK-ATF4 ER stress response pathway, including TRIB3 and ASNS,24, 25 also 
increased in response to 35G8. These results suggest that brain cancer cells rely on PDI to maintain 
redox homeostasis, and when PDI is inhibited, cells undergo irremediable ER stress that leads to 









Figure III-4 Effects of 35G8 treatment on cellular pathways. (A) Pathways from the Bru-seq analysis of 35G8-treated cells. (B) 
GSEA for “NFE2L2.V2,” the top gene set matched with upregulated genes from Bru-seq results. Functional terms represented by 
genes upregulated (C) and downregulated (D) at least 2-fold by 35G8 treatment. Pathway analysis was performed using DAVID 
(left) and GSEA (right). (E) Histograms of differentially expressed proteins between 35G8-treated and DMSO-treated U87MG 
cells. Fold change bars are in black for UPR genes, dark grey for autophagy-related genes, and light grey for Nrf2-related genes. 
(F) Western blot showing Nrf2-regulated proteins SLC7A11 and HMOX1 expression upon 24-hour treatment of U87MG cells 
with 1 or 2 μM 35G8. (G) Western blot of ER stress-induced proteins DDIT3 and GRP78 expression upon 24-hour treatment of 
U87MG cells with 1 and 2 μM 35G8. (H) Western blot of autophagy-related proteins LC3B, beclin 1, ATG3, ATG5, and ATG7 
expression upon 24-hour treatment of U87MG cells with 1 (+) and 2 (++) μM 35G8. -: vehicle-treated control. GAPDH used as a 
loading control. Experiments repeated in triplicate.  
 
We also identified several autophagic signaling genes that respond to ER stress triggered 
by 35G8, including TRIB3, IRS2, and TMEM74. TRIB3 (23-fold increase), as a downstream target 
of ATF4, mediates autophagy by inhibiting the mTORC1 pathway.26 IRS2 (12-fold increase) 
activation induces protective autophagy to clear unwanted protein aggregates27 and may also help 
remove damaged cells. TMEM74 (28-fold increase), a transmembrane protein localized to the 
lysosome and autophagosome, regulates autophagy.28 The increased transcription of these 
autophagy-related genes prompted us to measure protein expression of several autophagy markers. 
Cleaved LC3B expression increased significantly after 24-hour treatment with 2 μM 35G8, 
however expression levels of other autophagy markers, including ATG3, ATG5, ATG7, and beclin 
1, did not change, suggesting that autophagy may play a more protective role in this case. These 
results indicate that 35G8 induces the ER stress and Nrf2 response in brain cancer cells to 
contribute to cell death.  
Bru-seq analysis identifies novel glioblastoma markers 
AKR1C1, IL-6, CHAC1 and TNFSF9 are among the top 20 upregulated genes with 
significantly decreased expression in brain cancer compared to normal brain tissues (Figure III-5). 
Conversely, genes that were downregulated upon 35G8 treatment, including TXNIP (−7.40-fold 
change), EGR1 (−5.65-fold change), and ITGA3 (−3.89-fold change) are often overexpressed in 




mir181A2HG (Figure S6). These data suggest 35G8 inhibits transcription of these mRNA or 
inhibits an upstream regulator of ITGA3 and EGR1. The results also indicate a gene such as IL6 







Figure III-5 Effect of 35G8 treatment on RNA synthesis in U87MG cells. 35G8 induces transcription of (A) AKR1C1, (B) CHAC1 
and (C) TNFSF9 while corresponding box plots show downregulation of these genes in brain cancer. 35G8 inhibits the transcription 
of (D) TXNIP, (E) EGR1 and (F) ITGA3 while corresponding box plots show upregulation of these genes in brain cancer. FC: fold 




35G8 induces ROS formation 
Because the cells responded to 35G8 by upregulating the Nrf2-mediated oxidative stress 
response, we investigated the production of reactive oxygen species (ROS) by 35G8 and its 
analogues to determine whether the cytotoxicity of these compounds is dependent on ROS 
induction. We observed significant ROS induction by all 35G8 analogues tested at 5 μM as early 
as four hours after treatment, except for 4c (Figure III-6). ROS accumulation with these 
compounds was time-dependent. At 24 hours, 5 μM 35G8 treatment achieved maximal ROS 
induction, comparable to 100 μM H2O2 treatment. No change in the fluorescent signal in the 
samples containing 35G8 without H2DCFDA dye was observed, eliminating the possibility of 
endogenous fluorescence affecting the assay. N-
acetyl cysteine (NAC) did not affect the cytotoxicity 
of 35G8 significantly. This suggests 35G8-induced 
cell death is not solely dependent on ROS induction. 
35G8 induces ferroptosis 
Both transcription and protein expression of 
HMOX1 and SLC7A11 are highly upregulated by 
35G8. These proteins have been implicated in the 
non-apoptotic cell death mechanism, ferroptosis. 
HMOX1 is necessary for ferroptosis and is a major 
source of iron in the body.29 Inhibition of cysteine-
glutamate exchange through system xc-, of which 
SLC7A11 is a component, induces iron-dependent 
cell death.30 To determine whether 35G8 induces 
Figure III-6 ROS induction of 35G8 analogues at (A) 4 
hours, (B) 6 hours, and (C) 24 hours. In (C), H2O2 
concentration is 500, 100, and 20 μM, from left to right. 
Data are means from three independent experiments; 




ferroptosis in U87MG cells, we treated the cells in the presence or absence of deferoxamine (DFO), 
an iron chelator.31 In the presence of DFO, 35G8 is almost three times less potent (IC50 = 5.8 ± 1.0 
μM) than when used alone (IC50 = 2.2 ± 0.7 μM). These data suggest that PDI may play an 
important role in preventing ferroptosis in brain cancer.    
35G8 is expected to cross the blood-brain barrier 
The likelihood of blood-brain barrier (BBB) permeation, AlogP, water solubility, polar 
surface area, and number of rotatable bonds of 35G8 and its synthesized analogues were 
determined with a qualitative model in the ADMET predictor (Version 7.0). The AlogP of the 
compounds is between -1.1 and 1.1 and the likelihood of BBB permeation is high. The polar 
surface area of 35G8 is less than 90 Å2, the cutoff for predicted CNS penetration.32 The average 
molecular weight of marketed CNS compounds is 310, and the 35G8 analogues range in molecular 
weight from 207 – 315. Similarly, TMZ has a molecular weight of 194 Da, ClogP of -0.82, and a 
polar surface area of 108 Å2. These data demonstrate that 35G8 will be able to cross the blood-
brain barrier. 
Discussion 
The screen of 20,000 diverse compounds in a growth inhibition assay produced 35G8 as 
the most potent inhibitor of proliferation of the colon cancer cell line HCT116. 35G8 destabilizes 
PDI and blocks its reductase activity. As a consequence, 35G8 likely causes cell death via 
continuous activation of ER stress and disruption of homeostatic balance, among other factors. 
35G8 was validated in orthogonal assays to rule out that activity was not a consequence of its 
redox-cycling status. 35G8 generates H2O2 in the presence of DTT at the concentrations used in 




PDI (Figure III-7). The reactive nature of the pyrimidotriazinedione class underlines the 
importance of testing activity in a wide variety of assays, including non-fluorescent methods, in 
order to eliminate false positive results. Therefore, we performed several assays with various 
output methods to test our novel compounds.  
 
Figure III-7 PAINS characteristics of 35G8 do not interfere with PDI activity in the insulin turbidity assay. (A) Redox cycling 
assay measuring absorbance at 610 nm. Data are presented as mean ± standard deviation of three independent experiments. (B) 
H2O2 in insulin turbidity assay. Ability of PDI to reduce insulin measured in the presence of 10 μM and 100 μM H2O2, and 10 μM 
35G8. ● Sodium phosphate buffer only.  130 μM insulin in buffer and DTT  1 μM PDI + 130 μM insulin + DTT  10 μM 
35G8 in 1 μM PDI + 130 μM insulin + DTT  10 μM H2O2 in 1 μM PDI + 130 μM insulin + DTT  100 μM H2O2 in 1 μM PDI 
+ 130 μM insulin + DTT. 
The Bru-seq results revealed that 35G8 promoted the activation of the Nrf2 pathway. Of 
the top 20 upregulated genes following a 4-hour 35G8 treatment, four are implicated in the Nrf2 




normally is kept at low levels due to degradation mediated  by Keap1.33 Following exposure to 
ROS, Keap1 is inactivated and Nrf2 induces transcription of genes to counteract the oxidative 
insult.34 SLC7A11 is part of a cysteine-glutamate transporter (system xc-) that is regulated by Nrf2 
as well as ATF4.35 HMOX1, another Nrf2-regulated gene, increased over 19-fold upon 35G8 
treatment. We also found that transcription of the AKR1C1 gene, which is induced by ROS but 
expressed at low levels in gliomas, increased significantly following 35G8 treatment. Furthermore, 
the lncRNA LOC344887 has been shown to be activated by Nrf2.36 Nrf2-regulated genes may be 
responsible for treatment resistance in glioblastoma, providing further evidence that inhibiting PDI 
could be a sound strategy to treat glioblastoma.37, 38 
Several ER stress markers were induced in response to 35G8 treatment, including CHAC1, 
DDIT3, ASNS, and ATF3. Due to the strong upregulation of CHAC1, a pro-apoptotic marker 
regulated by ATF4, we hypothesize that the PERK-ATF4-DDIT3 branch of the UPR is likely 
activated upon PDI inhibition by 35G8 treatment. The ER stress response and autophagy are 
closely linked, and ER stress may induce autophagy in 35G8-treated cells. 
Autophagy is the process of protein and organelle degradation by lysosomes, used as a 
survival mechanism to provide energy for the cell.39 The ER stress response protein ATF4 
promotes autophagy40 by upregulating genes like TRIB3.41 While autophagy can be protective as 
a survival mechanism, increased autophagic signaling causes cell death. It is still unclear whether 
TMEM74 is regulated by ATF4, but upregulation of TMEM74 mRNA may lead to autophagic 
PI3K signaling. The increase of ARG2 expression upon 35G8 treatment may be a result of the 
activation of the UPR and lower cellular levels of arginine, leading to autophagy.42 IRS2, a key 
insulin signaling protein regulated by the UPR and silenced by JNK, is expressed to remove 




inducing autophagy to combat ER stress. Ultimately, unbalanced homeostatic mechanisms 
overwhelm the cellular machinery, and this leads to cell death. 
ROS induction is likely responsible for the increased expression levels of TXNRD1 (9-fold 
increase) and TXN (2-fold increase). TXNIP inhibits TXN activity, and TXNIP expression is 
significantly inhibited by 35G8 treatment (7.4-fold decrease). ER stress activates the ERK1/2 
MAP kinase signaling pathway, repressing TXNIP expression leading to thioredoxin nuclear 
translocation.44 Interestingly, TXNIP is overexpressed in brain cancer patients. Furthermore, 
TXNIP can bind PDI and increase its activity. Lower TXNIP levels allow TRX to bind ASK1 and 
prevent apoptosis.45 Therefore, decreased expression of TXNIP may contribute to the absence of 
apoptosis signaling observed upon 35G8 treatment.  
Another class of genes that were repressed by 35G8 are involved in DNA repair. GSEA 
analysis showed that several genes involved in mismatch repair, homologous recombination, base 
excision repair and nucleotide excision repair had reduced transcription following 35G8 treatment. 
It is possible that these genes share a common transcription factor that requires PDI-assisted 
protein folding for optimal function. Importantly, these findings suggest that 35G8 may be used 
in combination with DNA damaging agents or PARP1 inhibitors to augment their therapeutic 
effectiveness.   
The key Nrf2-regulated genes SLC7A11 and HMOX1 are essential markers for iron-
dependent, erastin-induced ferroptosis. SLC7A11 is a negative regulator of ferroptosis and 
upregulation of SLC7A11 occurs as a response to system xc- inhibition. Efforts to treat glioma 
patients by inhibiting system xc- have failed;46 however, combining SLC7A11 inhibition with a 




 System xc- imports cystine for glutathione synthesis to maintain intracellular redox 
balance, and the expression of this system is often elevated in several cancers, including gliomas.47 
System xc- inhibitors, in particular sulfasalazine, as single agents for the treatment of gliomas have 
been unsuccessful,48 but have been shown to sensitize glioma cells to radiation therapy.49 
Similarly, the ferroptosis inducer erastin sensitizes glioblastoma cells to temozolomide by 
inhibiting system xc-.50 These studies provide evidence that system xc- is an important target for 
combating resistance in brain cancer. Importantly, 35G8-induced cell death can be rescued by 
deferoxamine, suggesting that ferroptosis is occurring. Interestingly, Bru-seq analysis of 35G8-
treated cells revealed a pattern of gene expression similar to that of erastin-treated cells (Figure 
III-8), including induction of the ER stress response, unfolded protein response, and expression of 
the erastin-exposure pharmacodynamic marker, CHAC1.30 
 
Figure III-8 Venn diagram for the genes with greater than two-fold change in 35G8 and erastin treatments. 
This indicates that as a consequence of PDI inhibition, 35G8 blocks transport via system 
xc-. However, a link between PDI and SLC7A11 expression has not yet been established and 





We identified 35G8 as a markedly potent PDI inhibitor that may have therapeutic potential 
as a single agent and in combination with SLC7A11 inhibitors or DNA-damaging agents. 35G8 
and its analogues demonstrate activity in human brain cancer cells likely through upregulation of 
ER stress and UPR that leads to autophagy-mediated ferroptosis. Taken together, our data suggest 
35G8 is a useful investigational PDI inhibitor, expected to easily cross the blood brain barrier, that 
can be optimized to develop novel therapeutic agents to treat malignant glioma. 
Experimental Section 
Reagents. 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) was purchased 
from Amresco (Solon, OH). N-acetylcysteine (NAC) was purchased from Sigma-Aldrich (St. 
Louis, MO). Methyl (3S)-5-fluoro-3-[[(2S)-2-[[(2S)-3-methyl-2-(phenylmethoxycarbonylamino) 
butanoyl] amino] propanoyl] amino]-4-oxopentanoate (Z-VAD-FMK) was purchased from Tocris 
Bioscience (Bristol, UK). 5-(1H-indol-3-ylmethyl)-3-methyl-2-sulfanylideneimidazolidin-4-one 
(Necrostatin-1) was purchased from Cayman Chemical Company (Ann Arbor, MI). Phenol red, 
H2O2, and horseradish peroxidase (HRP) were purchased from Sigma-Aldrich (St. Louis, MO). 
Hank’s Balanced Salt Solution (HBSS) was purchased from Hyclone (Logan, UT), and sodium 
hydroxide was purchased from EMD (Gibbstown, NJ). 
Cell Culture. The human glioblastoma cells, U87MG, U118MG, NU04 and A172 (ATCC, 
Manassas, VA), were obtained in 2013 and were maintained in RPMI-1640 (Thermo Fisher 
Scientific, Waltham, MA) supplemented with 10 % fetal bovine serum (Thermo Fisher Scientific). 




tested for Mycoplasma contamination with the Mycoplasma detection kit, PlasmoTest (InvivoGen, 
San Diego, California). 
Growth Inhibition Assay. Cell growth inhibition was assessed by MTT assay as previously 
described.51 Cells were seeded in duplicate in 96-well plates at 7000 - 10000 cells/well. After 
overnight incubation at 37 °C and 5 % CO2, cells were treated with indicated compounds for 72 
hours. For the combination therapies, NAC was added to the well at the same time as 35G8 (24 
hours after plates were seeded), and Z-VAD-FMK and Necrostatin-1 were added to the well 1 hour 
prior to 35G8 addition. The plates were incubated with drug or vehicle control for 72 hours at 37 
°C and 5 % CO2. MTT solution (20 μL, 3 mg/mL) was added to the wells, and the cells were 
incubated for 4 hours at 37 °C. Supernatant was removed and DMSO (100 μl) was added to each 
well. The plates were shaken for 15 min at room temperature, and absorbance of the formazan 
crystals was measured at 570 nm. Cell growth inhibition was assessed by the cell viability rate as 
[1-(At-Ab)/(Ac- Ab)]×100 (At , Ac and Ab were the absorbance values from cells treated with 
compound, cells not treated with compound, and blank, respectively). Cell viability was 
determined with the MTT assay. U87MG cells were seeded at 5000 cells per well in 96-well plates. 
Deferoxamine (Sigma Aldrich) was added to cells in a five-point, three-fold dilution series from 
400 μM. 35G8 was added immediately after in a five-point, three-fold dilution series from 100 
μM. Cells were incubated with compounds for 12 hours at 37 °C, and MTT assay was performed 
as stated above. 
PDI Protein Purification. The expression vector of recombinant human PDI protein with N-
terminal His tag was a gift from Dr. Lloyd W. Ruddock (University of Oulu, Oulu, Finland). PDI 
expression and purification were performed as previously described with slight modifications.4 In 




medium with 200 μg/ml ampicillin (EMD Biosciences, La Jolla, CA) at 37 °C and incubated at an 
A600 of 0.5 for 4 hours with 1 mM isopropyl β-D-1-thiogalactopyranoside (GoldBio, St. Louis, 
MO). Cells were harvested by centrifugation (4000g for 15 min) and were re-suspended in one-
tenth volume Buffer A (20 mM sodium phosphate, pH 7.3). Cells were lysed by sonication and 
the cell debris was removed by centrifugation (17000g for 45 min). The supernatant was applied 
to a bed of Ni-nitrilotriacetic acid in a histidine-binding column (Qiagen, Hilden, Germany), 
equilibrated with 10 ml of Buffer A and incubated at 4 °C, overnight. After incubation, the column 
was washed in Buffer A and then in Buffer B (20 mM sodium phosphate, 0.5 M sodium chloride 
and 50 mM imidazole, pH 7.3). His-tagged proteins were eluted using Buffer C (20 mM sodium 
phosphate and 50 mM EDTA, pH 7.3) and eluent was dialyzed in 100 mM sodium phosphate 
buffer (pH 7.0) with 2 mM EDTA. 
Measurement of PDI Activity. PDI activity was assessed by measuring the PDI-catalyzed 
reduction of insulin as described previously.14 In brief, recombinant PDI protein (0.4 μM) was 
incubated with indicated compounds at 37 °C for 1 hour in sodium phosphate buffer (100 mM 
sodium phosphate, 2 mM EDTA, 8 μM DTT, pH 7.0). A mixture of sodium phosphate buffer, 
DTT (500 μM), and bovine insulin (130 μM; Gemini BioProducts, West Sacramento, CA) was 
added to the incubated PDI protein. The reduction reaction was catalyzed by PDI at room 
temperature, and the resulting aggregation of reduced insulin B chains was measured at 620 nm. 
PDI activity was calculated with the formula, PDI activity (%) = [(ODT80[PDI+DTT+compound] 
- ODT0[PDI+DTT+compound]) - (ODT80[DTT] - ODT0[DTT])] / [(ODT80[PDI+DTT] - 
ODT0[PDI+DTT]) - (ODT80[DTT] - ODT0[DTT])] × 100 (ODT0 and ODT80 were the absorbance 




Thermal Shift Assay. Thermal shift of purified PDI (0.3 mg/ml in 100 mM NaPO4, pH 7.0) in 
the presence or absence of 35G8 was determined as described.15 Briefly, 5 µl protein-dye (1,8-
ANS, 0.3 mM; Sigma Aldrich) solutions were dispensed in each well of a 384-well microplate 
(Thermo Scientific, AB1384K) and equal volumes of the test compound solutions were dispensed 
to each well. Then, 3 µl of silicone oil (Sigma Aldrich) was added to each well to prevent 
evaporation. DMSO (2 % in buffer) was used as control. Fluorescence emission was detected by 
measuring light intensity using a CCD camera. The plate was heated at a temperature range from 
25 to 90 °C at 1°C/minute in the ThermoFluor instrument (Johnson & Johnson, New Brunswick, 
NJ). Compounds were replicated three times in a 384-well plate.  
Cellular Thermal Shift Assay. The cellular thermal shift assay was performed following 
previously established procedure.52 U87MG cells were seeded at 2 x 106 cells/100 mm dish and 
allowed to attach overnight. Cells were treated with 0.5, 1.0, or 2.0 μM 35G8, or DMSO as the 
negative control, for 2 hours at 37 °C, 5 % CO2. After treatment, cells were trypsinized, washed 
with DPBS twice, and suspended in 600 μL DPBS. The cells were split into 100 μL aliquots, 
heated at indicated temperatures for 3 min in the Veriti Thermal Cycler (Applied Biosystems), and 
incubated for 3 min at room temperature. The cells were flash-frozen twice and spun at 14000g 
for 20 min at 4 °C. Supernatants were collected and loaded onto a 10 % polyacrylamide gel at a 
volume of 16 μL, with 4 μL 4X SDS loading dye. Subsequently, Western blotting was run 
following the procedure reported herein. 
Drug Affinity Responsive Target Stability. The DARTS assay was performed following 
previously established procedure.53 U87MG cells were grown to approximately 80-85% 
confluence, washed with ice-cold DPBS, and lysed with lysis buffer (150 mM NaCl, 1.0% NP-40, 




occur for 10 min on ice. Cells were spun at 18000g for 20 min at 4 °C to collect the supernatant. 
Protein concentration was determined via BCA assay. 100 μM PACMA31 or 35G8 or 1% DMSO 
were incubated with aliquots of cell lysate at 5 mg/ml for 30 min with shaking at room temperature. 
Pronase (Sigma Aldrich) was added to 20 μL aliquots of cell lysates at 0, 1:1000 (0.005 μg/μL), 
1:500 (0.01 μg/μL), or 1:250 (0.02 μg/μL) for 30 min at room temperature. Digestion was stopped 
by adding 1X protease inhibitor cocktail (Sigma Aldrich) and incubating the reactions on ice for 
10 min. SDS-PAGE loading buffer (6 μL of 5X) was added to the samples, and samples were 
heated for 10 min at 70 °C. Samples were spun down briefly and 20 μg of protein was loaded into 
acrylamide gels (10 %) for Western blot analysis. 
Bru-seq Analysis. Bru-seq experiments12 and analysis were performed as previously reported. 
Briefly, U87MG cells were placed in dishes on Day 1. Cells were changed to fresh media on Day 
5 and treated with DMSO or 35G8 at 1 μM for 4 hours. Bromouridine was added into the media 
to a final concentration of 2 mM to label newly synthesized nascent RNA in the last 30 min of 
treatment. Cells were then collected in TRIzol (Thermo Fisher Scientific) and total RNA was 
isolated. The bromouridine-containing RNA population was further isolated and sequenced. 
Sequencing reads were mapped to a reference genome.  
Bioinformatic Analysis. Bru-seq data of 35G8 treatment was filtered using the cut off value of 
gene size > 300 bp and mean (RPKM) > 0.5 and a total of 7,770 genes were ranked based on the 
fold change values versus control (DMSO). DAVID functional annotation analysis54, 55 was 
performed on 460 upregulated and 220 downregulated genes with fold change ≥ 2 and ≤ -2. IPA 
of Bru-seq data was performed using the IPA web-based application (Ingenuity Systems, Inc.) on 
the list of 680 up- and downregulated genes (fold change ≥ 2 and ≤ -2). Top canonical pathways 




GSEA of Bru-seq data was done on a pre-ranked gene list of 7,770 genes of 35G8 treatment based 
on the Kolmogorov–Smirnov statistic.56  
ROS Detection Assay. U87MG cells were detached with 0.05% trypsin-EDTA, neutralized, 
centrifuged and resuspended in cell culture media. Suspension was treated with 20 μM cell-
permeable H2DCFDA for 30 min at 37 °C. Cells were centrifuged again and washed with cell 
culture media to remove excess probe. After washing, cells were placed in a black-wall 384-well 
plate at 20,000 cells/well, incubated for 30 min and treated with compounds at designated 
conditions. Fluorescent signals were read at 493 nm/523 nm for ROS detection at designated time 
points (4, 6, and 24 hours).    
Western Blot. Primary antibodies for GRP78, HMOX1, CHAC1, CHOP, LC3B, GSTO1, and 
SLC7A11 and secondary antibodies were purchased from Cell Signaling (Danvers, MA). Primary 
antibody for P4HB was purchased from Protein Tech (Rosemont, IL). U87MG cells were treated 
with DMSO or 2 μM 35G8 for 1, 3, 6, 12, or 24 hours. Cells were harvested with a lysis buffer 
(25 mM tris(hydroxymethyl)aminomethane, 150 mM sodium chloride, 17 mM Triton X-100, 3.5 
mM sodium dodecyl sulfate, pH 7.4), lysed via sonication, and spun in a centrifuge at 13500g at 4 
°C for 10 min. Supernatant was collected and protein concentration determined with the BCA 
assay (Thermo Fisher Scientific, Waltham, MO). Samples were prepared with 50 μg protein and 
loaded onto 10 % (or 12 % for LC3B and DDIT3) acrylamide (Bio-Rad, Hercules, CA) gels. 
Protein from gels was electrotransferred to methanol-activated immobilon-FL PVDF membranes 
(EMD Millipore, La Jolla, CA). Membranes were blocked for 1 hour with Odyssey blocking buffer 
(LI-COR Biosciences, Lincoln, NE). Membranes were probed for proteins using primary 
antibodies (P4HB, 1:1000; GRP78, 1:1000; GSTO1, 1:1000; HMOX1, 1:1000; CHAC1, 1:1000; 




with secondary antibodies (anti-rabbit, 1:7500, or anti-mouse, 1:7500) and fluorescence was 
imaged by Odyssey imaging system (LI-COR Biosciences). 
Redox Cycling Assay. The redox cycling assay was adapted from a previously published 
experiment.57 In duplicate in a 384-well plate, 20 μL of HBSS buffer, 100 U of catalase, 100 μM 
H2O2, 100 μM H2O2 + 100 U catalase, 0.5% DMSO, 500 μM DTT, 10 μM 35G8, 10 μM 35G8 + 
500 μM DTT, or 10 μM 35G8 + 500 μM DTT + 100 U of catalase was added to a reaction mixture 
with HBSS to a final volume of 60 μL. The reaction was incubated at room temperature for 30 
min, and phenol red-HRP detection reagent was added to a final concentration of 100 μg/ml phenol 
red and 60 μg/ml HRP in each well. The reaction was incubated for an hour at room temperature. 
Sodium hydroxide (10 μL, 1 N) was added to wells and absorbance was measured at 610 nm.  
Statistical Analysis. IC50 values were calculated using GraphPad Prism 7 software (GraphPad 
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Design, Synthesis, and Biological Evaluation of Novel Allosteric Protein Disulfide 
Isomerase Inhibitors 
Introduction4 
Cancer cells require increased protein synthesis and respond to endoplasmic reticulum 
(ER) stress by activating the unfolded protein response (UPR) which is mediated by ER 
chaperones.1-3 ER chaperones such as protein disulfide isomerase (PDI) have emerged as 
interesting targets for cancer research. PDI is an oxidoreductase chaperone, located in the ER, that 
assists protein folding by catalyzing disulfide-bond formation (oxidation), breakage (reduction), 
and rearrangement (isomerization).4, 5 PDI is composed of four thioredoxin-like domains (a, a’, b, 
and b’), a linker between the a’ and b’ domains (x), and a C terminal acidic tail. Both the a and a’ 
domains contain structurally similar active sites, including a CGHC motif, and are responsible for 
the oxidoreductase activity.6 The b’ domain possesses a large hydrophobic pocket for substrate 
binding and recognition. The C-terminal domain functions in chaperone activity.7 All these 
domains are attached in a U-shaped structure that is open in the oxidized state and closed in the 
 
4 This work has been published and is being reprinted with permission from Yang, S., Shergalis, A., Lu, D., Kyani, 
A., Liu, Z., Ljungman, M., & Neamati, N. (2019). Design, synthesis, and biological evaluation of novel allosteric 
protein disulfide isomerase inhibitors. Journal of medicinal chemistry, 62(7), 3447-3474. 
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reduced state. In addition to the vital roles in protein folding, PDI is overexpressed in a variety of 
cancers but more significantly in GBM.4 Furthermore, upregulation of PDI is associated with 
acquired temozolomide resistance in GBM, thus inhibition of PDI enhances temozolomide-
mediated cell death through apoptosis via the ER stress response pathway.8 Selective PDI 
inhibitors can sensitize several cancer cell lines to chemotherapeutic agents such as etoposide, 
fenretinide, and velacade.9, 10 PDI inhibition induces acute ER stress in multiple myeloma cells 
accompanied by apoptosis-inducing calcium release.11 In addition, PDI is strongly expressed in 
invasive glioma cells, in both xenografts and at the invasive front of human GBMs, and PDI 
inhibition leads to reduced glioma cell migration and invasion by interfering with the integrin 
outside-in signaling pathway.12, 13 All these findings suggest that PDI is an important target for 
cancer therapy, especially for brain cancers, thus emphasizing the need for the development of 
novel and potent PDI inhibitors. 
Recently, we discovered the PDI inhibitor BAP2, a benzylidene acetophenone, with an 
IC50 value of 930 ± 90 nM, via a combination of high-throughput screening and experimental 
analysis.14 BAP2 shows in vitro and in vivo antiproliferative activities in human brain cancer 
models as a single agent. A simple chalcone is a 1,3-diaryl-2-propen-1-one in which the two 
aromatic rings are connected by a three-carbon α,β unsaturated carbonyl bridge. Chalcone is 
considered a valuable scaffold due to its simple chemistry, ease of synthesis, and wide biological 
activity, including anti-oxidant, anti-inflammatory, anti-bacterial, and antitumor properties.15 
Several chalcones, such as metochalcone, sofalcone,16, 17 PD-156707, licochalcone A, and 




are well-tolerated and non-toxic to humans, and they have reasonable pharmacokinetic properties 
(Figure IV-1).18 Herein, we report the synthesis of 67 novel BAP2 derivatives, a structure-activity 
relationship (SAR) analysis, and evaluation of PDI inhibitory activity and cytotoxicity against 
brain cancer cells. The most potent BAP2 analogues inhibited GBM migration and cell growth, 
lowered MMP9 expression, and blocked MMP2 secretion. Furthermore, extensive transcriptomic 
and proteomic analysis of analogue treatment in a brain cancer cell line demonstrated that BAP2 
and analogues induced ER stress, increased expression of G2M checkpoint proteins, and reduced 
expression of ribosomal and DNA replication proteins. While BAP2 and 59 have some thiol 
reactivity, we provide evidence that PDI inhibition by BAP2 analogues is dependent on allosteric 
binding in the b’ domain. 
 






Synthesis of BAP2 derivatives and their structure-activity relationship 
To investigate the structural aspects of the lead BAP2 for ability to inhibit PDI reductase 
activity, a series of derivatives were designed and prepared. For the synthesis of chalcones, the 
most commonly used method is the base-catalyzed Claisen-Schmidt condensation reaction 
between a methyl ketone and an aldehyde in the presence of sodium hydroxide (NaOH),19, 20 
potassium hydroxide (KOH),21 or lithium hydroxide (LiOH∙H2O).
22 However, the base-mediated 
reactions sometimes require longer reaction times (several days), give low chemical yields, and 
have a high possibility of side reactions such as the Cannizzaro reaction of an aldehyde, aldol 
condensation, or Michael addition reaction.23 On the other hand, the acid-catalyzed method 
involves the use of aluminum trichloride (AlCl3)
24 or dry HCl,25 and recently boron trifluoride 
etherate (BF3∙Et2O) has been used as a condensing agent.
26, 27 This new BF3∙Et2O-assisted method 
is advantageous over existing methods because it produces higher yields, requires shorter reaction 
times, and has minimal side reactions.26, 28, 29 Therefore, we applied the BF3∙Et2O method for the 
synthesis of most BAP2 derivatives in this study.  
Several 4-substituted acetophenones (3a-n) and benzaldehydes (4a-b) were prepared via 
typical methylation (3a),30 nucleophilic substitution reactions with amines (3b-i, 4b), activation of 
acid with thionyl chloride and the subsequent substitution reaction with nucleophiles (3j-m), 
hydroxylation at an aliphatic carbon of 3’-bromo-4’-methyl acetophenone (3n), and esterification 
of 3-carboxybenzaldehyde (4a) (Scheme IV-1). With the acetophenones (3) and benzaldehydes 




Claisen-Schmidt reaction (Scheme IV-2).26 Some BAP2 derivatives were synthesized by applying 
the base-catalyzed condensation reaction (8-9, 39),19 and pyrazine-containing derivatives were 
obtained in the presence of diethylamine in pyridine at 80-120 °C (29 and 56). Microwave-assisted 
one-pot reaction of a Sonogashira coupling of an aryl halide with an aryl alcohol and the 
subsequent base-catalyzed isomerization were carried out to provide the boronate-containing 
chalcone 71,31 and further oxidative cleavage of the boronate afforded the boronic acid chalcone 
72.32 Another boronic acid chalcone 31 was prepared by Miyaura borylation of aryl halide 10 and 
subsequent oxidative cleavage. Microwave-assisted Suzuki coupling of aryl halide 67 afforded 
chalcones 68 and 69. In addition, methylation of compounds 5 and 25, demethylation of 8, 
esterification of 37, and base-promoted hydrolysis of 53 afforded corresponding BAP2 derivatives 












Scheme IV-1 Synthesis of 4-substituted acetophenones (3a-n) and benzaldehydes (4a-b)a 
 
aReagents and conditions: (i) 3a: K2CO3, MeI, acetone, reflux; (ii) 3b: THF, rt; 3c-i: Et3N, anh THF, rt; (iii) 3j: (1) pyridine, anh 
DCM, rt; (2) 1 N HCl. 3k-m: (1) SOCl2, rt; (2) pyridine, DCM; (iv) 3n: (1) NBS, AIBN, MeCN, reflux; (2) CaCO3, dioxane, H2O, 









Scheme IV-2 Synthesis of BAP2 analogues 5-72a 
 
aReagents and conditions: (i) 5, 10-26, 28, 30-38, 40-44, 47-55, 57-67, 70: BF3∙Et2O, 1,4-dioxane, 80 °C. 8-9, 39: 60% NaOH, 
EtOH, 0 °C → rt 29, 56: (1) Et2NH, pyridine, 80-120 °C; (2) acetic acid; (ii) 71: DBU, PPh3, PdCl2(PPh3)2, THF, MW 120 °C, 40 
min; (iii) 6: (1) Py.HCl, 210 °C; (2) NaHCO3, pH 7-8; (iv) 7, 27: K2CO3, MeI, acetone, reflux; (v) 31: (1) Bis(pinacolato)diboron, 




(vii) 46: cat H2SO4, anh MeOH, reflux; (viii) 68: Pyridine-3-boronic acid, 10 mol% Pd(OAc)2, KF, PEG/EtOH, MW 110 °C, 30 
min; (ix) 69: Cs2CO3, Pd(PPh3)4, DMF, MW 130 °C, 20 min; (x) 72: (1) NaIO4, H2O, THF, rt; (2) HCl, H2O, rt.  
 
A total of 68 synthetic chalcone compounds were prepared and tested for the inhibitory 
effect against PDI using the PDI reductase assay.33, 34 Their structure-activity relationship (SAR) 
was analyzed by categorizing the derivatives into three clusters based on the substituent of ring B. 
In the first series of analogues (Table IV-1), we maintained the nitrile group of the lead BAP2 at 
R2 and made modifications at R1. Replacement of the hydroxyl group (6, IC50 of 0.85 μM) with 
bromine (10) led to a 2-fold decrease in the inhibition of PDI activity. Activity dropped 
substantially upon replacement of the hydroxyl group (5, IC50 of 1.87 μM and 6) with a methoxy 
group (7 and 8), amine (9), or heterocycle (11, 12), and upon the introduction of a pyrazine moiety 
to replace the phenyl ring (29). Similarly, the compounds containing at least one hydroxyl group 
retained activity or showed stronger activity depending on the additional substituent (21-24, 32-
36, IC50 range of 0.21 – 2.37 μM), regardless of the position of the nitrile at meta or para of R
2. 
However, introduction of a methoxy group (25, 26) seemed to be unfavorable for activity even 
with the hydroxyl group maintained (IC50 of 10.9 and 2.72 μM, respectively). Analogue activity 
decreased with dimethoxy groups (27) or dihalogen atoms (28) in place of the hydroxyl group, 
indicating the importance of the hydroxyl group for potency. Interestingly, several BAP2 
analogues lacking a hydroxyl group retained or even improved PDI inhibitory activity (13-20). 
These compounds contain a sulfonamide moiety in place of the hydroxyl group and increase in 
hydrophobic character with increasing alkyl chain. As hydrophobicity increased, the PDI 




most potent with IC50 values of 0.82 – 1.23 μM (15, 16, 19, 20). On the other hand, another type 
of sulfonamide-containing chalcone derivative (e.g. 30, IC50 of 8.51 μM) was not as potent as 20 
(IC50 of 1.11 μM) although they both have a bulky hydrophobic moiety, suggesting that electron 
withdrawing group such as -SO2NHR prepare the olefin for nucleophilic attack by the thiol in the 
active site. Potentially, the hydrophobic region would interact with a pocket near the active site to 
stabilize binding. These findings suggest that both active site and hydrophobic interactions play 
important roles in the activity of this series. 
Table IV-1 PDI inhibitory activity of the synthesized BAP2 derivatives 5-36a 
 
Compd Scaffold X R1 R2 IC50 (µM)b  
6 
(BAP2) 
A C 4-OH 3-CN 0.85 ± 0.14 
5 A C 3-OH 3-CN 1.87 ± 0.58 
7 A C 3-OMe 3-CN 8.13 ± 1.53 
8 A C 4-OMe 3-CN > 500 
9 A C 4-NH2 3-CN > 500 
10 A C 4-Br 3-CN            1.66 ± 0.42 
11 A C 4-Morpholine 3-CN > 500 
12 A C 4-Piperidine 3-CN > 500 
13 A C 4-SO2NH2 3-CN 6.64 ± 0.11 




15 A C 4-SO2NEt2 3-CN 1.23 ± 0.06 
16 A C 4-SO2NPr2 3-CN 0.82 ± 0.34 
17 A C 4-SO2NBu2 3-CN 1.34 ± 0.19 
18 A C 4-SO2NPe2 3-CN 0.16 ± 0.06 
19 A C 4-SO2NHCPh 3-CN 1.05 ± 0.76 
20 A C 4-SO2NHPh 3-CN 1.11 ± 0.14 
21 A C 2-OH, 4-F 3-CN 2.37 ± 1.22 
22 A C 3-OH, 4-F 3-CN 1.15 ± 0.08 
23 A C 3-F, 4-OH 3-CN 1.14 ± 0.17 
24 A C 3-CF3, 4-OH 3-CN 2.00 ± 0.37 
25 A C 3-OH, 4-OMe 3-CN 10.93 ± 0.73 
26 A C 3-OMe, 4-OH 3-CN 2.72 ± 0.74 
27 A C 3,4-OMe 3-CN >100 
28 A C 3-F, 4-Cl 3-CN >500 
29 A N H 3-CN >500 
30 B  
N-methyl-4-
nitrobenzenesulfonamide 
3-CN 8.51 ± 3.51 
31 B  B(OH)2 3-CN 0.83 ± 0.38 
32 A C 4-OH 4-CN 0.74 ± 0.09 
33 A C 2-OH, 4-F 4-CN 1.80 ± 0.60 
34 A C 3-OH, 4-F 4-CN 1.83 ± 0.49 
35 A C 3-F, 4-OH 4-CN 0.21 ± 0.08 
36 A C 3-CF3, 4-OH 4-CN 1.11 ± 0.33 
 
aInhibition of PDI was assessed by PDI reductase assay. bIC50 values are indicated as the mean ± SD (standard error) of at least 





Next, we investigated PDI inhibitory activity of the derivatives containing a carboxylic 
acid or carboxymethyl ester in place of the nitrile group at meta position of R2 (Table IV-2). The 
introduction of carboxylic acid at R2 (37-45) generally reduced potency, regardless of the presence 
of a hydroxyl group at R1. However, a carboxymethyl ester (46, 47, 49) increased potency with an 
IC50 range of 0.12 – 0.49 μM compared to compounds containing a nitrile group (5, 6, 24, IC50 
range of 0.85 – 2.0 μM), and we obtained the most potent analogue 46 with a carboxymethyl ester 
(IC50 = 120 ± 10 nM) at R
2. These results indicate that the carboxymethyl ester facilitates stronger 
binding affinity for PDI than chalcones containing other electron-withdrawing groups such as a 
nitrile group or carboxylic acid. Intriguingly, the activity was lost when the carboxymethyl ester 
at R2 was added to the sulfonamide-containing chalcones (51-53), suggesting that the chalcones 
with a hydroxyl group or a sulfonamide moiety at R1 may have different binding modes. 
 
Table IV-2 PDI inhibitory activity of the synthesized BAP2 derivatives 37-53a 
 
Compd Scaffold X R1 R2 IC50 (µM)b 
6 
(BAP2) 
A C 4-OH 3-CN 0.85 ± 0.14 
37 A C 3-OH 3-COOH 10.19 ± 1.41 
38 A C 4-NO2 3-COOH 40 < IC50 < 500 




40 A C 4-Morpholine 3-COOH > 100 
41 A C 4-Piperidine 3-COOH 40 < IC50 < 500 
42 A C 3-OH, 4-OMe 3-COOH > 100 
43 A C 3-F, 4-OH 3-COOH 9.10 ± 2.10 
44 A C 3-CF3, 4-OH 3-COOH 4.09 ± 1.31 
45 B  N-methyl-4-nitrobenzenesulfonamide 3-COOH 4.00 ± 0.60 
46 A C 3-OH 3-COOMe 0.12 ± 0.01 
47 A C 4-OH 3-COOMe 0.40 ± 0.16 
48 A C 3-OH, 4-OMe 3-COOMe 47.8 ± 11.0 
49 A C 3-CF3, 4-OH 3-COOMe 0.49 ± 0.13 
50 A C 3-Br, 4-CH2OH 3-COOMe 0.13 ± 0.03 
51 A C 4-SO2NPr2 3-COOMe > 100 
52 A C 4-SO2NBu2 3-COOMe > 100 
53 B  N-methyl-4-nitrobenzenesulfonamide 3-COOMe > 100 
aInhibition of PDI was assessed by PDI reductase assay. bIC50 values are indicated as the mean ± SD (standard error) of at least 




We also examined the potency of BAP2 derivatives containing different functional groups 
such as trifluoromethyl, hydroxy, methoxy, bromo, boronate, or boronic acid moieties at R2 (Table 
IV-3). Replacing the nitrile in BAP2 (6) and 32 with a trifluoromethyl group reduced the potency 
about 2 to 4-fold (55, 57), suggesting the electron-withdrawing properties at R2 are not driving 
inhibition. But interestingly, replacement with a heterocycle increased analogue activity with IC50 
values of 0.21 – 0.35 μM (68-70). In a series of carboxamide-, sulfonamide-, or carboxylate-
containing analogues (60-65), the compounds with a hydroxyl group at R2 afforded PDI inhibition 
with an IC50 range of 1.7 – 11 μM (60-62), but the potency was abolished upon replacement with 
a methoxy group (63-65), suggesting that the analogues with a hydrophobic moiety at R1 may 
require the hydroxyl anchor at R2 to position them for hydrophobic interactions around the binding 
pocket. In addition, the analogues containing -SO2NHR at R
1 and hydroxyl group at R2 (58, 59) 











Table IV-3 PDI inhibitory activity of the synthesized BAP2 derivatives 54-72a 
 
 
Compd Scaffold  X R1 R2 IC50 (µM)b 
6 
(BAP2) 
A C 4-OH 3-CN 0.85 ± 0.14 
 54 A C 4-OH 2-CF3 1.67 ± 0.29 
55 A C 4-OH 3-CF3 1.56 ± 0.36 
56 A N H 3-CF3 9.57 ± 0.52 
57 A C 4-OH 4-CF3 2.56 ± 1.01 
58 A C 4-SO2NEt2 3-OH 1.29 ± 0.31 
59 A C 4-SO2NPe2 3-OH 0.81 ± 0.56 
60 B  N-methylthiophene-2-carboxamide 3-OH 5.74 ± 0.10 
61 B  N-methylthiophene-2-sulfonamide 3-OH 11.13 ± 0.50 
62 B  Methyl thiophene-2-carboxylate 3-OH 1.75 ± 0.27 
63 B  N-methylthiophene-2-carboxamide 4-OMe > 500 
64 B  N-methylthiophene-2-sulfonamide 4-OMe 40 < IC50 < 500 
65 B  Methyl thiophene-2-carboxylate 4-OMe 40 < IC50 < 500 
66 A C 4-OH 4-OMe 1.74 ± 0.50 
67 A C 3-OH 4-Br 0.40 ± 0.04 
68 A C 3-OH 4-(Pyridin-3-yl) 0.35 ± 0.20 
69 A C 3-OH 3-(Pyridin-4-yl) 0.21 ± 0.19 
70 A C 3-OH 4-(Benzoimidazol-1-yl) 0.23 ± 0.09 
71 B  H 
 




72 B  H 4-B(OH)2 1.25 ± 0.19 
 
aInhibition of PDI was assessed by PDI reductase assay. bIC50 values are indicated as the mean ± SD (standard error) of at least 
three independent experiments.  
 
The SAR of all derivatives are summarized in Figure IV-2, and the results indicate there 
are two different series of active chalcone derivatives. The first series contains a hydroxyl group 
at meta or para position of ring A, and the potency of compounds decreases based on the functional 
group on ring B as follows: COOMe ≈ Br, pyridine, benzimidazole ＞CN ＞CF3 ≫ COOH. The 
second series contains a sulfonamide moiety or aromatic ring with linkers such as carboxamide, 
carboxylate, or sulfonamide at para position on ring A, and the potency of compounds decreased 
based on the functional group of ring B as follows: CN ≈ OH ＞OMe ≈ COOMe.  
 




BAP2 analogues selectively reduce brain cancer cell viability 
We selected 23 BAP2 analogues with IC50 values lower than 1.5 μM against PDI and tested 
for cytotoxicity in a panel of brain cancer cell lines (U87MG, A172, and NU04) (Table IV-4). 
Compound 19 was not soluble in DMSO and therefore not considered further in this study. The 
BAP2 analogues were moderately cytotoxic to U87MG cells, with IC50 values from 10 to 30 µM 
for most of the analogues. In general, the NU04 cells were more sensitive than the U87MG cells 
to treatment. Compounds more potent than BAP2 (6) in both A172 and NU04 cells included 18, 
59, 68, 69, and 70. Among the compounds, compound 18 was the most potent in both U87MG and 
A172 cells (IC50 = 5.6 ± 2.1 µM and 9.0 ± 3.4 µM, respectively). Compound 69 was the most 
potent in the NU04 cell line, with an IC50 value of 3.8 ± 0.1 µM. These chalcone derivatives also 
inhibited PDI activity more potently compared to PACMA3133, a previously reported PDI 
inhibitor (Figure IV-3). Next, we investigated the effect of five BAP2 derivatives on GBM cell 
proliferation. All compounds generally showed a dose-dependent inhibition of colony formation 
in U87MG cells. BAP2 was less potent in the colony formation assay than in the MTT assay as it 
inhibited less than 40 % of cell proliferation at 10 µM, whereas the IC50 value of BAP2 in U87MG 
cells was 10.7 ± 1.8 µM (Table IV-4). Interestingly, unlike BAP2, all other analogues except 59 
inhibited more than 50% of cell proliferation at a lower dose than their IC50 values in U87MG 






Table IV-4 Cytotoxicity of the 23 selected BAP2 analogues in a panel of human GBM cell linesa  
Compd 
IC50 (µM) 
U87MG A172 NU04 
6 (BAP2) 10.3 ± 2.3 16.8 ± 3.5 15.7 ± 3.4 
15 17.7 ± 4.6 26.4 ± 4.1 19.9 ± 8.3 
16 25.6 ± 5.0 35.0 ± 13.1 26.6 ± 0.7 
17 17.0 ± 3.3 67.3 ± 46.8 15.5 ± 4.2 
18               5.6 ± 2.1 9.0 ± 3.4                    5.0 ± 1.8 
19 NS NS NS 
20 48.5 ± 37.5 28.9 ± 3.0 18.7 ± 11.4 
22 22.9 ± 8.1 16.8 ± 3.3 10.6 ± 3.8 
23 29.1 ± 6.9 21.9 ± 7.1                    9.8 ± 1.3 
31             24.3 ± 11.0 20.2 ± 11.0 13.0 ± 2.2 
32 15.1 ± 5.6 20.0 ± 8.6 12.8 ± 2.7 
35 29.0 ± 9.3 28.4 ± 8.4                  15.8 ± 10.3 
36 26.4 ± 8.2 33.7 ± 13.5 10.4 ± 1.3 
46 16.5 ± 7.6 19.5 ± 6.9 22.7 ± 8.2 
47 28.8 ± 2.3 32.3 ± 1.6 30.6 ± 4.4 
49 11.6 ± 0.6 35.0 ± 35.7 10.3 ± 0.7 
50 13.6 ± 1.8 20.6 ± 10.4                  17.2 ± 10.2 
58             40.7 ± 14.5 31.2 ± 8.0                  19.2 ± 10.1 
59 15.0 ± 3.5 11.3 ± 0.3                    7.6 ± 3.1 
67             76.3 ± 23.8 67.8 ± 6.4                  26.2 ± 8.3 
68 10.7 ± 0.8 11.0 ± 0.8                    4.9 ± 1.0 
69             24.9 ± 12.1 11.3 ± 0.1                    3.8 ± 0.1 




72 31.2 ± 2.1 32.1 ± 1.1 22.9 ± 6.5 
 
aCytotoxicity was assessed by MTT assay. IC50 values are indicated as the mean ± SD (standard error) of at least three independent 
experiments for active compounds (IC50 < 20 μM). NS: not soluble in DMSO. 
 
Next, we tested the five BAP2 derivatives in HFF-1 normal human fibroblast cells to 
determine the therapeutic window of this series (Table IV-5). Interestingly, BAP2 had the largest 
therapeutic window, with a 5.8-fold difference in potency in NU04 (15.7 ± 3.4 µM) versus HFF-
1 cells (91.2 ± 13.1 µM). Compounds 59 and 68 demonstrated a 3.8-fold and 4.6-fold difference 
in potency, respectively, between cancer cells and normal cells. In the case of compound 18, 
potency was greater against the HFF-1 cells (3.4 ± 1.1 µM) than the NU04 cells (5.0 ± 1.8 µM). 
These results suggest that BAP2 and analogues may be effective in combination therapy because 











Table IV-5 Cytotoxicity of 6 BAP2 analogues in a human fibroblast cell line HFF-1 and comparison to NU04a 
ID 
IC50 (µM) 
NU04 (µM)  HFF-1 (µM) Fold Difference 
BAP2 15.7 ± 3.4 91.2 ± 13.1 5.80 
18   5.0 ± 1.8   3.4 ± 1.1 0.67 
46 22.7 ± 8.2 17.4 ± 3.5 0.77 
59   7.6 ± 3.1  29.2 ± 4.5 3.85 
68   4.9 ± 1.0 22.5 ± 8.0 4.57 
69   3.8 ± 0.1 31.8 ± 13.2 8.39 







Figure IV-3 Optimized BAP2 analogues inhibit colony formation and PDI activity. (A) Chemical structures of five optimized 




was incubated at 37 °C for 1 h in the presence or absence of indicated compounds. Reduction of insulin was followed by an increase 
in absorbance at 620 nm for 120 min. IC50 values were calculated at 80 min. (C) Colony formation ability of U87MG cells was 
determine in the presence of DMSO, or PDI inhibitors. Normalized well intensity from three independent experiments is shown in 
the right panel. 
 
BAP2 analogues stabilize PDI to thermal degradation 
In order to validate that our compounds interact with PDI and stabilize the protein to 
thermal denaturation, we further tested the compounds in the biochemical thermal shift assay. 
Compounds 18, 46, 59, 68, and 69 were tested at 100 µM against recombinant PDI, and an inactive 
compound 8 was used as a negative control in addition to DMSO. Typically, compounds that bind 
to a protein stabilize its secondary structure and increase the melting temperature; however, 
PACMA31, a validated PDI inhibitor, does not stabilize PDI. This may be explained by the 
irreversible covalent nature of binding to the reactive site cysteines. Because the bond is 
irreversibly covalent, it may not require additional interaction to inhibit PDI activity. On the other 
hand, estradiol, known to bind in the b’ domain of PDI and form critical interactions with His256,35 
stabilizes PDI to thermal denaturation.   
Similar to estradiol and BAP2, the analogues 46, 59, and 68 increased the melting 
temperature by more than 1 °C in a dose-dependent manner, suggesting that these compounds form 
important stabilizing interactions with PDI (Figure IV-4). However, compounds 18 and 69 did not 
stabilize PDI in the thermal shift assay, despite being potent inhibitors of PDI activity; these results 
suggest that these compounds may interact in the active site of PDI, instead of the hydrophobic 
pocket of the b’ domain. This suggests that BAP2 analogues 46, 59, and 68 may form critical 




our hypothesis, we prepared two mutants of PDI: H256A and C53S/C397S. The H256A mutant 
contains a point mutation from histidine to alanine at the key residue 256 where estradiol was 
proposed to bind. The C53S/C397S mutant contains serine residues replacing one cysteine from 
each of the CGHC active sites. In the thermal shift assay, the stabilization by estradiol and BAP2 
was abolished in the H256A mutant, but not the C53S/C397S mutant (Figure IV-4). Interestingly, 
the shift caused by analogues 46, 59, and 68 was not abolished by either mutation. This suggests 
that the histidine may be crucial for BAP2 binding, but other hydrophobic interactions are 
important for analogue binding and activity. Specifically, 46, 59, and 68 may react with the active 
site thiols. These results ultimately suggest that 46, 59, and 68 may be interacting with both the 





Figure IV-4 Optimized BAP2 analogues stabilize PDI. (A) Boltzmann melting temperatures calculated for PDI (0.5 µg/µl) in the 
presence of 100 µM PACMA31, 6, 8, 18, 46, 59, 68, 69, or DMSO. The change in melting temperature compared to DMSO is 
reported above each bar. (B) Dose-response effects of estradiol, 6, 46, 59, and 68 in the presence of PDI. Results are reported as 
the change in the melting temperature of the curve compared to the vehicle control. (C) Change in melting temperature of 0.5 µg/µl 
wild-type, C53S/C397S, and H256A PDI in the presence of indicated compounds at 100 μM (DMSO used as vehicle control.) P: 
PACMA31; E2: estradiol. Results are reported as mean ± standard deviation of three experiments. *: p < 0.05; **: p < 0.01; ***: 
p < 0.001, compared to wild-type PDI values. Statistical significance was measured using 2-way analysis of variance (ANOVA). 
 
BAP2 analogues induce ER stress in GBM cells 
PDI plays an important role in regulating the ER stress response, a mechanism that triggers 
the UPR and ultimately balances ER homeostasis.36 In this study, we hypothesized that inhibition 
of PDI by BAP2 analogues would exacerbate ER stress mechanisms by disrupting homeostatic 




eukaryotic translation initiation factor 2α (EIF2α) in U87MG and A172 cells (Figure IV-5). EIF2α 
is a translation initiation factor downstream of the PERK arm of the UPR, and phosphorylation of 
EIF2α in response to ER stress leads to inhibition of protein synthesis.36 Like tunicamycin, a 
protein glycosylation inhibitor, treatment with BAP2 analogues increased phosphorylation of 
EIF2α above basal levels in both GBM cell lines. Unexpectedly, PACMA31 did not induce 
phosphorylation of EIF2α. PACMA31, BAP2, and analogues also increased expression of GRP78 
(Figure IV-5). These results indicate that treatment of GBM cells with BAP2 analogues promotes 
ER stress, upregulates the UPR, and inhibits protein synthesis. Compound 46 significantly 
promotes the ER stress response in GBM cells. 
 
Figure IV-5 BAP2 analogues inhibit protein synthesis via EIF2α pathway. (A) U87MG cells were treated with tunicamycin (10 
µg/mL), 1.0 μM PACMA31, or 20 μM 6, 46, 18, 68, 69, or 59 for 2 hours and Western blots were performed as described in the 
Experimental Section.  (B) U87MG cells treated with tunicamycin (10 µg/mL), 1.0 μM PACMA31, or indicated compounds at 20 





BAP2 analogues inhibit GBM cell migration 
PDI is involved in the migratory capabilities of glioma cells via the integrin outside-in 
pathway.37 Therefore inhibiting PDI may prevent GBM cell invasion and metastasis. In order to 
determine whether the BAP2 analogues could inhibit cell migration, we performed the wound 
healing assay in A172 cells. BAP2 inhibited wound healing at 10 μM, and all analogues, except 
69, inhibited cell migration in a dose-dependent manner, similar to PACMA31 (Figure IV-6).  
An additional transwell migration assay was performed to validate the migration of A172 
cells in the presence of selected compounds, PACMA31, 6, 18, and 59 at subtoxic concentrations 
(Figure IV-6). Cells were treated with the compounds for 4 hours. All compounds inhibited 
migration at 30 μM, and 18 inhibited migration at 10 μM. We further examined the effect of the 
compounds on the expression level of migration markers including MMP2, MMP9 and p-FAK in 
U87MG cells at 10 µM for 48 hours. Gelatin zymography and Western blot analysis of the 
conditioned media confirmed that PACMA31 and 68 inhibit MMP2 activity and secretion. MMP2 
expression in cells did not change upon BAP2 analogue treatment; however, MMP9 expression 
decreased in the presence of PACMA31, 18, 59, and 68. FAK phosphorylation did not change 
with BAP2 analogue treatment. These results demonstrate that BAP2 analogues inhibit GBM cell 





Figure IV-6 BAP2 analogues inhibit cell migration in a dose-dependent manner. (A) Compounds tested in the wound healing assay 
for 24 hours. Cells were stained with Giemsa stain and images were taken at 10X magnification. (B) A172 cells migrated through 
an 8.0 µm membrane in the transwell migration assay, in the presence of 6, 18, 59, PACMA31, at indicated concentrations, or 
DMSO as a vehicle control. Wells without FBS were used as a control. Images are representative of 5 fields per well. (C) U87 cells 
were treated for 48 hours with 10 µM BAP2 analogues (or 0.25 µM PACMA31). The activity of MMP2 was assessed by gelatin 
zymography. (D) Western blot was performed on the conditioned media of the chalcone-treated cells to determine the expression 
of cleaved MMP2. (E) Western blot was performed on the cell lysates of the chalcone-treated U87MG cells to determine expression 
of MMP2 and MMP9. (F) Western blot was performed on chalcone-treated U87MG cells to assess changes in the phosphorylation 
of FAK. 
 
BAP2 and analogue 46 induce ER stress and downregulate DNA damage response genes 
 Previously, with nascent RNA sequencing (Bru-seq), we demonstrated that BAP2 
treatment of U87MG cells upregulated ER stress and UPR genes and decreased expression of DNA 




and found they had a similar effect on the cells. The transcription of ER stress response genes 
including DDIT3, CHAC1, ASNS, and XBP1 increased upon treatment with both compounds, 
though 18 increased transcription to a greater extent (Figure IV-7). Furthermore, both compounds 
also decreased transcription of RAD51 and E2F1 (Figure IV-7). Additionally, Gene Set 
Enrichment Analysis (GSEA) was performed on the log 2-fold changes of the abundance ratios of 
protein expression between DMSO- and compound-treated U87MG cells. GSEA confirmed that 
both 18 and 46 treatment resulted in profiles that positively correlated with UPR and negatively 
correlated with E2F signaling (Figure IV-8, Figure IV-9, Figure IV-10, Figure IV-11). We applied 
Hallmark pathway analysis via GSEA and identified that genes with decreased transcription upon 
46 treatment also correlated with epithelial-to-mesenchymal transition, TNFα signaling, and 





Figure IV-7 BAP2 analogues induce transcription of ER stress genes and downregulate DNA damage response genes RAD51 and 
E2F1. Traces of RNA transcripts derived from (A) ER stress genes, (B) RAD51, or (C) E2F1 loci in U87MG cells treated with 10 
μM 18 or 16 μM 46 for 4 hours. Traces represent RNA abundance following treatment. RPKM: reads/kilobase of transcript/million 
mapped reads. 
 To further validate the GSEA results, proteomics with tandem mass tag multiplexing was 
performed in U87MG cells treated for 24 hours with DMSO, 20 μM of BAP2 or 18. GSEA 
revealed that BAP2 treatment was positively correlated with the G2M DNA damage checkpoint 




positively correlated with an arsenic oxide signature and negatively correlated with DNA 
replication (Figure IV-12). These results suggest the analogues are targeting PDI and promoting a 
similar transcriptional profile in the cells as BAP2. Long, non-coding RNAs (lncRNA) can act as 
transcriptional regulators39 and impact glioma initiation and progression.40 GSEA of the Bru-seq 
transcription profiles of 18 and 46 also revealed non-coding genes with increased or decreased 
transcription. Transcription of NMRAL2P, a transcribed unprocessed pseudogene and target of 
Nrf2,41 increased upon both 18 (+ 2.72 log2 fold change) and 46 (+ 4.10 log2 fold change) 
treatment of U87MG cells.  
 
Figure IV-8 Upregulated GSEA of 18 treatment. Compound 18 treatment (10 μM in U87MG cells) positively correlates with 
enrichment of (A) HALLMARK_TNFA_SIGNALING_VIA_NFKB, (B) HALLMARK_MTORC1 _SIGNALING, (C) 
HALLMARK_UNFOLDED_PROTEIN_RESPONSE, (D) KEGG_ PROTEASOME, (E) TTCNRGNNNNTTC_HSF_Q6, and (F) 






Figure IV-9 Downregulated GSEA of 18 treatment. Compound 18 treatment (10 μM in U87MG cells) negatively correlates with 
enrichment of (A) HALLMARK_E2F_TARGETS, (B) HALLMARK_G2M_CHECKPOINT, and (C) E2F1_Q6. NES: normalized 
enrichment score; FDR q-val: false discovery rate q-value 
 
Figure IV-10 Upregulated GSEA of 46 treatment. Compound 46 treatment (16 μM in U87MG cells) positively correlates with 
enrichment of (A) HALLMARK_REACTIVE_OXIGEN_SPECIES_PATHWAY, (B) HALLMARK_MTORC1_SIGNALING, 
(C) HALLMARK_XENOBIOTIC_METABOLISM, (D) HALLMARK_UNFOLDED_PROTEIN_RESPONSE, (E) 






Figure IV-11 Downregulated GSEA of 46 treatment. Compound 46 treatment (16 μM in U87MG cells) negatively correlates with 
enrichment of (A) HALLMARK_E2F_TARGETS, (B) HALLMARK_EPITHELIAL _MESENCHYMAL_TRANSITION, (C) 
HALLMARK_TNFA_SIGNALING_VIA_NFKB, (D) HALLMARK_KRAS_SIGNALING_UP, (E) KEGG_RIBOSOME, and 
(F) BMI1_DN.V1_UP. NES: normalized enrichment score; FDR q-val: false discovery rate q-value 
 
 Additionally, PDI inhibition by 18 and 46 induces an immune response. Treatment of 
U87MG cells with 18 increases transcription of genes involved in the 
GO_ANTIGEN_PROCESSING_AND_PRESENTATION_OF_EXOGENOUS_PEPTIDE_AN
TIGEN_VIA_MHC_CLASS_I gene set (NES = +2.37; FDR q-val = 0), and treatment with 46 
correlates with the REACTOME_CLASS_I_MHC_MEDIATED_ANTIGEN_PROCESSING 
_PRESENTATION gene set (NES = + 1.47; FDR q-val = 0.24). Furthermore, treatment with 
compound 18 correlates with both an inflammatory and immune response. PDI has been 
demonstrated to play a role in the immune response, and PDI is required for the degradation of 
major histocompatibility complex (MHC) class I, a protein responsible for antigen presentation 




PDI forms a key disulfide bond with the α2 domain of the MHC class I heavy chain to aid early 
folding of the complex,44 and another PDI family member, ERp57, may also aid stabilization of 
the MHC class I heavy chain via disulfide bond formation.45 Thus, the role of PDI in the immune 
response is complex and the upregulation of transcription in these pathways in response to PDI 
inhibition may be a feedback response to pathway inhibition. 
 
Figure IV-12 GSEA analysis of proteome perturbation by BAP2 and 18 reveals increased expression of G2M checkpoint and 
arsenic trioxide response and reduced expression of proteins involved in ribosome and DNA replication. Gene set enrichment 
analysis was used to assess the effect of PDI inhibitors BAP2 and 18 on the proteome of U87MG cells. GSEA plots of (A) 
upregulated and (B) downregulated pathways upon 20 μM BAP2 treatment: G2M Checkpoint and Ribosome, respectively. GSEA 
plots of (C) upregulated and (D) downregulated pathways upon 20 μM 18 treatment: Response to Arsenic Trioxide and DNA 
replication, respectively. 
BAP2 analogue treatment is synergistic with arsenic trioxide 
Previously, we demonstrated that BAP2 treatment induces transcription of genes similar 
to that of arsenite treatment.38 Furthermore, we observed increased expression of proteins involved 
in the response to arsenic oxide upon treatment with compound 18. Arsenic oxide has been used 
to treat patients with acute promyelocytic leukemia46 and synergy between tetra-arsenic oxide and 
paclitaxel in cancer cells has been observed.47 BAP2 and derivatives 13, 14, and 45 inhibit GBM 




combination index value below 1 using the Chou-Talalay method.48 Our results suggest that these 
BAP2 analogues may best function in combination with other drugs. 
 
Figure IV-13 BAP2 analogues synergize with As2O3. (A) U87MG cells were treated with indicated compounds and As2O3 for 24 
hours and the ability of cells to form colonies was measured. (B) Combination index of the concentration response in Panel A, 
calculated with the Chao Talalay method. Points below the 1.0 indicate synergistic combinations. Points above the line indicate 
antagonistic combinations. (C) Surface representation of the concentration response in Panel A. 
BAP2 analogue treatment synergizes with radiation 
Since PDI inhibition and BAP2 treatment cause global downregulation of DNA damage 
repair genes, we next determined whether BAP2 analogues would synergize with radiation to 




assay demonstrated synergy upon combination of PDI inhibitors and ionizing radiation (IR) 
compared to either modality alone (Figure IV-14). Both BAP2 and 68 treatment synergized with 
IR; however, PACMA31 at 0.05 μM did not. It is likely that the dose of PACMA31 was too low 
to demonstrate synergy, because the enzymatic IC50 value of PACMA31 inhibition of PDI is 
around 10 μM. Therefore, the more potent BAP2 analogues likely synergize with IR by inhibiting 
PDI. These findings provide a strong rationale for the development of PDI inhibitors as agents to 
combine with DNA damage-inducing therapies such as IR. 
 
Figure IV-14 BAP2 and analogue 68 synergize with radiation to inhibit clonogenic growth. (A) D54 cells were treated with 
indicated compounds after exposure to 0, 1, 2, 4, or 6 Gy of radiation. Cells were allowed to form colonies for ten days before 
staining and imaging. Survival curves were generated and radiation enhancement ratio (RER) was calculated for PACMA31 (B), 




BAP2 analogue activity varies against H256A mutant PDI 
As we previously demonstrated that BAP2 requires His256 in the b’ domain for activity, 
similar to estradiol binding, we also tested the BAP2 analogues in the PDI reductase assay against 
H256A PDI (Figure IV-15). The activity of BAP2 analogues, except 59, was reduced upon 
mutation of His256 to Ala similar to BAP2, suggesting the analogues also bind in the b’ domain 
of PDI and require His256 for activity. To further confirm their binding, we used the fluorescent 
dye, 1-anilinonaphthalene-8-sulfonic acid (ANS), which is known to bind and fluoresce 
selectively in the b’ domain of PDI.49 As expected, BAP2 and active analogues hindered the 
ability of ANS to fluoresce at 370 nm, whereas PACMA31, which binds in the active site of 
PDI, and inactive BAP2 analogues (8 and 29) did not hinder dye fluorescence (Figure IV-15). 
Compound 59 is active against the H256A mutant, but competes with ANS for the b’ domain, 
further suggesting a complex binding mode. It is possible that 59 inhibits PDI by binding in 
between the a’ and b’ domains or binds in both sites. To address the potential role of thiol-
dependent inhibition, we tested the BAP2 analogues after competition with N-acetyl cysteine 
(NAC). As a positive control, the activity of PACMA31 was significantly abolished after 
competition with NAC (Figure IV-15). Activity of BAP2 and 68 were unaffected by up to 5 mM 
NAC. Activity of 46 and 59 was abolished by 5 mM NAC, but not by lower concentrations, 
suggesting they may be attacked by the thiol groups on the cysteine active sites. For compound 
59, this is further confirmed by the fact that activity is not dependent on His256. These results, in 
combination with the alanine mutation of His256, suggest that analogue 68 binds in the b’ domain 





Figure IV-15 BAP2 analogues interact with the b’ domain of PDI. (A) Activity of PDI inhibitors at 10 μM (PACMA31 tested at 
30 μM) against wild-type and H256A PDI, measured with the PDI reductase assay. Results are reported as mean ± standard 
deviation of three independent experiments. (B) ANS spectral scan with 5 μM PDI and 100 μM PDI inhibitors (estradiol, BAP2, 
PACMA31, 46, 68, and 59) or inactive BAP2 analogues (8 and 29). (C) Activity of PDI inhibitors at 40 μM in the presence of 
indicated concentrations of N-acetyl cysteine (NAC). P: PACMA31. DMSO used as a negative control. **: p < 0.01; ***: p < 
0.001 compared to wild-type PDI result in the same treatment group. Statistical significance was measured using 2-way analysis 





BAP2 analogues interact with hydrophobic residues in the b’ domain 
We hypothesized that BAP2 derivatives may interact with the b’ domain to enhance 
binding to PDI. This hypothesis is supported by the observation that the replacement of residue 
His256 with Ala abolishes the activity of BAP2 and its analogues. Using a computational 
approach, we docked all BAP2 analogues into three PDI ligand binding sites, including two 
catalytic sites as well as the hydrophobic pocket in the b’ domain (Figure IV-16). The catalytic 
sites contain reactive Cys56 and Cys397, where PACMA31 binds33, and the b’ domain contains a 
hydrophobic pocket for substrate recognition. Molecular docking demonstrated that BAP2 
analogues preferentially interact with the b’ domain of PDI compared to catalytic sites, supporting 
the mutagenesis results (Figure IV-16).  
 
Figure IV-16 BAP2 analogues interact with the b’ domain of PDI. (A) Molecular docking of 68 BAP2 derivatives into three binding 
sites of PDIA1 (PDB ID: 4EKZ): Cys56 (Top right), His256 (middle) and Cys397 (top left). (B) Heat map plot for binding affinities 






In this study, we report a novel target, PDI, for a series of chalcones, perform an extensive 
SAR study, determine their activity on human glioblastoma cell lines, and propose their 
mechanism of action as allosteric inhibitors of the b’ domain of PDI. Electron-deficient olefins 
such as Michael acceptors are susceptible to reactions with nucleophiles, resulting in a covalent 
bond with threonine and cysteine residues of proteins.50, 51 For example, PACMA31, which was 
previously discovered as PDI inhibitor, irreversibly inhibits PDI through its propynoic acid amide 
moiety by covalently binding to cysteine residues in the active site 33, and this is further supported 
by the results herein that demonstrate that PACMA31 inhibition of PDI is challenged by N-acetyl 
cysteine. We would expect chalcone analogues would also inhibit PDI via Michael addition 
reaction with the nucleophilic cysteines in the PDI active site because of their olefin structure. 
However, the activity of BAP2 and its analogues 46 and 68 is unaffected by NAC. Instead, their 
ability to inhibit PDI is abolished upon mutation of the key residue, His256, that is responsible for 
substrate-binding interactions in the b’ domain.35, 52 Furthermore, the stabilizing shift caused by 
BAP2 and analogues in the thermal shift assay is also abolished upon H256A mutation, and BAP2 
and analogues compete with ANS for the b’ hydrophobic binding pocket of PDI. These results 
suggest that the b’ domain is at least critical for BAP2 analogue binding. It should be noted that 
the activity of some BAP2 analogues, such as 59, is not His256-dependent, and the electron-
withdrawing sulfonamide may activate the olefin for nucleophilic attack., These findings indicate 




When the substituent on ring A is an electron-withdrawing group such as a sulfonamide, 
the carbonyl may be activated for a Michael addition with the thiols in the PDI active sites. Without 
an electron-withdrawing group on ring A, the carbonyl is a weak electrophile, and other 
hydrophobic interactions, such as the hydrogen bond with His256, may play a more important role 
instead. It remains to be determined whether b’ domain-binding analogues such as BAP2 and 46 
also interact reversibly with the active site cysteines. As a whole, the mutagenesis evidence 
suggests that BAP2 and analogue 46 inhibit PDI not by attack on the weak Michael acceptor, but 
by interaction with the hydrophobic binding pocket of PDI. This agrees with the recent findings 
that chalcones without any substituents on the olefin do not induce Nrf2, possibly because no 
effective alkylation reaction occurs between the electrophilic chalcone compound and the distinct 
cysteine residues in Keap1.53 Finally, although all the tested chalcones contain the Michael 
accepting site, only few are potent PDI inhibitors. Additionally, the SAR profile of the analogues 
was not flat, demonstrating that these compounds do not all bind the active site cysteines, but have 
a more complex binding mode.  
Nascent RNA transcription analysis of BAP2 analogue treatment provided a blueprint of 
their effect on GBM cell transcription. Cells treated with BAP2 analogues 18 and 46 demonstrated 
increased transcription of genes related to the UPR after four hours of treatment. The increased 
transcription of UPR genes suggests the compounds inhibit PDI in the cells, leading to an increase 
in the unfolded protein load. This result is consistent with the findings of another research group 
that treatment with 2'-hydroxy-2,3,5'-trimethoxychalcone induces the UPR in MDA-MB-231 
breast cancer cells.54 Additionally, BAP2 analogues 18 and 46 decreased transcription of E2F 




reduced E2F expression.38 These results provide further target engagement validation and suggest 
BAP2 analogues inhibit PDI activity in the cells.  
In addition to their role in tumor proliferation, PDI family members are involved in tumor 
immune recognition. Immune response proteins, such as antibodies, are secretory molecules and 
require maturation through the ER to be prepared for secretion. Tumors evade immune recognition 
by “shedding” key immune signal proteins from the tumor cell surface. Neutrophil L-selectin 
adhesion to lymphocytes is dependent on disulfide bonds. PDI inhibition promotes neutrophil L-
selectin shedding, suggesting that PDI promotes signaling for immune pathways to eliminate 
tumor cells.55 Furthermore, PDI has been shown to promote antibody production and the humoral 
immune response in GM-CSF-secreting cancer cells.56 However, ERp5 is necessary for shedding 
of the soluble major histocompatibility complex class-I-related ligand MICA, and thus allows the 
tumor to evade the immune response.57 ERp5, along with ADAM10 (a disintegrin and 
metalloproteinase 10), were also found to block the anti-tumor immune response in classic 
Hodgkin’s lymphoma by shedding NKG2D (natural killer group 2D) receptor ligands.58 Thus, the 
increase in transcription of MHC-related genes that we observe upon treatment with BAP2 
analogues may be a response to MHC complex degradation. Clearly, thiol-based redox reactions 
play a key role in regulating the humoral immune response; however, the precise role of PDI in 
each pathway remains to be defined. 
In summary, we explored the structure of BAP2 by modifying the substituents around ring 
A and ring B and identified potent analogues that may be promising treatment strategies for GBM. 




compounds that induced ER stress and inhibited GBM cell migration and MMP9 expression. 
Especially, the analogues 18 and 46 induced genes involved in the UPR and decreased expression 
of E2F target genes, validating PDI inhibition in the cells. Additionally, we demonstrated the 
therapeutic window afforded with the derivatives and the potential for combination with As2O3. 
Furthermore, preliminary results suggest that the interaction between the compounds and PDI may 
rely on more than a nucleophilic attack with the Michael acceptor region of the compound, and 
hydrophobic interaction in the b’ domain of PDI may play the most significant role. Further 
structural studies are needed to confirm the binding pose of the BAP2 analogues. Our data 
demonstrate that PDI inhibitors should be tested in combination with other targeted agents as well 
as cytotoxic chemotherapy to deliver significant beneficial effects. 
Experimental section 
Cell Culture. The human cell lines, U87MG, A172, and NU04 (ATCC, Manassas, VA), were 
obtained in 2013 and were maintained in RPMI-1640 or DMEM (Thermo Fisher Scientific, 
Waltham, MA) with 10 % fetal bovine serum (Thermo Fisher Scientific, Waltham, MA). Cells 
were grown as monolayer cultures at 37 °C in a humidified atmosphere of 5 % CO2 and tested for 
Mycoplasma contamination with the Mycoplasma detection kit, PlasmoTest (InvivoGen, San 
Diego, California). All cell lines were authenticated with STR DNA profiling (University of 
Michigan, Michigan) and matched to reference profiles from the ATCC database.  
PDI Protein Purification. PDI for this project was purified as reported in Chapter 3. PDI wild-
type, C53S/C397S, and H256A expression and purification were performed as previously 




Measurement of PDI Activity and Competition With N-Acetyl Cysteine. PDI activity was 
assessed by measuring the PDI-catalyzed reduction of insulin as previously described.17 In brief, 
recombinant PDI protein (0.4 μM) was incubated with indicated compounds at 37 °C for 1 hour in 
sodium phosphate buffer (100 mM sodium phosphate, 2 mM EDTA, 8 μM DTT, pH 7.0). For the 
PDI reductase assay containing H256A PDI, the compounds were tested at 10 μM. A mixture of 
sodium phosphate buffer, DTT (500 μM), and bovine insulin (130 μM; Gemini BioProducts, West 
Sacramento, CA) was added to the incubated PDI protein. The reduction reaction was catalyzed 
by PDI at room temperature, and the resulting aggregation of reduced insulin B chains was 
measured at 620 nm. PDI activity was calculated with the formula, PDI activity (%) = 
[(ODT80[PDI+DTT+compound] - ODT0[PDI+DTT+compound]) - (ODT80[DTT] - ODT0[DTT])] / [(ODT80[PDI+DTT] - 
ODT0[PDI+DTT]) - (ODT80[DTT] - ODT0[DTT])] × 100 (ODT0 and ODT80 were the absorbance values at 0 
min and 80 min after the reduction reaction, respectively).  
To assess the effect of NAC on compound activity, compounds were pre-treated with NAC 
for 30 min at 37 °C. The compound:NAC complexes were added to the PDI reductase assay as 
described above to a final concentration of 40 μM and 0, 1, 2, or 5 mM NAC.  
Thermal Shift Assay. Thermal shift of purified PDI (0.5 mg/mL in 50 mM Tris, pH 7.0) in the 
presence or absence of 100 μM compound was determined as described.18 Briefly, 5 µl PBS, 2 µL 
PDI, 1 µL ligand in 100% DMSO, 2.5 µL 8X ROX dye (from Protein Thermal Shift Dye Kit, 
Thermo Fisher Scientific), and water to 20 µL, were dispensed in each well of a 384-well 
microplate. DMSO (5 % in buffer) was used as control. The plate was heated at a temperature 




Fisher Scientific), and melt curves were analyzed with the Protein Thermal Shift software (Thermo 
Fisher Scientific).  
Growth Inhibition Assay. Cell growth inhibition was assessed by MTT assay as previously 
described in Chapter 3.61 Cells were seeded in 96-well plates at 4000 cells/well (A172, NU04) or 
5000 cells/well (U87MG).  
Colony Formation Assay. U87MG cells were seeded in 96-well plates at 200 cells/well. After 
overnight incubation at 37 °C and 5 % CO2, cells were treated with indicated compounds for 24 
hours. The media was removed and replaced with fresh media, and the cells were incubated ten 
days at 37 °C and 5 % CO2. Media was then removed, and crystal violet solution was added (50 
μL) for 30 min. Crystal violet was removed, and cells were washed twice with water and imaged 
with the Odyssey imaging system (LI-COR Biosciences).  
Western Blot Analysis. For ER stress analysis, 0.5 x 106 U87MG cells/well in 6-well plates were 
treated with 20 µM chalcone analogues, 1 µM PACMA31, or DMSO for 24 hours to assess 
changes in GRP78 expression. As a positive control, cells were treated with 10 µg/mL tunicamycin 
for 2 or 24 hours before cells were harvested. For EIF2α phosphorylation analysis, cells were 
treated with 1 μM PACMA31 or 20 μM 6, 18, 46, 59, 68, or 69 for 2 hours. Cells were harvested 
with a lysis buffer (25 mM tris(hydroxymethyl)aminomethane, 150 mM NaCl, 17 mM Triton X-
100, 3.5 mM SDS, pH 7.4), lysed via sonication, and spun in a centrifuge at 13,500g at 4 °C for 
10 min. Supernatant was collected, and protein concentration determined with the BCA assay 
(Thermo Fisher Scientific). Samples were prepared with 30 μg protein and loaded onto 10 % 




immobilon-FL PVDF membranes (EMD Millipore, La Jolla, CA). Membranes were blocked for 
1 hour with Odyssey blocking buffer (LI-COR Biosciences). Membranes were probed for proteins 
using primary antibodies (PDI, Cell Signaling, Danvers, MA, 1:4000; GRP78, Cell Signaling, 
Danvers, MA, 1:2000; pEIF2α, Cell Signaling, 1:200; EIF2α, Cell Signaling, 1:200; actin, Santa 
Cruz, 1:3000; MMP2, Cell Signaling, 1:1000; MMP9, Cell Signaling, 1:1000; p-FAK, Cell 
Signaling, 1:1000; FAK, Cell Signaling, 1:1000) overnight at 4 °C. Membranes were incubated 
with secondary antibodies (anti-rabbit, Cell Signaling, 1:7500, or anti-mouse, Cell Signaling, 
1:5000) and fluorescence was imaged with the Odyssey imaging system (LI-COR Biosciences). 
Gelatin Zymography. U87MG cells were seeded at 0.5 x 106 cells/well in 6-well plates and 
allowed to attach overnight. Cells were serum-starved for 12 hours prior to designated treatment 
with chalcone analogues for 24 hours. Conditioned media was collected, cleared, and mixed with 
5X SDS loading buffer, and 5 µg of protein was subjected to electrophoresis on a 10% SDS-PAGE 
gel containing 0.1% gelatin. After electrophoresis, the gels were washed in washing buffer (50 
mM Tris HCl, 5 mM CaCl2, 1 µM ZnCl2, 2.5 % Triton X-100) twice for 30 min each time, then 
washed for 5 min in incubation buffer (50 mM Tris HCl, 5 mM CaCl2, 1 µM ZnCl2, 1.0 % Triton 
X-100). Incubation buffer was replaced, and the gels were incubated overnight at 37 °C to allow 
for digestion of the gelatin. The gelatinolytic activity of MMPs was visualized by staining the gels 
with 0.5% Coomassie blue R-250 in 45 % methanol and 10 % acetic acid for 1 hour. The gels were 
destained with 45 % methanol and 10 % acetic acid until clear bands appeared. Gels were imaged 




Wound Healing Assay. A172 cells were seeded in 12-well plates at 50,000 cells/well. After 
overnight incubation at 37 °C and 5 % CO2, media was replaced with serum-free DMEM and the 
cells were incubated another 24 hours. A scratch was made in each well, and compounds were 
added at indicated concentrations in media containing 10 % FBS. Cells were allowed to grow for 
24 hours, until the scratch in the negative control wells containing DMSO closed. Cells were 
stained with Giemsa stain (Sigma Aldrich) and imaged with the Olympus IX83 inverted 
microscope at 10X magnification.  
Transwell Migration Assay. The transwell migration assay was performed with BioCoat Control 
Inserts with 8.0 μm PET membrane (Corning, Corning, NY). 1 x 105 A172 cells were treated with 
indicated compounds and seeded into inserts containing serum-free medium. 500 μL DMEM with 
10 % FBS was added to the bottom of each well. The cells were incubated for 4 hours and stained 
with the Giemsa stain. The stained cells were imaged with the Olympus IX83 inverted microscope 
at 10X magnification.  
Bromouridine RNA Sequencing (Bru-seq). Bru-seq was performed as previously described.59 
U87MG cells were treated with DMSO, 18 (10 μM), or 46 (16 μM) for 4 hours. 2 mM Bru was 
added in the last 30 min of treatment. Cells were collected, and total RNA was isolated with TRIzol 
reagent. Bru-labeled RNA was captured from total RNA by incubation with anti-BrdU antibodies 
(BD Biosciences) conjugated to magnetic beads (Dynabeads, goat anti-mouse IgG; Invitrogen). 
Bru-containing RNA population was isolated and sequenced. Sequencing reads were mapped to 




by fold change in transcription compared to control. Sequencing results were filtered using cutoff 
value of gene size > 300 bp and mean RPKM > 0.5. 
The datasets were interrogated with Gene Set Enrichment Analysis (GSEA).60 A pre-
ranked gene list of 7,749 genes was analyzed for gene enrichment using GSEA gene sets based on 
the Kolmogorov-Smirnov statistic. For each gene set, an enrichment score (ES) was normalized to 
account for the difference in gene set size, and a false discovery rate (FDR) was calculated based 
on the normalized enrichment score (NES) values.  
The datasets were also interrogated with Connectivity Map (CMap, 
https://www.broadinstitute.org/connectivity-map-cmap). Bru-seq gene sets were used with a cut 
off of ≥ 2-fold change in transcription. Some genes were omitted from analysis because they had 
no connection in CMap. 
Proteomics with Tandem Mass Tag Multiplexing. U87MG cells were seeded and allowed to 
attach overnight. Cells were treated with DMSO, 20 μM BAP2 or 20 μM 18. Cells were washed 
three times in DPBS and suspended in RIPA buffer. Proteomics experiment and analysis 
performed by the Mass Spectrometry-Based Proteomics Resource Facility in the Department of 
Pathology at the University of Michigan with the TMTsixplex™ Isobaric Label Reagent Set 
(Thermo Fisher). The abundance ratio datasets were transformed to log2(fold change) values and 
interrogated with GSEA.  
Protein Identification and Relative Quantitation by TMT labeling and LC-Tandem MS. 
Tandem Mass Tag (TMT) labeling was performed using the TMT-6plex™ isobaric labeling kit 




minor modifications. Briefly, 75 μg of protein from each sample was reduced with DTT (5 mM) 
at 45 °C for 1 h followed by alkylation with 2-chloroacetamide (15 mM) at room temperature for 
30 min. Proteins were precipitated by adding 6 volumes of ice cold acetone and incubating 
overnight at -20 °C. Precipitated proteins were pelleted by centrifuging at 8000g for 10 min at 4 °C 
and supernatant was discarded. The pellet was resuspended in 100 μL of 100 mM TEAB and 
digested overnight at 37 °C by adding 1.5 μg of sequencing grade, modified porcine trypsin 
(Promega, V5113). TMT reagents were reconstituted in 41 μL of anhydrous acetonitrile and 
digested peptides were transferred to the TMT reagent vial and incubated at room temperature for 
1 h. The reaction was quenched by adding 8 μL of 5 % hydroxylamine and incubating it for further 
15 min. The samples were combined and dried. 
Prior to MS analysis, two-dimensional separation of the samples was performed. For the 
first dimension, an offline fractionation of an aliquot each sample mix (200 μg) using high pH 
reverse phase fractionation kit into 10 fractions was performed following the manufacturer’s 
protocol (Pierce, catalogue no. 84868). Fractions were dried and reconstituted in 12 μL of loading 
buffer (0.1 % formic acid and 2 % acetonitrile). 
Liquid chromatography-mass spectrometry analysis (LC-MultiNotch MS3). The 
MultiNotch-MS3 method was employed.61 Orbitrap Fusion (Thermo Fisher Scientific) and RSLC 
Ultimate 3000 Nano-UPLC (Dionex) were used to acquire the data. Two μM of each fraction was 
resolved in the second dimension on a nano-capillary reverse phase column (Acclaim PepMap 
C18, 2 μm, 75 μm i.d. x 50 cm, ThermoScientific) using a 0.1% formic/acetonitrile gradient at 300 
nl/min (2-22% acetonitrile in 150 min; 22-32% acetonitrile in 40 min; 20 min wash at 90% 




source (ThermoFisher Scientific). Mass spectrometer was set to collect one MS1 scan (Orbitrap; 
120K resolution; AGC target 2×105; max IT 100 ms) followed by data-dependent, “Top Speed” 
(3 seconds) MS2 scans (collision induced dissociation; ion trap; NCD 35; AGC 5×103; max IT 
100 ms). For multinotch-MS3, top 10 precursors from each MS2 were fragmented by HCD 
followed by Orbitrap analysis (NCE 55; 60K resolution; AGC 5×104; max IT 120 ms, 100-500 
m/z scan range). 
Proteome Discoverer (v2.1; Thermo Fisher) was used for data analysis. MS2 spectra were 
searched against SwissProt human protein database (release 2015-11-11; 42084 sequences) using 
the following search parameters: MS1 and MS2 tolerance were set to 10 ppm and 0.6 Da, 
respectively; carbamidomethylation of cysteines (57.02146 Da) and TMT labeling of lysine and 
N-termini of peptides (229.16293 Da) were considered static modifications; oxidation of 
methionine (15.9949 Da) and deamidation of asparagine and glutamine (0.98401 Da) were 
considered variable.  Identified proteins and peptides were filtered to retain only those that passed 
< 1% FDR threshold.  Quantitation was performed using high-quality MS3 spectra (average signal-
to-noise ratio of 6 and < 40% isolation interference). 
1-Anilinonaphthalene-8-sulfonic Acid (ANS) Spectral Scan. The ANS spectral scan was 
performed as previously described.49 Briefly, 5 μM PDI was incubated in the presence 100 μM 
compounds or equivalent DMSO concentration in 50 μL of TBS at 37 °C for 1 hour. Subsequently, 
50 mM ANS was added and the mixture was incubated in the dark at 25 °C for 20 min. 




Clonogenic Assay. D54 cells were irradiated with 0, 1, 2, 4, or 6 Gy and immediately plated in 6-
well plates at 200, 200, 400, 600, and 1000 cells/well, respectively. Cells were treated with DMSO, 
0.05 μM PACMA31, 1 μM BAP2, 1 μM 59, or 1 μM 68 and incubated for 10-12 days before 
colonies were stained using 0.1% crystal violet solution. 
Molecular Docking. Molecular docking of BAP2 derivatives on PDI was performed in the two 
catalytic sites and the hydrophobic binding site using a crystal structure of PDI (Protein Data Bank 
4EKZ). In three separate docking studies, all analogues were docked into the three binding sites 
using Autodock Vina.62 The structures of the BAP2 derivatives were optimized using steepest 
descent geometry optimization with the MMFF94 force field and PyRx tool.  
AutoDock (version 1.5.6; Molecular Graphics Laboratory, La Jolla, CA, USA) was used 
to prepare the input pdbqt file by merging nonpolar hydrogen atoms of PDI and calculating 
Gasteiger charges. Docking was conducted by defining the SG atom in Cys56 and Cys397 and 
NE1 in His256 as the center of the grid box for the catalytic and hydrophobic sites, respectively. 
The grid cavity size was set to 15 × 15 × 15 in the dimensions of x, y and z using 0.375 Å spacing. 
The 2D and 3D diagrams for receptor-ligand interactions were plotted using Discovery Studio 
Visualizer v17.2.0.16349. 
Statistics. The 50 % inhibitory concentration values (IC50) were determined by analyzing the log 
of the concentration−response curves by nonlinear regression analysis using GraphPad Prism 
(version 5). Biochemical and cell culture experiments were performed at least three separate times 
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CHAPTER V  
Characterization of Alpha-Aminobenzylphenol Analogues in Glioblastoma Cell Lines 
 
Introduction5 
 GBM cells survive by upregulating the protein folding oxidoreductase protein disulfide 
isomerase (PDIA1, also known as PDI). PDI reduces, oxidizes, and isomerizes disulfide bonds in 
nascent polypeptides and other substrates via two catalytic CGHC active sites that sit 15-30 Å 
apart in two homogenous domains.1 PDI is overexpressed in several cancers to meet the increased 
demands in protein synthesis.2-4 PACMA31, an irreversible inhibitor of PDI, demonstrated in vivo 
efficacy in a mouse model of ovarian cancer.5 Furthermore, PACMA31 exhibited synergy with 
the multi-kinase inhibitor sorafenib in a mouse model of hepatocellular carcinoma.6  
 The a and a′ domains of PDI are connected by b and b′ domains, which share identity with 
the a and a′ domains, but do not contain the CGHC active sites. As evidenced by the pKa values, 
the N-terminal cysteine in each a and a′ domain active site (Cys53 and Cys397) is stabilized in the 
thiolate form, while the C-terminal cysteine thiolate is destabilized. This allows the nucleophilic 
N-terminal cysteines to attack substrates and form mixed disulfides. The C-terminal cysteines 
 
5 Author contributions: Ding Xue synthesized all compounds and prepared Tables V-6, V-7, and V-8. Hannah Driks 
generated data for Figure V-6F, Figure V-8, and Figure V-10. Kirin Cromer generated data for Figure V-10, V-11, 





more selectively react with the N-terminal cysteines, mediated in the a domain by the pKa of Cys56 
that is lowered by the local environment, containing a conserved Arg120.7 This reaction generates 
a reduced substrate and oxidized state of PDI.  
 The thiolate form of the redox active N-terminal cysteines reacts with electrophilic 
compounds. Thus, many electrophilic compounds have been identified as covalent PDI inhibitors, 
including PACMA315, KSC-348, 3,4-methylenedioxy-β-nitrostyrene (MNS)9, and 16F1610 
(Figure V-1). One of the main challenges of characterizing the many PDI inhibitors identified to 
date, only recently emphasized by Foster, et al., is competition with endogenous levels of 
glutathione.11 Active site PDI inhibitors, especially reactive electrophiles such as PACMA31, may 
compete with glutathione for binding the cysteine thiols of PDI. This strategy is further confounded 
by the fact that numerous PDI family members share similar active site motifs, and although the 
CGHC active site is one of the most reactive of the thioredoxin superfamily, electrophiles that bind 
this site may also bind to other CxxC-containing PDI family members. To address this 
characteristic, we assessed whether the PDI inhibitors retained activity in the presence of 






Figure V-1 Previously reported PDI inhibitors studied in the context of ovarian cancer (PACMA31), Huntington’s disease 
(LOC14), brain cancer (BAP2 and 35G8), thrombosis (Bepristat 1a and isoquercetin), and multiple myeloma (CCF642). KSC-
34 is an a-site selective probe and estradiol is an endogenous ligand of PDIA1. 
 In addition to upregulated PDI expression, glioblastoma cells upregulate the antioxidant 
defense system and are increasingly dependent on glutathione as the tumor grows.12 Glutathione 
is one of the most abundant molecules in the cell, with concentrations of reduced glutathione 
(GSH) estimated to reach up to 10 mM in cellular compartments. The tripeptide composed of 
glutamic acid, glycine, and cysteine is a key redox buffer and antioxidant molecule involved in 
many cellular processes including reactive oxygen species removal, signal transduction, and 





endoplasmic reticulum, the ratio of reduced to oxidized glutathione dictates its role in each 
compartment. In the cytosol, glutathione is present mainly in its reduced form, with a ratio of 
GSH:GSSG of ~50,000:1; the ER is a more oxidizing compartment, with an estimated GSH:GSSG 
ratio of less than 7:1.14 The oxidizing environment of the ER aids in protein folding and specifically 
disulfide bond formation. 
 The initial goal of this study was to characterize a new class of PDI inhibitors in the context 
of glioblastoma. Via a medium-throughput biochemical screen, we identified a series of α-
aminobenzylphenols as inhibitors of PDI that likely target the active site cysteines of PDI via a 
retro-Michael addition reaction. Similar compounds have been reported for multiple targets, 
including HDACs15, MIF tautomerase16-19, STAT3/520, and frataxin21, among others. Furthermore, 
we synthesized two BODIPY-labeled analogues that covalently bound at least two proteins in the 
cell lysate. In addition, cytotoxicity was enhanced when the cells were pre-treated with BSO. Thus, 
the compounds are cell-permeable; however, they may target other thiol-containing proteins in the 
cell. Further optimization to consider these compounds as selective PDI inhibitors in the cells is 
warranted. In all, this study represents the importance of validating in-cell target engagement early 
in the drug discovery process and provides extensive characterization of a class of cysteine-
reactive small molecules. 
Results 
Lead Compound AS15 Is a Nanomolar Inhibitor of PDI. A screening campaign of 1000 highly 





afforded almost 200 compounds that inhibited 50% of PDI activity (Figure V-2). Those 
compounds were screened for cytotoxicity in U87MG and MiaPaCa-2 cell lines, and compounds 
with > 40% inhibition of cell growth at 30 μM were subjected to dose response assays in both the 
MTT assay and PDI reductase assays. AS15 and CD343 emerged as lead scaffolds with IC50 values 
in the PDI reductase assay of 300 ± 90 nM and 150 ± 40 nM, respectively (Figure V-2). When a 
residue in the b′ domain of PDI important for substrate binding, Histidine 256, was mutated to an 
alanine residue, both AS15 and CD343 retained their activity (Figure V-3). AS15 inhibited activity 
of PDIp and ERp57 (Figure V-3). Interestingly, CD343 demonstrated selectivity for PDI, was 
relatively inactive against PDIp, and inactive up to 40 μM against ERp57. The lead compounds 
decreased viability of U87MG cells with IC50 values of 18.3 ± 9.2 μM for AS15 and 10.6 ± 0.7 
μM for CD343 (Figure V-3). Interaction with PDI was further probed with the thermal shift assay; 
however, AS15 and CD343 did not stabilize PDI to thermal degradation, similar to PACMA31. 
These initial results suggested that the compounds inhibit PDI by binding to the active site 






Figure V-2 Discovery and characterization of AS15 and CD343. (A) Discovery funnel. (B) Structures of AS15 and CD343, and 
IC50 values calculated in the PDI reductase assay. (C) Dose-response curves of PACMA31, AS15, and CD343 in the PDI reductase 








Figure V-3 AS15 selectivity for PDIA1 (A) Activity of AS15 and CD343 against wild-type PDIA1 (wt) and H256A mutant PDIA1 
(H256A) in the PDI reductase assay (B) Activity of AS15 and CD343 at 40 μM against PDIp and ERp57 in the PDI reductase 
assay (C) Dose response curves of PDI inhibitors in the MTT assay against U87MG cells. Cells were treated with compounds for 
72 hours before cell viability was measured. 
 
Structure-Activity Relationships Reveal AS15 Analogues Are Not Substrate-Binding 
Domain Inhibitors. To further assess the mechanism of inhibition of AS15 and CD343 and 
determine the structural requirements for their activity, we obtained 89 analogues from Chem Div 
libraries and the NCI Cancer Therapeutics program and tested their potency in the PDI reductase 
assay (Table V-1; Table V-2; Table V-3; Table V-4). Compounds were tested for purity, and only 
compounds with purity > 95 % were used for structure-activity relationship analysis. Generally, 
all AS15 and CD343 analogues possess an α-aminobenzylphenol core that has a 2-phenol, amino 





hydroxybenzo[d][1,3]dioxole (AS15 analogues) or 8-hydroxyquinoline (CD343 analogues) 
moiety consistent as the phenolic moiety and explored more diverse structures in the amino and 
phenyl moieties. For compounds with 5-hydroxybenzo[d][1,3]dioxole moiety, a variety of cyclic 
amines like morpholine, piperidine, piperazine and pyrrolidine were incorporated. Most of the 
compounds inhibited PDI with IC50 values below 1 µM, and different halogens and electron 
donating groups such as chloro, fluoro, methoxy, amino and hydroxy were well-tolerated. Some 
of those compounds showed moderate cytotoxicity with IC50 values of 10-30 µM; however, 
correlation with PDI inhibition was not well observed (Table V-1). Aromatic amines such as 
aminopyridine, aminopyrimidine and imidazole were generally accepted, and PDI inhibition was 
comparable to those with saturated cyclic amines. Ureas were not tolerated, and lead to a complete 
loss of activity, possibly because the basicity contributes to PDI binding (Table V-2). Compounds 
without the bicyclic aromatic core or hydroxy group were inactive against PDI and non-toxic 
(Figure V-5). Furthermore, compounds without the tertiary amine were inactive against PDI and 
were non-toxic, with the exception of compounds containing the tri-methoxy substituent on the 
aromatic ring (Table V-5). The CD series compounds possess the 8-hydroxyquinoline core along 
with aromatic amines such as 2-aminopyridines and anilines, and inhibition of PDI was 
comparable to the AS15 analogues, except that the 4-methyl substitution of the pyridine was not 
compatible when methyl or chloro was present on the phenyl moiety. Interestingly, many of these 
compounds showed stronger cytotoxicity with IC50 values as low as 2.1 ± 0.1 µM.  


















PDI IC50  
(μM)a 




3,4-di-OCH3 0.30 ± 0.09 18.3 ± 9.2 
NC016 368260 3,4,5-tri-OCH3 0.64 ± 0.31 > 10 
NC133 381577 2,4,6-tri-OCH3 0.98 ± 0.30 13.6 ± 1.7 
NC107 368248 3,4-OCH2O- < 0.2 > 30 
NC108 368256 2-OH, 3-OCH3 0.90 ± 0.75 > 10 
NC110 368261 3-OCH3, 4-OH 0.23 ± 0.11 27.1 ± 2.4 
NC161 364724 4-OCH3 0.13 ± 0.06 > 10 
NC134 381579 2-OCH3 0.33 ± 0.05 27.7 ± 2.7 
NC115 368275 4-Cl 0.092 ± 0.023 > 30 
NC117 368277 4-F 0.23 ± 0.06 > 30 
NC141 667921 2-OH 0.34 ± 0.09 > 30 







3, 4, 5-tri-OCH3 0.70 ± 0.13 > 10 
NC022 368274 4-OCH3 0.88 ± 0.36 28.3 ± 1.6 
NC020 368273 4-N(CH3)2 1.27 ± 0.34 24.7 ± 2.4 
NC024 370278 2,4-di-OCH3 2.59 ± 1.84 > 30 
NC162 368254 3,4-OCH2O- 0.35 ± 0.11 > 10 
NC116 368276 4-F 0.27 ± 0.04 > 30 
NC120 369090 
 
4-OH 0.68 ± 0.35 > 30 
NC025 370279 
 
2,4-di-OCH3 0.36 ± 0.05 > 30 
NC026 370281 4-OCH3 1.52 ± 0.02 22.6 ± 5.9 
NC027 370283 4-N(CH3)2 < 0.20 > 30 
NC028 370285 2-OH, 3-OCH3 1.65 ± 0.65 > 10 
NC122 370280 4-F < 0.20 > 30 
NC123 370282 3,4-OCH2O- 0.023 ± 0.017 > 30 
NC124 370284 3,4,5-tri-OCH3 0.18 ± 0.02 24.2 ± 7.1 
aInhibition of PDI was assessed by PDI reductase assay. IC50 values are indicated as the mean ± SD (standard deviation) of 







Table V-2 SAR of compounds with 5-hydroxy benzo[d][1,3]dioxole and other amine moieties 







PDI IC50  
(μM)a 




3,4-OCH2O- 0.072 ± 0.017 > 10 
NC300 368281 3,5-di-OCH3, 4-OH 0.17 ± 0.04 > 10 
NC017 368265 
 
3,4-OCH2O- 1.18 ± 0.11 > 10 
NC019 368270 4-OCH3 1.30 ± 0.39 > 10 
NC165 368268 2-OH, 3-OCH3 9.02 ± 4.61 > 10 
NC299 368279 3,5-di-OCH3, 4-OH 2.20 ± 0.53 > 10 
NC166 368278 4-F 12.72 ± 3.47 > 10 
NC118 368280 
 
4-F 0.67 ± 0.14 > 10 
NC119 369087 4-OCH3 0.62 ± 0.04 > 10 
NC023 ` 
 
4-OH > 40 > 10 







3,4,5-tri-OCH3 > 40 > 10 
NC168 371005 4-F > 30 > 10 
aInhibition of PDI was assessed by PDI reductase assay. IC50 values are indicated as the mean ± SD (standard deviation) of 










Table V-3 SAR of compounds with 8-hydroxyquinoline and 2-aminopyridine moieties 







PDI IC50  
(μM)a 




3,5-di-OCH3, 4-OH 0.18 ± 0.06 7.4 ± 1.2 
CD343 4896-2958 
 
4-Cl 0.17 ± 0.05 10.6 ± 0.7 
CD345 4896-3004 2,6-di-Cl 1.89 ± 0.31 6.9 ± 1.6 
CD639 7706-0076 2-Cl 0.50 ± 0.17 9.4 ± 0.6 
CD611 4896-3086 4-CH3 0.46 ± 0.07 > 10 
CD344 4896-3003 4-CH2CH3 0.17 ± 0.12 9.3 ± 5.9 
CD346 4896-3082 2,5-di-CH3 0.73 ± 0.12 13.8 ± 5.9 
CD355 4896-4013 2,4,6-tri-CH3 0.19 ± 0.09 10 ± 0.6 
CD638 4896-3084 3-OCH3 2.86 ± 2.37 11.9 ± 0.4 
CD626 G856-2546 2-F 0.47 ± 0.17 > 10 







- < 0.20 > 10 
CD354 4896-4000 2-CH3 > 40 > 10 
CD361 5994-0131 2,5-di-CH3 > 40 > 10 
CD350 4896-3501 4-F 0.14 ± 0.06 > 10 
CD377 7706-0074 2-F 0.88 ± 0.23 13.1 ± 3.5 
CD341 4896-0018 2-F, 6-Cl > 40 20.6 ± 7.8 
CD373 7033-0321 3-F 0.35 ± 0.07 9.2 ± 0.4 
CD348 4896-3250 2-Cl > 40 9.9 ± 1.4 
CD349 4896-3254 2,6-di-Cl > 40 7.2 ± 2.2 
CD352 4896-3773 4-OBn 0.62 ± 0.29 9.3 ± 0.9 
CD362 5994-0331 4-CH2CH3 5.39 ± 0.68 8.9 ± 2.2 
CD601 G856-2531 4-CF3 26.50 ± 19.15 2.1 ± 0.1 
CD363 5994-0397 4-NO2 0.53 ± 0.15 3.4 ± 0.6 
CD594 5704-0657 3-OH, 4-OCH3 0.15 ± 0.02 > 10 
aInhibition of PDI was assessed by PDI reductase assay. IC50 values are indicated as the mean ± SD (standard deviation) of 














PDI IC50  
(μM)a 
MTT IC50  
(μM)b 
NC266 1008 - 0.11 ± 0.04 > 10 
NC268 1010 4-NO2 0.15 ± 0.05 > 10 
NC269 1011 4-COOH 0.30 ± 0.05 > 10 
NC270 1012 2-COOH 1.48 ± 1.52 > 10 
NC273 1015 2-COOC2H5 < 0.20 > 10 
NC282 84087 2-OCH3 0.39 ± 0.11 > 10 
aInhibition of PDI was assessed by PDI reductase assay. IC50 values are indicated as the mean ± SD (standard deviation) of 












   
5617-0627 (CD358) 
IC50 > 40 μM 
MTT > 30 μM 
 4364 (NC275) 
IC50 > 40 μM 
MTT > 10 μM 
4365 (NC276) 
IC50 > 40 μM 
MTT > 10 μM 
86164 (NC284) 
IC50 > 40 μM 





IC50 = 7.48 ± 1.11 μM 
MTT > 10 μM 
212412 (NC332) 
IC50 > 40 μM 












R1 R2 R3 R4 R5 
PDI IC50  
(μM)a 
MTT IC50  
(μM)b 
NC002 269128 -H -H -OMe -H -H > 40 > 10 
NC003 269130 -Me -H -OMe -H -H > 40 > 10 
NC007 353647 -H -H -OMe -H -Me > 40 > 10 
NC008 353649 -Me -H -OMe -OMe -Me > 40 > 10 
NC013 363959 -H -OMe -OMe -OMe -Me > 30 0.67 ± 0.46 
NC006 352687 -CH2CH3 -H -OMe -OMe -Me > 40 9.6 ± 0.4 
NC005 350123 -Me -H -OCH2O- -H > 40 > 10 
NC010 355074 -Me -H -OCH2O- -CH2COOH > 40 > 10 
NC011 358073 -Me -Me -OCH2CH3 -Me -Me > 40 > 10 
NC012 363958 -H -H -OCH2CH3 -H -Me > 40 > 10 
aInhibition of PDI was assessed by PDI reductase assay. IC50 values are indicated as the mean ± SD (standard deviation) of 





 Having explored the SAR around the amino and phenyl moieties, which generally had a 
nominal impact on PDI inhibition, we synthesized and tested an additional 38 new compounds to 
diversify the phenolic moiety and probe the impact on PDI inhibition. Notably, this is, to our 
knowledge, the first comprehensive synthesis and biological study of diverse α-
aminobenzylphenol compounds that have distinct heterocyclic phenolic moieties other than 
phenols, hydroxy naphthalenes, hydroxybenzo[d][1,3]dioxoles, and hydroxyquinolines. 
Compounds were classified into three types based on the substitution pattern around the phenolic 
moiety. We speculated that the chelating 8-hydroxyquinoline in the CD series of compounds might 
improve PDI inhibition, acting as a H-bond donor-acceptor pair; thus, several other heterocyclic 
structures with similar characteristics were incorporated to yield Type I compounds (Table V-6). 
The PDI inhibitory effects of Type I compounds indicated that 8-hydroxyquinazoline, 5-
hydroxyquinoxaline, 4-hydroxybenzothiazole, 7-hydroxybenzofuran, 4-
hydroxybenzo[d][1,3]dioxole and 5-hydroxy-1,4-benzodioxane are all well tolerated. The 5-
hydroxy-1,4-benzodioxane DX1-114 inhibited PDI most potently with an IC50 value of 290 ± 120 
nM. The importance of the H-bond acceptor was further validated when replacement with a 4-
indanol structure (DX1-31) resulted in a loss of potency. Interestingly, the position of the H-bond 
donor was flexible (DX1-88), indicating that binding may be supported by interactions with 
surrounding amino acids in the binding pocket. The fact that DX1-113 lost its activity despite 
containing the H-bond donor-acceptor group suggested a bicyclic structure is necessary to fulfill 
the steric requirement around this moiety. Using DX1-133 as a model compound, different 





exhibited IC50 values below 0.2 µM. For Type II compounds with a similar substitution pattern as 
AS15 (Table V-7), both 5-hydroxybenzo[d][1,3]dioxole and 6-hydroxy-1,4-benzodioxane are 
preferred, with 6-hydroxylindoline leading to a moderate loss of activity (DX1-158). Adding a di-
fluoro substitution to DX1-1 improved activity, suggesting the di-fluoro analogue is a potential 
analogue to improve metabolic stability (DX1-17). Compound DX1-69 and DX1-97 lost activity 
completely, again demonstrating the importance of a H-bond acceptor on the bicyclic phenolic 
moiety. Type III compounds with substitution patterns different from AS15 and CD343 were also 
synthesized by incorporating different phenolic moieties (Table V-8). Most compounds lost their 
activity, suggesting an unfavorable binding mode. The exceptions contained a 5-hydroxyindole or 
5-hydroxyindazole, with the latter leading to comparable inhibition of PDI at sub-micromolar IC50 
values for all its analogues. This might be due to the -NH group of indole/indazole forming 
additional interactions with PDI as a H-bond donor. Most of the synthesized α-
aminobenzylphenols were not cytotoxic at 30 µM, which was similar to the trend observed with 












Table V-6 SAR of Type I compounds 
 
 
Compound R R1-N-R2 Phenol Moiety IC50 (μM) 
MTT (% 
inhibition 
at 30 μM) 
DX1-23 2,3-OMe-Ph 
  
0.39 ± 0.03 74 
DX1-24 4-F-Ph 
  
0.69 ± 0.13 54 
DX1-48 4-F-Ph 
  
4.86 ± 2.04 > 30 
DX1-58 4-F-Ph 
  




0.66 ± 0.13 > 30 
DX1-116 4-F-Ph 
  




0.56 ± 0.13 > 30 
DX1-114 4-F-Ph 
  
0.29 ± 0.12 > 30 
DX1-115 4-F-Ph 
  
2.83 ± 1.26 > 30 
DX1-88 4-F-Ph 
  























0.41 ± 0.11 > 30 
DX1-202 
   
< 0.2 > 30 
DX1-203 
   











Table V-7 SAR of Type II compounds 
 
 






1.06 ± 0.31 66 
DX3-59B 4-F 
  
2.9 ± 2.4 > 30 
DX1-155 4-F 
  
0.67 ± 0.29 > 30 
DX1-158 4-F 
  
7.01 ± 1.39 > 30 
DX1-17 2,3-OMe 
  
0.51 ± 0.13 > 30 
DX1-69 4-F 
  
> 30 > 30 
DX1-97 4-F 
  







Table V-8 SAR of Type III compounds 
 
 






> 30 > 30 
DX-96 4-F 
 
> 100 > 30 
DX1-101 4-F 
 
> 100 > 30 
DX1-137 4-F 
 
10.20 ± 2.88 > 30 
DX1-138 4-F 
 
> 100 > 30 
DX1-147 4-F 
 
1.81 ± 0.06 > 30 
DX1-98 4-F 
 
0.35 ± 0.14 87 
DX-142 4-CF3 
 
0.71 ± 0.10 > 30 
DX-143 4-NO2 
 
0.52 ± 0.36 > 30 
DX1-150 
  











0.83 ± 0.29 > 30 
 
 AS15 Analogues Covalently Bind to PDI. We addressed the importance of the phenolic 
hydroxy and amine moiety of the series with two compounds; DX1-185 lost activity with the 
replacement of the phenolic hydroxy (DX1-133) with a methoxy (Figure V-6). Similarly, replacing 
the piperidine in DX3-59B with a cyclohexane abolished its PDI inhibition. Both compounds 











Figure V-6 SAR indicates that compounds are covalent PDI inhibitors. (A) Comparison of compounds with free hydroxy or 
methoxy on the bicyclic moiety. (B) Comparison of compounds with piperidine or cyclohexane moiety. (C) Proposed mechanism 
of inhibition via retro-Michael addition reaction. (D) DX1-1 covalently binds to PDI. 100 μM DX1-1 was incubated with 10 μM 
PDI for 30 minutes prior to injection. (E) DX1-1 binds to PDI preferentially over GSTO1. 100 μM DX1-1 was incubated with a 
mixture of 10 μM PDI and 10 μM GSTO1 for 30 minutes prior to injection. (F) Concentration- and time-dependent PDI inhibition 
curves for kinact/KI determination of PACMA31, 16F16, and AS15. Activity was measured using the PDI reductase assay. 
Absorbance was monitored over time at various concentrations and preincubation times with indicated compounds. (G) Gel-based 
competition with recombinant PDI and PACMA57. +: 20 μM; ++: 100 μM 
         The covalent disulfide bond is a reversible covalent interaction; thus, small molecules could 
also bind reversibly to the cysteine thiols. For example, a Michael-type conjugate addition of 2-
cyanoacrylates to thiols was discovered to be a rapid reversible reaction at physiological pH.24 Due 
to the nature of reversible disulfide bonds, we hypothesized that the AS15 analogues, although 
demonstrating reversible inhibition, may be attacked by the nucleophilic cysteine thiols in the 
active sites of PDI. Upon base-mediated fragmentation to expose the Michael acceptor, the free 
thiol on PDI could react and form a covalent adduct (Figure V-6). This type of retro Michael 
addition to protein thiols has been observed with hydroxyquinolines like CD343. A zinc-dependent 
mechanism opened a quinone methide for selective reaction with HDAC5 and HDAC915, another 
quinone methide intermediate was found to react with protein thiols over forming DNA adducts25, 
and co-crystallization confirmed pyridinylmethyl quinoline fragment binding to MIF tautomerase 
via a proline residue.16 In the case of the pyridinylmethyl quinoline fragment, the compound bound 
via a retro Michael addition reaction that formed the quinone methide intermediate. This 
intermediate was primed to undergo the aza-Michael addition to covalently link to a proline residue 
in MIF tautomerase.  
 To confirm AS15 analogues covalently label PDI, we incubated 10 μM PDI with 100 μM 
DX1-1 or DX1-69 and monitored adduct formation with quadrupole time-of-flight mass 





rapidly (< 5 minutes) after the compound was added. DX1-1 bound oxidized PDI at three sites. 
When DX1-1 was incubated in a mixture of 1:1 PDI:GSTO1, the mass of PDI increased by two 
equivalents of the fragment, demonstrating in vitro selectivity. An inactive analogue of DX1-1 
without the aromatic benzoxole (DX1-69) did not demonstrate covalent binding under the same 
conditions (Figure V-7). 
 
Figure V-7 Spectrum of inactive AS15 analogue, DX1-69 
 To assess the covalent binding nature, we measured the kinact/KI of the lead compounds. 
For covalent inhibitors, the kinact/KI is the ratio of the observed rate of inactivation after a reversible 
reaction to form a protein-inhibitor (P-I) complex with all the protein molecules (kinact) to the 
concentration of inhibitor required to reach half of the maximum rate of covalent bond formation 
(KI). The kinetics of covalent PDI inhibitors 16F16, PACMA31, and AS15 were measured by 
assessing activity in the PDI reductase assay at incubation times from 5 to 60 minutes. AS15 
inhibited PDI with a kinact/KI of 2.6 x 10





102 M-1s-1 and kinact/KI for 16F16 was 1.7 x 10
2 M-1s-1. Thus, AS15 more efficiently inhibited PDI 
than both covalent inhibitors PACMA31 and 16F16. Furthermore, a gel-based competition assay 
with the fluorescent probe of PACMA31, PACMA57, confirmed AS15 analogues could compete 
with PACMA57 to bind PDI.5  
 To address whether the AS15 analogues targeted the active site cysteines of PDI, like 
PACMA31, we performed washout experiments with the PDI reductase assay. AS15 (50 μM) was 
incubated with 40 μM PDI for 3 hours at room temperature. After 3 hours, the PDI-AS15 complex 
was diluted 100-fold into reaction buffer, the reaction was incubated for another hour at 37 °C, 
and insulin was added as a substrate to initiate the reaction. PACMA31 (an irreversible inhibitor) 
at 1 and 100 μM and BAP2 (a reversible inhibitor) at 0.5 and 50 μM were used as controls (Figure 
V-8). We found that both AS15 and CD343 did not maintain the characteristics of the high 
concentration of inhibitor after dilution to the low concentration. These results indicate that AS15 
and CD343 behaved as reversible inhibitors in this wash out experiment. We further tested whether 
the compounds were binding in the b′ domain with the ANS (anilinonaphthalene sulfonic acid) 
spectral scan.26 ANS is a dye that fluoresces upon binding hydrophobic pockets and specifically 
targets the b′ domain in PDI. B′ domain-selective inhibitors of PDI such as estradiol and bepristat 
1a compete with ANS.26 AS15 and CD343 did not lower the fluorescence of ANS (Figure V-8). 
Our combined results from the thermal shift assay, washout experiment, and ANS spectral scan 
demonstrated that AS15 and CD343 are likely not substrate-binding domain inhibitors like 






Figure V-8 Recovery of PDI activity upon treatment with PACMA31 (A), BAP2 (B), AS15 (C), or CD343 (D). (F) ANS spectral 
scan with 5 μM PDI and 100 μM PACMA31, estradiol, or AS15. 
 
AS15 Analogues Compete with Glutathione. Because the AS15 analogues seemed highly 
reactive toward nucleophilic attack, we hypothesized that glutathione may also react with the 
compounds. Glutathione is present in high concentrations in the cytoplasm and is an important 
redox regulator in the ER.27 The oxidizing environment of the ER is maintained by the ratio of 
reduced to oxidized glutathione, which is lower than the ratio in the cytoplasm. Incubating the 
compounds with NAC before adding them to the PDI reductase assay rendered the compounds 
inactive (Figure V-9). AS15 analogues were also inactivated with competing glutathione at 





provided further support that the AS15 analogues act via addition to the active site cysteines in 
PDI.  
 
Figure V-9 N-Acetyl cysteine and glutathione inactivate AS15 analogues. (A) N-Acetyl cysteine competition in PDI reductase 
assay. (B) Glutathione competition in PDI reductase assay. (C) Top two AS15 analogues least sensitive to competition with 5 mM 
GSH in the PDI reductase assay. 
 
 To assess trends in the glutathione sensitivity of the AS15 series, we screened all the 
analogues in the PDI reductase assay in the presence of 5 mM GSH. The high concentrations of 
glutathione in the cytoplasm may inactivate the compound in vivo; thus, the in vitro IC50 value 
may not be a reliable indicator of in vivo activity.11 Although the PDI reductase assay is performed 
at a relatively high concentration of DTT (500 μM), we added 5 mM glutathione to mimic a more 
physiological environment. This issue is particularly relevant because the analogues behave as 
reversible thiol adducts (Table V-9). Substrate-binding domain inhibitors isoquercetin and BAP2 
remained active in the presence of high GSH concentrations. We found two AS15 analogues out 





Table V-9 Percent inhibition of AS15 analogues in the absence or presence of 5 mM GSH in the PDI reductase assay 
 10 μM  
 
10 μM  
 
10 μM 
 - GSH + GSH 
 - GSH + GSH  - GSH + GSH 
PACMA31 95 -2 DX1-114 29 23 NC108 62 0 
isoquercetin 54 42 DX1-115 53 31 NC110 86 5 
CD343 100 15 DX1-116 42 20 NC115 85 3 
CD344 97 3 DX1-125 86 30 NC116 98 9 
CD345 -21 17 DX1-133 99 36 NC117 100 7 
CD346 106 2 DX1-137 32 29 NC118 94 11 
CD350 95 14 DX1-147 47 49 NC119 95 3 
CD352 27 -2 DX1-150 79 32 NC121 100 20 
CD355 90 14 DX1-152 72 47 NC122 97 27 
CD362 98 1 DX1-153 79 55 NC123 100 21 
CD363 -16 1 DX1-155 40 41 NC124 105 31 
CD373 101 -3 DX1-158 40 43 NC133 96 19 
CD377 101 7 DX1-187 99 46 NC134 87 20 
CD528 98 -1 DX1-199 99 42 NC141 102 15 
CD594 109 2 DX1-201 100 53 NC161 98 11 
CD601 -22 -1 DX1-202 100 44 NC162 102 -1 
CD611 102 3 DX1-203 99 47 NC163 99 10 
CD613 123 10 DX1-205 100 52 NC165 0 -1 
CD626 101 9 NC014 100 52 NC166 0 23 
CD638 93 5 NC015 101 55 NC266 101 19 
CD639 30 3 NC016 100 63 NC268 0 21 
CD640 101 4 NC017 60 56 NC269 97 15 
DX1-001 58 29 NC018 95 13 NC270 98 18 
DX1-017 101 34 NC019 27 13 NC272 33 13 
DX1-023 93 23 NC021 97 13 NC273 61 15 
DX1-024 41 33 NC022 100 9 NC282 65 35 
DX1-030 55 21 NC024 95 12 NC299 0 18 
DX1-048 37 21 NC025 -17 11 NC300 97 22 
DX1-058 100 44 NC026 98 23 NC301 0 23 
DX1-088 98 12 NC027 96 4    
DX1-098 73 20 NC028 92 7    
DX1-101 28 31 NC055 97 8    






 We observed that DX1-58 spontaneously formed a dimer after long-term storage, so we 
repurified the monomeric and dimeric forms of DX1-58 and tested each form in the PDI reductase 
assay in the presence of glutathione (Figure V-10). The dimeric form of DX1-58 was less sensitive 
to glutathione competition than the monomer (Figure V-10). Furthermore, we found that both the 
monomer and dimer of DX1-58 bound to PDI (Figure V-10). Incubation with the a′c domain gave 
a species with two fragments of DX1-1 bound, suggesting the compound binds two sites in the a′c 
domain, likely at least at the N-terminal redox-active cysteine Cys397 (Figure V-10). Furthermore, 
when we incubated the monomer and dimer of DX1-58 with a C53S mutant of PDI, we observed 







Figure V-10 Dimerized analogue is less sensitive to GSH treatment. (A) Structure of DX1-58 dimerization. (B) Percent inhibition 





confirms fragment of DX1-58 binds to PDI. (D) One fragment of DX1-58 binds the a′c domain. (E) DX1-58 and DX1-58 dimer 
bind C53S mutant PDI. Toxicity of PACMA31 (F), AS15 (G), CD343 (H), DX1-58 monomer (I), and DX1-58 dimer (J) in the 
colony formation assay in the absence or presence of BSO. U118MG cells were pretreated with BSO for 24 h prior to compound 
addition.   
 Although the PDI disulfides are 500-fold more reactive than glutathione28, we 
hypothesized that glutathione may be inactivating the AS15 analogues and contributing to lower 
their potency. Pretreatment of GBM cells with BSO for 24 hours before adding the compounds 
increased potency in the colony formation assay (Figure V-10; Figure V-11). While the monomer 
of DX1-58 was more sensitive to BSO addition, the DX1-58 dimer was more potent, and its 
potency was not dependent on BSO addition. These results support the hypothesis that glutathione 






Figure V-11 Colony formation assay of PDI inhibitors in combination with BSO in (A) U118MG and (B) A172 cells. Cells were 
pretreated with BSO for 24 h prior to compound addition. 
AS15 Analogue Target Identification. We sought to confirm whether the AS15 analogues could 
target PDI in the cells by synthesizing two analogues of DX3-59 with a BODIPY fluorescent tag 
on the phenyl ring (Figure V-12). The BODIPY-labeled compounds differed in the linker length 
between the parent compound and the tag. DX3-173B contained a two-carbon linker separating 
the amide groups on the BODIPY structure. The first BODIPY analogue did not inhibit PDI 
activity in the PDI reductase assay (Figure V-13). However, it did covalently bind proteins around 





cell-free medium supplemented with fetal bovine serum demonstrated that the compounds bound 
to serum albumin (Figure V-12). Although DX3-173B bound to serum albumin, it inhibited PDI 
activity with an IC50 value comparable to the unlabeled analogue of 1.37 ± 0.23 μM (Figure V-12). 
To verify the band from DX3-159 was not PDI, a Western blot was run with cells treated with 
DX3-159 and DX3-173B. The GFP band from the DX3-159-treated cells runs closer to the 
molecular weight of albumin (69 kDa) than the PDI band around 55 kDa (Figure V-14). 
Additionally, when the cells are treated with DX3-159 after serum starvation, the band disappears 
(Figure V-14). Furthermore, treatment with DX3-173B results in several bands, suggesting the 
compound may have more than one target. With recombinant PDI, DX3-173B covalently binds, 
and binding can be blocked with DTT, further supporting the mechanism of inhibition of this series 






Figure V-12 AS15 analogues bind serum albumin. (A) Structures of BODIPY-labeled AS15 analogues (B) U118MG cells treated 
with 40 μM DX3-159B overnight (C) Cell-free DMEM treated with 20 μM DX3-159B or DX3-173B overnight at 37 °C. (D) DX3-
173B dose-response curve in the PDI reductase assay. (E) Cell lysates incubated with indicated compounds for 24 h at room 







Figure V-13 Activity of DX3-159 against wild-type PDIA1 in the PDI reductase assay   
 
Figure V-14 DX3-159B protein band migrates higher than PDI (A) U118MG cells (in medium supplemented with 10 % FBS) 
incubated with DMSO, 40 μM DX3-159B or 2 μM DX3-173B for 24 hours before being collected in Cell Lytic M buffer and run 
on a 10 % polyacrylamide gel. The gel was imaged in the GFP channel prior to probing for PDI and GAPDH in Western blot 
analysis. (B) U118MG cells were serum starved overnight before incubation with 10 μM DX3-159B for 24 hours before being 







Figure V-15 DTT outcompetes DX3-173B for binding to PDI (A) 250 ng/μL recombinant PDI was incubated with indicated 
concentrations of N-acetyl cysteine (NAC) and DX3-173B at room temperature for 24 hours and run on a 10 % acrylamide gel. 
The PDI band was imaged with the GFP channel on the iBright (Thermo Fisher Scientific). (B) 250 ng/μL recombinant PDI was 
incubated with indicated concentrations of dithiothreitol (DTT) and DX3-173B at room temperature for 24 hours and run on a 10 % 
acrylamide gel. The PDI band was imaged with the GFP channel on the iBright. 
 To further investigate whether the BODIPY-labeled AS15 analogues can target PDI, we 
treated cell lysates with the compounds for 24 hours. DX3-159 did not covalently label proteins in 
the cell lysate, however, DX3-173B bound in two major bands around 55 and 40 kDa, and a minor 
band below 55 kDa (Figure V-12; Figure V-16). In addition, the unlabeled, parent compound 
competed for labeling both bands in a dose-dependent manner, but seemed to compete off the 55 
kDa band at a lower concentration (5x [probe]) than the 40 kDa band (20x [probe]). In addition to 
inhibiting PDIA1 activity, AS15 could also inhibit PDIA3 activity; thus, the band around 55 kDa 
could contain both PDIA1 and PDIA3. Additionally, DX3-173 bound PDIA1, PDIA2, and PDIA3, 
in addition to BSA, and was competed off by the parent compound. Competition was not observed 
for binding to BSA, likely due to multiple binding sites for DX3-173 on BSA (Figure V-17). DX3-
59 dose-dependently competed off DX3-173B for binding PDIA2 and PDIA3 (Figure V-18). 
Combining BSA with PDIA1 for 24 hours with DX3-159 or DX3-173B did not improve binding 





incubated with BSO prior to BODIPY-labeled compound treatment to determine whether 
depleting the cells of glutathione would improve on-target binding. BSO addition improved 
binding for DX3-159, however, binding was non-selective. Furthermore, addition of 10 % FBS 
decreased binding, further confirming the interaction between this series and serum albumin 
(Figure V-20). Incubation of the cell lysate with DX3-173B consistently resulted in three major 
bands (Figure V-20).  
 
 
Figure V-16 AS15 analogues bind multiple proteins. (A) U118MG cell lysates (30 ug) incubated with 50 μM DX3-59 and 10 μM 
DX3-159 or DX3-173B for 24 h at room temperature after cell lysis. (B) U118MG cell lysates (30 ug) treated with increasing 
concentrations of parent compound DX3-59 before addition of BODIPY-labeled DX3-173B. (c) MiaPaCa-2 cell lysates (30 ug) 
incubated with 50 μM DX3-59 and 10 μM DX3-159 or DX3-173B for 24 h at room temperature after cell lysis. (D) MiaPaCa-2 
cell lysates (30 ug) treated with increasing concentrations of parent compound DX3-59 before addition of BODIPY-labeled DX3-






Figure V-17 DX3-59 competition with BODIPY-labeled probe. Fluorescence imaging of recombinant PDI family members and 
BSA at 3.5 μM treated with 100 μM DX3-59 overnight at room temperature. The samples were then treated for 30 minutes at room 
temperature with 20 μM DX3-159 (top) or DX3-173B (bottom). Samples were prepared under reducing conditions and BODIPY 







Figure V-18 Competitive inhibition of BODIPY-labeled AS15 analogue (A) DX3-159 or (B) DX3-173B binding to 10 μM PDIp 
or ERp57 was assessed by in-gel fluorescence imaging. Recombinant protein was incubated with compounds for 24 h at room 
temperature before being analyzed by SDS PAGE. 
 
 
Figure V-19 Competitive inhibition of 20 μM BODIPY-labeled AS15 analogue in BSA. DX3-159 (left) or DX3-173B (right) 
binding to 3.5 μM BSA or PDIA1 was assessed by in-gel fluorescence imaging. Recombinant protein was incubated with 






Figure V-20 Cell-based binding of BODIPY-labeled AS15 analogues DX3-159 (left) or DX3-173B (right) in U118MG cells in the 
presence of 20 μM BSO or 10 % FBS. Cells were serum-starved and/or treated with BSO for 24 hours before compound addition. 
Cells were treated with compounds for 24 hours, then lysed and binding was assessed by in-gel fluorescence imaging under 
reducing or non-reducing conditions. (b) A172 cells were serum-starved 24 hours prior to addition of 20 μM DX3-173B (+). After 
24 hours, cells were lysed in Cell Lytic M buffer, and 40 ug was subjected to SDS-PAGE under reducing conditions. Bands were 
submitted for proteomic analysis. L: protein ladder 
  Proteomic analysis of each of the bands revealed lists of potential target proteins (Table 
V-10; Table V-11; Table V-12). Several PDI family members have a molecular weight around 40 
kDa, including ERp44, PDIA6, and TXNDC5, which could be responsible for the lower band 
(Table V-13). Reported targets of similar scaffolds include MIF tautomerase, HDAC5/9, and 





that the AS15 analogues do not bind these proteins, or the proteins have low abundance in the cell 
lines tested (Table V-14). Furthermore, those known targets, as well as STAT3, STAT5, Mcl-1, 
frataxin, and P2Y12 were not found in the bands analyzed with the proteomics experiment. In 
addition, confocal microscopy revealed that the BODIPY-labeled analogues mainly reside in the 





















Actin, cytoplasmic 1 (ACTB) 6 
cytoskeleton; cytosol; 
membrane; nucleus 
74 21 184 9 41.7 
P00558 Phosphoglycerate kinase 1 
(PGK1) 
7 
cytosol; membrane 69 24 84 20 44.6 
P68133 Actin, alpha skeletal muscle 
(ACTA1) 
6 








72 21 67 18 39.4 
P05783 Keratin, type I cytoskeletal 18 
(KRT18) 
0 
cytosol; nucleus 70 29 113 28 48 
O43852 




59 19 48 19 37.1 





71 32 155 27 53.7 
P08670 
Vimentin (VIM) 1 
cytoskeleton; cytosol; 
membrane 






57 16 54 16 36 
O15260 
Surfeit locus protein 4 (SURF4) 4 
endoplasmic reticulum; 
Golgi; membrane 
18 4 42 4 30.4 
P04439 HLA class I histocompatibility 
antigen, A-3 alpha chain (HLA-
A) 
5 
cell surface; endoplasmic 
reticulum; Golgi; membrane 
53 15 28 2 40.8 




cytosol; nucleus 47 19 44 19 47.7 
O75874 Isocitrate dehydrogenase 




53 19 33 17 46.6 
P00505 Aspartate aminotransferase, 
mitochondrial (GOT2) 
7 
cell surface; membrane; 
mitochondrion 
38 15 31 15 47.5 
P04264 
Keratin, type II cyto 





57 33 101 29 66 
P24752 Acetyl-CoA acetyltransferase, 
mitochondrial (ACAT1) 
5 
membrane; mitochondrion 37 12 18 12 45.2 
P07339 
Cathepsin D (CTSD) 9 
extracellular; membrane 
vacuole 





aPSMs: post-translational modifications bMW: molecular weight 
 
  
Q99536 Synaptic vesicle membrane 





52 13 45 13 41.9 
P30460 HLA class I histocompatibility 
antigen, B-8 alpha chain (HLA-
B) 
6 
cell surface; endoplasmic 
reticulum; Golgi; membrane 
40 11 20 4 40.3 





30 7 10 7 33.5 





55 18 19 18 46.2 
Q96I99 Succinate--CoA ligase [GDP-
forming] subunit beta, 
mitochondrial (SUCLG2) 
6 























76 36 225 33 53.6 
P06733 Alpha-enolase (ENO1) 
6 
cell surface; cytosol; 
membrane; nucleus 
66 20 79 16 47.1 






55 16 82 7 50.1 




74 21 184 9 41.7 




71 32 155 27 53.7 
P05783 Keratin, type I cytoskeletal 18 
(KRT18) 0 
cytosol; nucleus 70 29 113 28 48 






57 33 101 29 66 
P07954 Fumarate hydratase, 
mitochondrial (FH) 3 
cytoplasm; mitochondrion 54 17 34 17 54.6 




39 13 25 13 48.1 
P60842 Eukaryotic initiation factor 4A-
I (EIF4A1) 4 
cytosol; membrane; nucleus 53 18 37 10 46.1 




50 26 84 23 58.8 






53 17 82 1 50.1 





59 19 48 19 37.1 




55 18 29 18 46.4 




56 20 49 20 52.9 
O60664 Perilipin-3 (PLIN3) 
3 
cytosol; endosome; Golgi; 
membrane 
63 19 41 19 47 
P49411 Elongation factor Tu, 
mitochondrial (TUFM) 6 
membrane; mitochondrion 54 19 41 19 49.5 
O75390 Citrate synthase, mitochondrial 
(CS) 4 





aPSMs: post-translational modifications bMW: molecular weight 
  
Q8NBS9 Thioredoxin domain-containing 
protein 5 (TXNDC5) 12 
endoplasmic reticulum; 
extracellular 
39 13 23 13 47.6 
P35527 Keratin, type I cytoskeletal 9 
(KRT9) 4 
cytosol; membrane; nucleus 59 26 75 25 62 






32 14 24 14 50.1 




53 17 24 17 47.3 
























P08670 Vimentin (VIM) 1 
cytoskeleton; cytosol; 
membrane 
76 36 225 33 53.6 
Q71U36 






53 17 82 1 50.1 
P04350 





72 22 107 4 49.6 
P27797 Calreticulin (CALR) 8 
cytosol; endoplasmic 
reticulum; extracellular; 
Golgi; membrane; nucleus 
71 27 52 27 48.1 
P05787 





71 32 155 27 53.7 
P06576 
ATP synthase subunit beta 
(ATP5F1B) 
16 
cell surface; membrane; 
mitochondrion; nucleus 
68 25 68 25 56.5 
P07437 Tubulin beta chain (TUBB) 7 
cytoskeleton; extracellular; 
membrane; nucleus 
67 21 134 4 49.6 
P68104 






55 16 82 7 50.1 
P25705 
ATP synthase subunit alpha 
(ATP5F1A) 
2 membrane; mitochondrion 52 23 48 23 59.7 
P60709 Actin, cytoplasmic 1 (ACTB) 6 
cytoskeleton; cytosol; 
membrane; nucleus 
74 21 184 9 41.7 
P68371 





67 21 118 1 49.8 
P04264 






57 33 101 29 66 
P00352 
Retinal dehydrogenase 1 
(ALDH1A1) 
11 cytosol 59 25 31 23 54.8 
P35527 
Keratin, type I cytoskeletal 9 
(KRT9) 
4 cytosol; membrane; nucleus 59 26 75 25 62 
P00367 
Glutamate dehydrogenase 1 
(GLUD1) 
6 cytoplasm; mitochondrion 43 20 25 20 61.4 
P13645 





50 26 84 23 58.8 
P50995 Annexin A11 (ANXA11) 6 
cytoskeleton; cytosol; 
membrane; nucleus 






















mitochondrion;  nucleus 




10 mitochondrion 33 13 18 13 54.1 
Q07960 





52 16 18 16 50.4 
P06733 Alpha-enolase (ENO1) 6 
cell surface; cytosol; 
membrane; nucleus 








53 19 20 19 55.5 
Q16658 Fascin (FSCN1) 11 cytoskeleton; cytosol 44 18 19 18 54.5 
P54727 
UV excision repair protein 




44 12 12 10 43.1 
P68366 










Table V-13 PDI family members and molecular weight 
Gene name Size (kDa) Gene name Size (kDa) 
P4HB 55 PDIA12 (TMX2) 34 
PDIA2 55 PDIA13 (TMX3) 52 
PDIA3 (ERp57) 54 PDIA14 (TMX4) 39 
PDIA4 (ERp72) 71 (TMX5) not reported 
PDIA5 (PDIR) 57 PDIA15 (ERp46) 48 
PDIA6 (P5) 46 PDIA16 (ERp19, AGR1) 18 
PDIA7 (PDILT) 67 PDIA17 (AGR2, HAG-2) 20 
PDIA8 (ERp27) 30 PDIA18 (AGR3, HAG-3) 19 
PDIA9 (ERp29) 
29 PDIA19 (ERdj5) 91 
PDIA10 (ERp44) 
44 PDIB1 (CASQ1) 45 
PDIA11 (TMX1) 







Table V-14 Known targets of similar inhibitors 






HDAC5/HDAC915 122/111 14/11 nucleus 
 
STAT3/520 88/91 14/10 nucleus 
 
Mcl-129 37 2 nucleus 
 














frataxin21 23 2 cytoplasm 
 







Figure V-21 Confocal microscopy images at 60X magnification of A172 cells treated with 10 μM DX3-159B (A) or 2 μM DX3-
173B (B) for 24 h prior to fixation and staining for PDI 
 
AS15 Analogue Activates the Unfolded Protein Response. We performed nascent RNA 
sequencing of one of the most potent analogues of AS15, DX1-202, to analyze changes in gene 
transcription in U87MG cells (Figure V-22).32 Four hours after 20 μM DX1-202 treatment, 68 
genes were upregulated at least two-fold and 12 genes were downregulated at least two-fold. We 
performed Gene Set Enrichment Analysis on the pre-ranked gene list of 7907 genes and identified 
that DX1-202 upregulates transcription of genes involved in the unfolded protein response (Figure 
V-23). STRING (Search Tool for the Retrieval of Interacting Genes/Proteins) interactions of 
significant genes in the DX1-202 Bru-seq dataset also demonstrated genes affected were involved 
in protein folding, ER stress, and response to ER stress (Figure V-22; Table V-15). Affected UPR 
genes included CALR, HSPA5, MYZAP, NQO1, and SLC7A11. Calreticulin (CALR) is an 
endoplasmic reticulum chaperone like PDI, specifically folds glycoproteins to be secreted, and 
mediates calcium homeostasis in the organelle.33 Calreticulin acts as a sensor of ER stress because 





regulate glycoprotein isomerization.34 However, DX1-202 treatment did not increase total cellular 
CALR expression in brain cancer cells (Figure V-22). HSPA5 encodes for GRP78/BiP, an 
important chaperone responsible for promoting tumor growth.35 Nascent polypeptides enter the 
endoplasmic reticulum and interact with GRP78/BiP to initiate protein folding. Increased 
transcription of GRP78/BiP indicates the cells are undergoing an unfolded protein stress response. 
NAD(P)H Quinone Dehydrogenase 1 (NQO1) is a cytosolic quinone reductase that promotes 
quinone-glutathione conjugation and removal from the cells. It is generally highly expressed in 
cancers and allows the tumor to cope with increased cytotoxic stress.36 SLC7A11 encodes for a 
cystine/glutamate antiporter protein that resides on the cell membrane. SLC7A11 is part of the 
system xc
- antiporter system that uptakes extracellular cystine as a precursor for GSH biosynthesis 
in exchange for glutamate.37 Interestingly, we observed upregulated transcription of SLC7A11 
upon treatment with PDI inhibitor 35G8 as well.38 Our results indicate that PDI inhibition may be 
synthetically lethal with system xc
- inhibition. Myocardial Zonula Adherens (MYZAP) is part of a 
transcriptional unit containing downstream gene POLR2M (polymerase (RNA) II (DNA directed) 
polypeptide M). MYZAP protein is expressed in cardiac tissue and is involved in signaling via 
Rho-related GTP-binding proteins. The Bru-seq RNA sequencing genes affected support DX1-






Figure V-22 DX1-202 upregulates transcription of genes involved in the unfolded protein response. (A) Structure of DX1-202. (B) 
DX1-202 promoted gene set enrichment similar to the unfolded protein response. NES: normalized enrichment score. FDR q val: 
false discovery rate q value. Criteria for GSEA was p < 0.05 and false discovery rate < 25%. (C) STRING interactions of significant 
genes in DX1-202 Bru-seq dataset. Four-hour treatment with DX1-202 increases transcription of representative unfolded protein 
response genes including CALR (D), HSPA5 (E), MYZAP (F), NQO1 (G), and SLC7A11 (H). (I) U118MG cells were treated with 






Figure V-23 Compound DX1-202 treatment (20 μM in U87MG cells) positively correlates with enrichment of (A) 
HALLMARK_MYC_TARGETS_V1, HALLMARK_MTORC1 _SIGNALING, and KEGG_PROTEASOME, and negatively 
correlates with enrichment of (B) KEGG_TASTE_TRANSDUCTION, KEGG_SYSTEMIC_LUPUS_ERYTHEMATOSUS, and 
HALLMARK_UV_RESPONSE_DN. NES: normalized enrichment score; FDR q-val: false discovery rate q-value 
 







discovery rate matching proteins in your network (labels) 
protein folding 7 214 0.00021 CALR,CLU,FKBP4,HSPA2,HSPA5,P4HB,PPIB 
response to endoplasmic 
reticulum stress 
7 240 0.00022 CALR,HSPA5,HYOU1,P4HB,PSMC3,PSMC5,SRPR 
proteasome-mediated ubiquitin-
dependent protein catabolic 
process 






 We further analyzed the Bru-seq signature of DX1-202 with the Connectivity Map (Table 
V-16; Table V-17).39 Because less than ten genes were significantly downregulated upon DX1-
202 treatment, the Connectivity Map analysis included only upregulated genes. DX1-202 had a 
similar gene expression signature as the seleno-organic glutathione peroxidase mimetic ebselen.40 
Ebselen is an antioxidant that is known to react with cysteines, and it targets GTPase protein Rac1 
in humans.41, 42 Interestingly, ebselen inhibits MIF tautomerase activity as well.18 This indicates 
that the signature of DX1-202 may be an artifact of global cysteine reactivity rather than selective 
target inhibition. Furthermore, the signature of DX1-202 demonstrated similarity with knockdown 
of KDELR3 (KDEL endoplasmic reticulum protein retention receptor 3). KDELR3 contains four 
cysteines and is upregulated as part of the unfolded protein response.43 The protein is in a family 
of three KDEL receptors localized to the ER and Golgi complex. These results confirm that DX1-











Table V-16 Top 25 compounds that positively correlate with DX1-202 treatment in CMap. 
Name Description CMap Score 
avrainvillamide-analog-3 nucleophosmin inhibitor 99.47 
BRD-K06817181 JAK inhibitor 99.40 
perospirone dopamine receptor antagonist 99.33 
ebselen GTPase inhibitor 99.33 
hydroquinidine antiarrhythmic 99.25 
devazepide CCK receptor antagonist 99.19 
tosyl-phenylalanyl-chloromethyl-ketone chymotrypsin inhibitor 98.84 
erbstatin-analog EGFR inhibitor 98.41 
SA-792728 sphingosine kinase inhibitor 98.30 
isoliquiritigenin guanylate cyclase activator 98.17 
sappanone-a tyrosinase inhibitor 97.60 
exemestane aromatase inhibitor 96.86 
CA-074-Me cathepsin inhibitor 96.76 
RITA MDM inhibitor 96.62 
penicillic-acid other antibiotic 96.44 
ABT-737 BCL inhibitor 96.30 
tyrphostin-AG-82 EGFR inhibitor 95.36 
NVP-AUY922 HSP inhibitor 95.35 
capsazepine TRPV agonist 94.82 
INCA-6 calcineurin inhibitor 93.42 
dihydro-7-desacetyldeoxygedunin HSP inhibitor 93.30 
etacrynic-acid sodium/potassium/chloride transporter inhibitor 93.14 
PD-160170 neuropeptide receptor antagonist 92.87 
MNITMT lymphocyte inhibitor 90.69 






Table V-17 Top 25 compounds that negatively correlate with DX1-202 treatment in CMap. 
Name Description CMap Score 
dexbrompheniramine histamine receptor antagonist -99.93 
KU-C103428N CDC inhibitor -99.93 
cabergoline dopamine receptor agonist -99.93 
RO-90-7501 beta amyloid inhibitor -99.93 
calyculin protein phosphatase inhibitor -99.93 
motesanib KIT inhibitor -99.89 
L-745870 dopamine receptor antagonist -99.89 
TUL-XXI039 serine/threonine kinase inhibitor -99.86 
tandutinib FLT3 inhibitor -99.82 
etilefrine adrenergic receptor agonist -99.82 
telenzepine acetylcholine receptor antagonist -99.79 
scopolamine acetylcholine receptor antagonist -99.79 
erythromycin NFkB pathway inhibitor -99.79 
rufloxacin bacterial DNA gyrase inhibitor -99.75 
xanthoxyline antifungal -99.74 
nefopam cyclooxygenase inhibitor -99.74 
andarine androgen receptor modulator -99.72 
mofezolac cyclooxygenase inhibitor -99.72 
AR-A014418 glycogen synthase kinase inhibitor -99.72 
damnacanthal SRC inhibitor -99.71 
tiaprofenic-acid cyclooxygenase inhibitor -99.69 
axitinib PDGFR receptor inhibitor -99.68 
NAS-181 serotonin receptor antagonist -99.61 
betaxolol adrenergic receptor antagonist -99.61 







  Target engagement in cells is a critical aspect of preclinical targeted drug 
development. It is important to understand and verify that the compound can hit the target, and 
that interaction causes the observed phenotype. There are multiple techniques used to assess target 
engagement, including direct assays such as the cellular thermal shift assay (CETSA), drug affinity 
responsive target stability (DARTS), the NanoLuc thermal shift assay, and bioluminescence 
resonance energy transfer (BRET), or indirect methods such as knockdown effects or biomarker 
expression.44 The core scaffold of AS15 contains a phenolic Mannich base, which is a known 
promiscuous structure.45 Thus, these compounds require careful assessment beyond lead 
discovery, especially in terms of selective target engagement. In order to determine on-target 
labeling of PDI in cells, we synthesized two variations of BODIPY-labeled AS15 analogues. Our 
initial discovery upon treating cells with these compounds was that the compounds bind to serum 
albumin, an abundant protein containing 35 cysteine residues. When the AS15 analogues were 
incubated with the cell lysates, we observed binding in three major bands, indicating that the 
compounds bound to proteins around 57 and 40 kDa. While plasma protein binding is a 
consideration for improvement of potency of this series, it will be important to establish whether 
one of the bands in the lysate contains PDIA1, and what the other targets of the compounds are. If 
the targets are identified, selectivity could be optimized to one or more of the targets. 
 These results corroborate previous findings with this Mannich base series. Targets 
identified for this series of compounds are summarized in Table V-14. The frataxin inhibitor, 





toxic up to 100 μM in cells and dose-dependently prevented the ubiquitination of frataxin. The 
authors did not perform selectivity experiments since they were measuring a cellular protein 
function; however, they did show that the compound did not bind denatured protein. In the same 
year, another group reported a series of hydroxyquinolines similar to CD343 as selective Mcl-1 
inhibitors. With an SAR campaign, they demonstrated that the hydroxyl group and nitrogen were 
important for Mcl-1 activity. While we did not test their reported Compound 9, DX1-23 and DX1-
24 are similar compounds, with the piperazine replaced by a morpholino group or pyrazine group. 
These compounds had submicromolar IC50 values in the PDI reductase assay, similar to the IC50 
against Mcl-1 in the fluorescence polarization assay. In terms of selectivity, the researchers were 
able to demonstrate a correlation between a downstream response to Mcl-1 inhibition – 
cytochrome c release, and the extent of mitochondrial priming in cells.29 Further targets of this 
series include HDAC5/9 and STAT3/5, BRAFV600E, and P2Y12. NC124 was highly potent against 
leukemia cell lines (THP-1 and KASUMI-1), though it was much less potent against U87MG cells 
(IC50 = 24.2 ± 7.1 μM), possibly because TET1 expression is relatively lower.
46 Interestingly, 
several of the groups remarked that this series of compounds passed protein reactivity filters. 
 Because the analogues we tested were inactivated by GSH addition in the PDI reductase 
assay, we tested whether GSH depletion in a cell-based assay would influence potency. The 
compounds were all more potent when the cells were treated with non-toxic concentrations of 
BSO, the glutathione synthesis inhibitor. This result suggests that either the compounds are being 





prevents PDI from rescue. Thus, a potential strategy for further modification would include 
decreasing GSH reactivity of the series. 
 The glutathione-mediated antioxidant defense system is upregulated in cancer cells 
compared to normal cells to mitigate the harmful byproducts of increased cell metabolism.47 Thus, 
increased concentrations of GSH are responsible for resistance to anti-cancer therapy. 
Temozolomide-resistant GBM tumors rely on glutathione antioxidant signaling pathways for 
survival.48 Glutathione promotes metastasis in liver cancer and overexpression of glutathione 
synthesis enzymes has been linked with drug resistance.49, 50 
 Starting from a lead compound containing a benzobenzoxole scaffold and morpholine 
moiety, we investigated modifications around the core. The trends in the structure-activity 
relationships of the analogues that a tertiary amine and hydroxyl group were critical for activity 
demonstrated that the inhibitors likely bound to the active site cysteines of PDI. These results were 
validated by protein mass spectrometry that showed that AS15 analogues bound in the active site 
of PDI. Though the compounds were potent in vitro inhibitors of PDI, glutathione inactivated the 
compounds, and target engagement will need optimization to move this series forward. The 
promiscuity of this series requires careful medicinal chemistry optimization to pursue as a target-
based anti-cancer strategy. Because of the binding pattern of the AS15 analogues and reactivity 








Cell Culture. Human glioblastoma cells U87MG, NU04 and A172 were obtained from the ATCC 
(Manassas, VA), and NU04 and A172 were maintained in RPMI-1640 (Thermo Fisher Scientific, 
Waltham, MA) supplemented with 10 % fetal bovine serum (FBS) (Thermo Fisher Scientific). 
Dulbecco′s phosphate-buffered saline (DPBS) was purchased from Thermo Fisher Scientific. 
U87MG and HEK293T cells were maintained in DMEM supplemented with 10 % FBS. Cells were 
grown as monolayer cultures at 37 °C in a humidified atmosphere of 5 % CO2 and tested for 
Mycoplasma contamination with the Mycoplasma detection kit, PlasmoTest (InvivoGen, San 
Diego, California). All cell lines were authenticated with STR DNA profiling (University of 
Michigan, Michigan, USA) and matched to reference profiles from the AATC database. 3-(4,5-
dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) was purchased from Amresco 
(Solon, OH). Small molecule screening libraries were purchased from ChemDiv (San Diego, CA) 
or obtained from the National Cancer Institute through the Developmental Therapeutics Program. 
 
PDI protein purification. PDI for this project was purified as reported in Chapter 3. PDIp, 
ERp57, and the a′c domain of PDI were purified as described previously.22 
Site-directed mutagenesis. H256A and C53S mutants of PDI were obtained using wild-type PDI 
as the DNA template with the QuikChange II XL Site Directed Mutagenesis kit (Agilent 
Technologies, Santa Cruz, CA). Procedure was performed according to the manufacturer’s 





observed. Mutant PDI constructs were transformed into BL21 DE(3) cells and purified according 
to the wild-type PDI purification protocol. 
PDI reductase assay. PDI activity was assessed by measuring the PDI-catalyzed reduction of 
insulin as described previously.17 In brief, recombinant PDI protein (0.4 μM or 50 nM for PDIA1, 
1.6 μM PDIp or ERp57) was incubated with indicated compounds at 37 °C for 1 hour in sodium 
phosphate buffer (100 mM sodium phosphate, 2 mM EDTA, 8 μM DTT, pH 7.0). A mixture of 
sodium phosphate buffer, DTT (500 μM or 125 μM for 50 nM PDI reaction), and bovine insulin 
(130 μM; Gemini BioProducts, West Sacramento, CA) was added to the incubated PDI protein. 
The reduction reaction was catalyzed by PDI at room temperature, and the resulting aggregation 
of reduced insulin B chains was measured at 620 nm. PDI activity was calculated with the formula, 
PDI activity (%) = [(ODT60[PDI+DTT+compound] − ODT0[PDI+DTT+compound]) − (ODT60[DTT] − ODT0[DTT])] / 
[(ODT60[PDI+DTT] − ODT0[PDI+DTT]) − (ODT60[DTT] − ODT0[DTT])] × 100 (ODT0 and ODT60 were the 
absorbance values at 0 and 60 min after the reduction reaction, respectively). For reactions 
containing 50 nM PDI, PDI activity was measured at T180, or 180 min after insulin was added. 
 To determine the Kinact/kI of covalent PDI inhibitors, the published procedure was adapted 
with the following modifications.8 Compounds were incubated at 13.2 μM,19.8 μM, 29.6 μM, 44.4 
μM, 66.7 μM, 100 μM, and 150 μM for 5, 15, 30, 45, or 60 min before addition of the insulin 
solution. The linear portions of the slopes of each kinetic curve obtained were used to calculate 
the Kobs in GraphPad Prism. The kobs at each concentration was plotted to obtain the slope of the 





Growth inhibition assay. Cell growth inhibition was assessed by MTT assay as previously 
described in Chapter 3.61 Cells were seeded in duplicate in 96−well plates at 3000 − 5000 
cells/well. For glutathione depletion experiments, cells were pretreated for 24 h with buthionine 
sulfoximine (1 mM in A172 or 4 μM in U118MG) before compound addition.  
Thermal shift assay. Thermal shift of purified PDI (0.3 mg/ml in 100 mM NaPO4, pH 7.0) in the 
presence or absence of indicated compounds was determined as described.18 Briefly, PDI, 100 μM 
compound or DMSO as a vehicle control, 1X ROX dye, and 5 μl Protein Thermal Shift Buffer 
were mixed to a 20 μl total volume in a 384−well microplate. Each reaction was repeated in 
quadruplicate and reactions were mixed before measurements were taken. The plate was heated 
from 25 to 90 °C at 0.05 °C/second with the ViiA 7 Real−Time PCR System (Thermo Fisher 
Scientific, Waltham, MO). Melt curves were analyzed with the Protein Thermal Shift software 
(Thermo Fisher Scientific) and Boltzmann melting temperatures were reported. 
Reversibility Assay. PDI activity was assessed by measuring the PDI−catalyzed reduction of 
insulin as described previously.17 In brief, 0.4 μM recombinant PDI was incubated with 
compounds at indicated concentrations at 37 °C for 1 hour in sodium phosphate buffer (100 mM 
sodium phosphate, 2 mM EDTA, 8 μM DTT, pH 7.0). For samples containing diluted 
protein−compound complexes, 40 μM PDI was incubated with 100 μM PACMA31, 50 μM BAP2, 
50 μM AS15, or 50 μM CD343 for 3 h at room temperature. The mixtures were diluted 100−fold 
into buffer (100 mM sodium phosphate, 2 mM EDTA, 8 μM DTT, pH 7.0) and added to the 
384−well, black, clear−bottom plate. A mixture of sodium phosphate buffer, DTT (500 μM), and 





PDI−compound samples. The reduction reaction was catalyzed by PDI at room temperature, and 
the resulting aggregation of reduced insulin B chains was measured at 620 nm. Absorbance at 620 
nm was measured in a 384−well black−walled, clear−bottom plate. 
1-Anilinonaphthalene-8-sulfonic acid (ANS) Spectral Scan. The ANS spectral scan was 
performed as previously described.26 Briefly, 5 μM PDI was incubated in the presence 100 μM 
compounds or equivalent DMSO concentration in 50 μL of TBS at 37 °C for 1 hour. Subsequently, 
50 mM ANS was added and the mixture was incubated in the dark at 25 °C for 20 min. 
Fluorescence spectrum (Ex: 370 nm, Em: 400–700 nm) was measured in a 384−well black−walled, 
clear−bottom plate.  
Bromouridine RNA Sequencing (Bru-seq). Bru-seq was performed as previously described.51 
U87MG cells were treated with DMSO or DX1-202 (20 μM) for 4 h. 2 mM Bru was added in the 
last 30 min of treatment. Cells were collected, and total RNA was isolated with TRIzol reagent. 
Bru-labeled RNA was captured from total RNA by incubation with anti-BrdU antibodies (BD 
Biosciences) conjugated to magnetic beads (Dynabeads, goat anti-mouse IgG; Invitrogen). Bru-
containing RNA population was isolated and sequenced. Sequencing reads were mapped to the 
hg38 reference genome. Pre-ranked gene lists were generated for each treatment ranking genes by 
fold change in transcription compared to control. Sequencing results were filtered using cutoff 
value of gene size > 300 bp and mean RPKM > 0.5. 
The datasets were interrogated with Gene Set Enrichment Analysis (GSEA).52 A log2(fold change) 





on the Kolmogorov-Smirnov statistic. For each gene set, an enrichment score (ES) was normalized 
to account for the difference in gene set size, and the false discovery rate (FDR) was calculated 
based on the normalized enrichment score (NES) values.  
Western blot. Cells were harvested with a lysis buffer (25 mM 
tris(hydroxymethyl)aminomethane, 150 mM NaCl, 17 mM Triton X-100, 3.5 mM SDS, pH 7.4), 
lysed via sonication, and spun in a centrifuge at 13,500g at 4 °C for 10 min. Supernatant was 
collected and protein concentration determined with the BCA assay (Thermo Fisher Scientific, 
Waltham, MO). Samples were prepared with 30 μg protein and loaded onto 10 % acrylamide (Bio-
Rad, Hercules, CA) gels. Protein from gels was electrotransferred to methanol-activated 
immobilon-FL PVDF membranes (EMD Millipore, La Jolla, CA). Membranes were blocked for 
1 hour with Odyssey Blocking Buffer (LI-COR Biosciences, Lincoln, NE). Membranes were 
probed for proteins using primary antibodies (PDI, Cell Signaling, Danvers, MA, 1:1000) 
overnight at 4 °C. Membranes were incubated with secondary antibodies (anti-rabbit, Cell 
Signaling, 1:7500, or anti-mouse, Cell Signaling, 1:7500), and fluorescence was imaged by 
Odyssey imaging system (LI-COR Biosciences). 
Proteomics. U118MG cells were seeded in a 6-well plate at 0.5 x 106 cells/well in RPMI 
supplemented with 10 % FBS and allowed to attach overnight. Cells were treated with DMSO or 
40 μM DX3-159 overnight. Cells were washed with PBS and harvested with Cell Lytic M buffer 
(Sigma). The cells were lysed by incubation for 1 h on ice and spun in a centrifuge at 13,500g at 
4 °C for 10 min. Supernatant was collected and protein concentration determined with the BCA 





cell lysates in Cell Lytic M buffer were incubated with 10 μM DX3-173B overnight at room 
temperature. Samples were prepared with 50 μg protein boiled with Laemmli sample buffer and 
loaded onto 1 mm 10 % acrylamide gels. The gel was immediately imaged on the iBright with the 
GFP channel and stained with Coomassie. The band containing the BODIPY-labeled compound 
was cut out, digested, and analyzed at the University of Michigan Proteomics Resource Facility in 
the Department of Pathology. 
Confocal imaging. A172 cells were treated with 10 μM DX3-159 or 2 μM DX3-173B overnight. 
Cells were fixed in 4% paraformaldehyde for 15 minutes at room temperature and washed with 
1X PBS before blocking in 10% fetal bovine serum for 60 minutes. PDI antibody (Cell Signaling; 
3501S) was applied at 1:100 dilution in overnight at 4 °C. ProLong Diamond with DAPI 
(Invitrogen) was used to prepare the slides for analysis on the ZEISS Laser Scanning Microscope. 
Gel-based binding assays. Gel-based binding assays were performed with recombinant protein 
and cell lysate, as indicated. Briefly, cells were coated in 6-well or 12-well plates. After overnight 
attachment, cells were either serum-starved, treated with BSO, or treated with test compounds at 
indicated concentrations overnight at 37 °C, 5 % CO2. Cells were then washed with PBS and lysed 
using Cell Lytic M buffer (Sigma) for 60 min on ice. A unit of 30-50 μg of whole-cell protein was 
boiled with Laemmli sample buffer or non-reducing sample buffer (62.5 mM Tris–HCl, pH 6.8. 
10% glycerol. 2% SDS. 0.05% bromophenol blue) and resolved on a 10% polyacrylamide gel. 
Gels were immediately imaged on an iBright imaging system (Thermo Fisher Scientific). For cell 
lysates, cells were harvested as above prior to compound treatment, then incubated with 





binding assays with recombinant PDIA1, PDIp, ERp57, and BSA were performed using 3.5 μM 
protein in Cell Lytic M buffer incubated with compounds overnight at room temperature.  
Statistical analysis. The IC50 values were calculated using GraphPad Prism 7 software (GraphPad 
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Current state of glioblastoma drug discovery research 
 The aggressive nature and complex genetic origin of glioblastoma render most targeted 
therapies inactive against GBM tumor growth and underline the urgent need for research into new 
treatments. Even the current standard of care, temozolomide, a non-selective DNA alkylating 
agent, prolongs survival by only a few months before the tumor regains the ability to proliferate. 
Research into targeted agents has uncovered a variety of “driver” mutations and proteins, such as 
mTOR and BRAF V600 mutations, but the research has not yet resulted in targeted therapies for 
patients.1, 2 Furthermore, brain cancer research should be built carefully on the foundation of 
neuroscience and an understanding of brain biology.  
 Several small molecules are undergoing clinical trials to treat glioblastoma. Ribociclib is a 
cyclin D1/CDK4 and CDK6 inhibitor approved to treat breast cancer that was tested in a Phase 0 
study in patients with recurrent glioblastoma. Ribociclib was able to penetrate the blood-brain 
barrier, but exhibited limited efficacy in the small cohort (progression-free survival: 9.7 weeks, 
cohort size: 6 patients).3, 4 Olaparib has also been tested in combination with the standard-of-care 
for GBM. Olaparib is a poly(ADP-ribose) polymerase (PARP) inhibitor that sensitizes tumors to 
radiation and chemotherapy. Olaparib typically causes hematological toxicity. However, patients 





toxicity.5 These results provided the rationale to continue into a randomized Phase II trial to further 
evaluate the efficacy of the combination. Dacomitinib, an irreversible EGFR tyrosine kinase 
inhibitor, was tested in patients with recurrent GBM with EGFR amplification in the GEINO11 
trial.6 Four of the 30 patients with EGFR amplification without EGFRvIII mutation were 
progression-free at 6 months; however, even though the study did not reach its endpoint, three 
patients were progression-free at 12 months. These results indicate that mutation status of other 
GBM drivers or outside factors may play a role in drug efficacy. Despite the low success rate of 
small molecules in GBM clinical trials, treatments based on the genetic characterization of the 
tumor may provide more promising results in future studies. 
 Small molecules are not the only glioblastoma treatment undergoing research. Extensive 
research is underway to study the efficacy of antibodies, vaccines, nanoparticles, stereotactic 
surgery and other types of radiotherapy on brain cancer prognosis. Of the eight completed Phase 
III trials from 2005 to 2016, only one had positive results.7 The successful study used tumor-
treating fields (TTF), or low-intensity, alternating electric fields administered on the scalp, to treat 
patients with glioblastoma who had completed concomitant chemotherapy following surgical 
resection. TTFields, when combined with temozolomide, significantly improved overall survival 
compared with patients receiving chemotherapy alone (20.9 months versus 16.0 months).8 
Immunotherapy has become another area of great interest for glioblastoma treatment, even though 
the tumor microenvironment enlists immunosuppressive mechanisms to limit drug efficacy.9 For 
example, a dendritic cell vaccine generated with autologous tumor lysate, DCVax-L, was effective 
and preliminary results from the ongoing trial reported that early median survival of patients 





killer cells to destroy the tumor. An autologous dendritic cell vaccine is prepared by isolating the 
dendritic cells from a patient’s blood and stimulating the cells with a cancer associated antigen. 
Dendritic cell vaccines represent a potential novel immune-oncology therapeutic strategy to treat 
glioblastoma, in addition to peptide vaccines and checkpoint inhibition. Furthermore, the oncolytic 
adenovirus DNX-2401, developed from the cold virus, showed promising activity in a Phase I trial 
in patients with recurrent malignant glioma. Of the 25 patients who received treatment, 20 % 
survived over 3 years after treatment.11 Thus, the rationale for treating brain tumors with immune 
and viral therapy is growing. In the future, it could be possible that small molecules could be 
harnessed to hijack the complex pathways activated by these macromolecular therapies, to improve 
drug delivery and efficacy.  
 In addition to the novel types of glioblastoma therapies being explored, it will be likely that 
single agent targeted therapy would be ineffective at wiping out glioblastoma. Unlike the success 
of imatinib in chronic myeloid leukemia – a cancer that originates from a specific chromosomal 
abnormality – targeted therapies have had limited efficacy in glioblastoma. More likely, an arsenal 
of specific targeted agents will be able to selectively attack the tumor cells. Synthetic lethal 
screening campaigns, discussed in detail in Chapter 1, have attempted to identify potent 
combination therapies. Interestingly, a genome-wide CRISPR-Cas9 lethality screen revealed no 
synthetic lethal targets for common alterations including RB1mut, TERT expression, or 
TP53loss/mut.12 This suggests that the cancer cell growth is either mediated by different pathways, 
or inhibition is more complex than the knockout of just two genes. While their results were not 
published, Hoellerbauer, et al. indicate that GBM cell growth is mediated by the RTK/Ras and 





including clinical trial design, better preclinical models, and the involvement of the tumor 
microenvironment.13  
Challenges of developing PDI inhibitors 
 Developing effective PDI inhibitors requires careful consideration; thiol-reactive 
compounds are common pan-assay interference compounds because of their promiscuity. The 
mainstay of PDI inhibitor development is the PDI reductase assay because it is amenable to high 
throughput screening. However, because the assay requires the reducing agent dithiothreitol, redox 
cycling compounds can be false positives, as well as reactive electrophiles. The PDI reductase 
assay uses insulin as a substrate. Under reducing conditions, PDI reduces the disulfide bonds in 
insulin to break apart the a chain and b chain. In the PDI reductase assay, the b chain aggregates. 
Thus, thiol-reactive compounds can inhibit PDI activity, but thiol reactive compounds can be 
promiscuous, as demonstrated by the AS15 analogues that inhibit PDI, but also MIF tautomerase, 
HDACs, STATs, and other targets. Thus, it is critical to validate PDI inhibitors with orthogonal 
assays during the initial phase of lead discovery to rule out promiscuous hits. To confirm PDI 
inhibition, we used multiple assays including the thermal shift assay, ANS spectral scan, drug 
affinity responsive stability (DARTS), and the cellular thermal shift assay. Furthermore, the 
endoplasmic reticulum as an organelle and its effects on small molecules should be considered. 
Firstly, the ER is a highly oxidizing environment that could modify reactive small molecules, 
especially substituents that are prone to oxidation. Additionally, phase I metabolic enzymes such 
as cytochrome P450 reside in the endoplasmic reticulum of various tissues including the liver, 





 Because of the potential issues for selectivity with thiol directed PDI inhibitors, b’ domain 
inhibitors represent a more selective approach for PDI inhibition. The b’ domain is specific to PDI 
family members, and each b’ domain of the PDI family members is unique for diverse substrate 
recognition. Several inhibitors have been characterized to bind in the substrate-binding pocket, 
including estradiol14, bepristat 1a15, isoquercetin16, and BAP217. With the exception of BAP2, 
these inhibitors are less toxic than active site PDI inhibitors. For example, isoquercetin analogues 
are in clinical trials for thrombosis-related indications16. The low cytotoxicity of substrate-binding 
domain inhibitors may be related to their low binding affinity. For example, the Kd of quercetin, 
measured by isothermal calorimetry, is 18.3 μM, and the binding Kd for BAP2 is 9.4 μM.
18 The 
low binding affinity for small molecules in the substrate-binding domain may be explained by the 
mechanism of PDI substrate proteins associating and dissociating with the pocket. If substrate-
binding domain inhibitors were optimized for binding affinity, we may find a more potent 
cytotoxic PDI inhibitor that is ideally more selective. 
Summary of the dissertation 
 In this dissertation, a detailed preclinical evaluation of an extensive library of PDI 
inhibitors was carried out with a focus on scaffolds of three lead compounds: 35G8, BAP2, and 
AS15. PDI plays a critical role in the proper disulfide bond formation of nascent polypeptides in 
the ER, and brain cancer cells are highly addicted to PDI. PDI knockdown is lethal to cancer cells, 
and PDI inhibition prevents neurosphere formation in patient derived GBM cells. Thus, PDI 
inhibition represents a potential anti-cancer strategy. Major strategies for small molecule inhibitor 
develop focus on thiol-directed inhibitors of the active site cysteines or hydrophobic reversible 





demonstrated as a b’ domain inhibitor, while AS15 was revealed to covalently bind to PDI to 
inhibit its function. 
 
Figure VI-1 Potential drivers of GBM tumors based on TCGA analysis 
 
 Chapter 1 of this dissertation provides an overview of the research on small molecule 
treatment of glioblastoma (Figure VI-1). Importantly, we used a bioinformatics approach to probe 
the TCGA survival data and identify potential drivers of disease. In this review, we found 20 genes 
associated with reduced survival, 5 of which (ELOVL6, ESR2, TH, FURIN, and GZMB) are 
druggable protein targets. This study demonstrated a bioinformatics approach to generating 
hypotheses about previously unknown genes that may be responsible for disease progression. 






Figure VI-2 PDI modulators in different diseases 
 
 Chapter 2 of this dissertation provides an overview of PDI function and the unique roles it 
plays in different disease states (Figure VI-2). Because PDI has numerous substrates, its function 
or dysfunction has been reported in neurological disorders, atherosclerosis, and diabetes, as well 
as in cancer. Thus, PDI inhibitors, or modulators, may be useful in a wide range of indications. 
With respect to cancer, PDI has been demonstrated to play a role in glioblastoma, multiple 
myeloma, ovarian cancer, and non-small cell lung cancer. The importance of PDI in the 
progression of these diseases emphasizes the need for a potent, selective small molecules inhibitor 






Figure VI-3 Discovery of 35G8 as a PDI inhibitor 
 
 In Chapter 3, we characterized 35G8 as a novel, potent PDI inhibitor (Figure VI-3). Much 
effort was involved in validating that the compound did not exhibit its PDI inhibition via its PAINS 
redox cycling properties before pursuing this scaffold as a bona fide PDI inhibitor. After 
confirming 35G8 inhibited PDI activity and destabilized PDI in the cells, we compared its 
transcriptomic profile with that of PDI knockdown. 35G8 induced an ER stress response and a 
ferroptosis cell death signature. To confirm this, we rescued cell death with iron chelator DFO. 






Figure VI-4 Lead compound BAP2 optimization 
 In Chapter 4, we detail an extensive structure-activity relationship campaign of 67 chalcone 
analogues that supported the identification of the binding pocket of the lead compound to further 
structure-based drug design and optimization (Figure VI-4). Although BAP2 and optimized 
analogue 59 have modest thiol reactivity, mutation of His256 to Ala abolishes BAP2 analogue 
activity. Importantly, analogues inhibit glioblastoma cell growth, induce ER stress, increase 
expression of G2M checkpoint proteins, and reduce expression of DNA repair proteins. 






Figure VI-5 Identification of AS15 analogues that covalently bind PDI 
 
 Lastly, Chapter 5 details yet another potent PDI inhibitor series (Figure VI-5). We report 
the benzyl-benzodioxole AS15 analogues as potent PDI inhibitors and investigate modifications 
to the scaffold to optimize PDI inhibition and target engagement. We performed the first 
systematic synthesis of diverse α-aminobenzylphenol modifications to the-
hydroxybenzo[d][1,3]dioxole core. Furthermore, we were able to identify the binding mechanism 
as a retro Michael addition to thiolate anions in the a′ and a domains, though the compounds likely 
bind other sites in the protein as well. Nascent RNA sequencing revealed that an active analogue 
of AS15 triggers the unfolded protein response in glioblastoma cells. Based on the mechanism of 
action of the AS15 analogues, we confirmed that the compounds are sensitive to glutathione in 
vitro, and glutathione blocks target binding. Additionally, glutathione synthesis inhibitor BSO 
sensitized glioblastoma cells to AS15 analogue treatment. However, the compounds likely have 
more than one target in the cells and are not selective for PDI. Thus, this series would require 





Significance of the study 
 This work details the successful preclinical evaluation of several small molecules as 
inhibitors of PDI. These molecules were identified through both phenotypic and target-based 
screens. The lead compounds are potent at inhibiting PDI reductase activity and bind to PDI in the 
in-cell target engagement assays. Furthermore, we identified PDI inhibitors that sensitized GBM 
cells to radiation and had in vivo efficacy in a subcutaneous xenograft. Collectively, this 
dissertation provides further evidence for PDI as a target in GBM and rationalizes the pursuit of 
combinations of PDI inhibitors with the standard-of-care in more robust preclinical models, and 
finally, clinical trials. 
Future Directions 
Validation of PDI as a target in brain cancer 
 Although glioblastoma is not a secretory cancer, PDI expression correlates with GBM 
disease progression, and PDI knockdown inhibits patient derived neurosphere formation. These 
observations provide strong initial validation to target PDI in glioblastoma. Further validation 
could include more robust models of glioblastoma and CRISPR/Cas9-mediated PDI knockout. 
Using the limiting dilution method in Cas9-expressing cells, we used CRISPR RNA targeting exon 
2 of PDI to knockout the gene. By using this method, we selected for cells that survived gene 
knockout, and the cells had a similar doubling time as the wild-type cells. Extensive 
characterization of the RNA profile of three PDI knockout clones is underway to determine how 





of resistance to promote survival. It is also possible that transient transfection of cells with PDI 
crRNA provides a more realistic response that would mimic the effect of a potent PDI inhibitor. 
Structure-based drug design 
 Because of the complexity and flexibility of PDI, binding should be the first priority after 
identifying a potent lead compound in order to rationally optimize the compound as a PDI 
inhibitor. The substrate-binding domain offers opportunities for structure-guided design because 
there are several residues available for hydrophobic and electrostatic interactions. Ideally, an active 
site inhibitor could also be modified to make critical non-covalent interactions with residues 
around the CGHC motif to improve selectivity and binding. NMR studies with PDI fragments may 
be the most efficient strategy for structure-based drug design. A PDI crystal structure has eluded 
researchers for over 30 years, potentially because we do not fully understand the complex 
oligomerization of the protein, its flexibility, and presence as a mixture of multiple 
oxidized/reduced conformations. Hopefully researchers will continue to pursue this challenge and 
solve a co-crystal structure with PDI and its inhibitors. 
Novel assay development and the limit of detection 
 To characterize the inhibition of PDI, we used one enzymatic activity assay– the PDI 
reductase assay. This assay measures the ability of PDI to reduce disulfide bonds in insulin over a 
period of a few hours. The assay is a standard PDI activity assay because of its ease of use and 
robust applicability for high throughput screening. However, the standard protocol requires a 
relatively high concentration of PDI (400 nM), especially when we are reaching the limit of 





my dissertation project, I was able to optimize the reductase assay to run with 50 nM PDI, and 
with the optimized assay we could characterize IC50 values down to 25 nM. However, another 
important issue remains. PDI catalyzes reactions on nascent polypeptides in its oxidized state. 
Therefore, the ability of PDI to oxidize thiols should be tested to mimic the physiological 
environment as closely as possible. PDI oxidase assays do exist, but they are complex and require 
the observation of multiple folding intermediates of substrates such as BPTI via mass 
spectroscopy. Thus, they are typically set aside for the more convenient alternative. However, in 
the future it will be critical to develop a robust PDI oxidase assay, both in vitro and cell-based, to 
identify PDI inhibitors that would inhibit PDI in cells. 
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